0	1	a	bromocriptine receiving patient in infarction
1	1	a	Bromocriptine implicated in reports of infarction
2	1	a	clonidine resulting in block
3	1	a	clonidine of dose of addition After developed block
4	1	a	clonidine mg bid developed block
5	1	a	clonidine resulting in block hypotension
6	1	a	clonidine of dose of addition After developed block hypotension
7	1	a	verapamil clonidine resulting in block
8	1	a	verapamil clonidine resulting in block hypotension
9	0	a	verapamil with treated woman with hyperaldosteronism
10	0	a	spironolactone d treated woman with hyperaldosteronism
11	0	a	S-312 , S-312-d antagonists showed effects on convulsions
12	0	a	S-312-d antagonists showed effects on convulsions
13	0	a	S-312-l S-312-d antagonists showed effects on convulsions
14	0	a	calcium channel antagonists showed effects on convulsions
15	0	a	flunarizine of that was were showed effects on convulsions
16	0	a	S-312-d of effects observed against convulsions
17	0	a	S-312-d of effects observed observed in convulsions
18	1	a	pentylenetetrazole by induced convulsions
19	1	a	pentylenetetrazole by induced convulsions against observed observed in convulsions
20	1	a	bemegride mg/kg pentylenetetrazole by induced convulsions
21	1	a	bemegride mg/kg pentylenetetrazole by induced convulsions against observed observed in convulsions
22	0	a	aspartate by induced convulsions in observed observed against convulsions
23	0	a	aspartate by induced convulsions
24	1	a	picrotoxin aspartate by induced convulsions in observed observed against convulsions
25	1	a	picrotoxin aspartate by induced convulsions
26	0	a	S-312-d be in therapy of types of epilepsy
27	1	a	alendronate of administration after Diffuse pain
28	1	a	alendronate of administration after admitted with pain
29	0	a	bisphosphonates used caused Osteoporosis
30	0	a	bisphosphonate related pain considered report patients with osteoporosis
31	0	a	bisphosphonate related pain considered before ascribing to osteoporosis
32	0	a	Alendronate is effective for treatment of osteoporosis
33	0	a	biphosphonate Alendronate is effective for treatment of osteoporosis
34	0	a	bisphosphonate related pain considered report pain
35	0	a	bisphosphonate related pain
36	0	a	cocaine intoxication after infarction of pallidus
37	0	a	cocaine intoxication after infarction of pallidus
38	0	a	cocaine of use after infarcts
39	0	a	alcohol cocaine intoxication after infarction of pallidus
40	0	a	alcohol cocaine intoxication after infarction of pallidus
41	0	a	Cocaine is factor for stroke
42	0	a	Cocaine is factor for stroke
43	0	a	alcohol after present case of man with ischemia of pallidus
44	1	a	cocaine use alcohol after present case of man with ischemia of pallidus
45	1	a	heroin with associated infarctions
46	1	a	heroin use without infarcts
47	0	a	cocaine to related arrhythmia
48	0	a	cocaine to related arrhythmia dysfunction
49	0	a	cocaine to related In were causes of hypoperfusion
50	0	a	ethanol use cocaine to related arrhythmia
51	0	a	ethanol use cocaine to related arrhythmia dysfunction
52	0	a	ethanol use cocaine to related In were causes of hypoperfusion
53	1	a	Penicillin anaphylaxis
54	1	a	penicillin anaphylaxis
55	1	a	penicillin anaphylaxis of case described reviewed terminology occurrence manifestations pathogenesis of anaphylaxis
56	1	a	penicillin anaphylaxis
57	1	a	Cephalothin induced anemia
58	1	a	cephalothin therapy receiving developed anemia
59	0	a	cephalothin therapy receiving developed patient with disease
60	0	a	everolimus in patients with NSCLC
61	0	a	RAD001 everolimus in patients with NSCLC
62	0	a	RAD001 shown phase efficacy in NSCLC
63	0	a	RAD001 day was showing activity in NSCLC
64	0	a	RAD001 of Evaluation therapy for NSCLC
65	0	a	rapamycin of target of inhibitor RAD001 shown phase efficacy in NSCLC
66	0	a	platinum regimens with patients IIIb NSCLC
67	0	a	tyrosine inhibitors received until progression toxicity
68	0	a	RAD001 received until progression toxicity
69	1	a	Flumazenil induces seizures
70	1	a	flumazenil of Administration unmask seizures
71	1	a	Flumazenil unmask seizures
72	1	a	cocaine diazepam intoxications in seizures
73	1	a	cocaine benzodiazepine intoxication in seizures
74	1	a	cocaine diazepam intoxications of model in increase unmask seizures
75	1	a	diazepam intoxications in seizures
76	1	a	diazepam intoxications of model in increase unmask seizures
77	0	a	benzodiazepine antagonist flumazenil of Administration unmask seizures
78	0	a	benzodiazepine intoxication in seizures
79	1	a	amitriptyline therapy during Encephalopathy
80	1	a	amitriptyline therapy of course in developed encephalopathy
81	0	a	amitriptyline therapy during Encephalopathy are syndrome
82	0	a	amitriptyline therapy during Encephalopathy are syndrome disorders spectrum syndrome
83	0	a	amitriptyline therapy of course in developed encephalopathy of case describes during remission of depression
84	1	a	carbonate therapy on patients in Etiology of hypercalcemia
85	1	a	carbonate to switching after became hypercalcemic
86	0	a	phosphate binder as switching after became hypercalcemic
87	0	a	calcium reabsorption rate of parameters compared In order identify factors associated with development of hypercalcemia
88	0	a	calcium values with episodes hypercalcemic
89	0	a	calcium values with episodes experiencing to addition In exhibited patients in group hypercalcemic
90	0	a	calcium concentration in increase exhibited In addition to experiencing episodes hypercalcemic
91	0	a	calcium concentration in increase exhibited patients in group hypercalcemic
92	0	a	calcium reabsorption rate of parameters compared with results in patients length etiology of disease
93	0	a	epinephrine infusion required treat hypotension
94	0	a	clentiazem against injury
95	0	a	clentiazem attenuated injury
96	0	a	epinephrine induced injury
97	0	a	epinephrine induced injury
98	0	a	clentiazem antagonist on cardiomyopathy
99	0	a	1,5-benzothiazepine calcium antagonist on cardiomyopathy
100	0	a	calcium antagonist on cardiomyopathy
101	1	a	epinephrine induced cardiomyopathy
102	0	a	epinephrine infusion With died observed lesions
103	0	a	epinephrine induced death prevented attenuated lesions
104	0	a	epinephrine infusion With died observed lesions fibrosis
105	0	a	epinephrine induced death prevented attenuated lesions fibrosis
106	0	a	clentiazem with Treatment prevented attenuated lesions
107	0	a	clentiazem with Treatment prevented attenuated lesions fibrosis
108	1	a	sulfate on infections
109	1	a	sulfate of mg of inoculation Intravenous followed by leukopenia
110	0	a	sulfate given inoculation resulted in infection
111	1	a	Neuroleptic associated hyperprolactinemia
112	1	a	medications with associated outpatients with hyperprolactinemia
113	1	a	neuroleptic associated hyperprolactinemia
114	1	a	medications with associated outpatients with hyperprolactinemia oligomenorrhea amenorrhea
115	1	a	neuroleptic associated hyperprolactinemia galactorrhea amenorrhea
116	1	a	medications with associated outpatients with hyperprolactinemia oligomenorrhea
117	0	a	bromocriptine with treated outpatients with hyperprolactinemia
118	0	a	bromocriptine evaluated as therapy for hyperprolactinemia
119	0	a	bromocriptine with treated outpatients with hyperprolactinemia oligomenorrhea amenorrhea
120	0	a	bromocriptine evaluated as therapy for hyperprolactinemia galactorrhea amenorrhea
121	0	a	bromocriptine with treated outpatients with hyperprolactinemia oligomenorrhea
122	1	a	bromocriptine taking worsened symptoms
123	0	a	bromocriptine evaluated as therapy for hyperprolactinemia galactorrhea
124	0	a	neuroleptic associated hyperprolactinemia galactorrhea
125	0	a	valproate started had number of admissions with hemiparesis
126	0	a	valproate started for migraine
127	0	a	aspartate were showed changes consistent with encephalopathy
128	0	a	NMDA aspartate were showed changes consistent with encephalopathy
129	0	a	NMDA encephalitis encephalopathy
130	0	a	valproate induced encephalopathy
131	0	a	valproate induced encephalopathy encephalitis
132	0	a	NMDA encephalitis
133	0	a	chebula against injury
134	0	a	fruits of extract of effect examined induced damage
135	1	a	isoproterenol by induced injury
136	1	a	isoproterenol in examined induced damage
137	0	a	lamivudine with combined globulin B
138	0	a	lamivudine with combined in prevention of recurrence B
139	0	a	lamivudine HBIg globulin B
140	0	a	lamivudine HBIg globulin in prophylaxis of recurrence of B
141	0	a	HBsAg patients of survival improved globulin B
142	0	a	HBsAg patients of survival improved globulin in prophylaxis of recurrence of B
143	1	a	flecainide concentrations with patient in Delirium
144	1	a	flecainide induced delirium
145	1	a	Flecainide cause delirium
146	1	a	flecainide substrate paroxetine inhibitor reports of delirium
147	1	a	flecainide induced delirium
148	1	a	flecainide was cause of delirium
149	1	a	flecainide between interaction indicates was cause of delirium
150	1	a	flecainide concentrations cause delirium
151	1	a	paroxetine with interaction of role Delirium
152	1	a	paroxetine with interaction with associated delirium
153	1	a	paroxetine inhibitor reports of delirium
154	1	a	paroxetine flecainide between interaction indicates was cause of delirium
155	0	a	Flecainide started prior for fibrillation
156	0	a	sodium channels with interact agents Flecainide cause delirium
157	0	a	flecainide prescribed occur toxicity
158	0	a	flecainide concentrations monitored occur toxicity
159	0	a	paroxetine with prescribed occur toxicity
160	0	a	etoposide therapy after dysfunction
161	0	a	etoposide therapy for glioma
162	0	a	etoposide therapy of toxicity for glioma
163	0	a	Etoposide used in treatment of tumors
164	0	a	213 Etoposide used in treatment of tumors
165	0	a	Etoposide used in treatment of tumors malignancies
166	0	a	213 Etoposide used in treatment of tumors malignancies
167	0	a	etoposide therapy of toxicity
168	1	a	warfarin users in users in range to increased were IS In analysis of ICH
169	1	a	warfarin users in users in range to increased were frequent in ICH
170	1	a	warfarin users vs nonusers with ICH
171	1	a	warfarin users in none CI was in users vs nonusers with ICH
172	1	a	warfarin users with ICH
173	1	a	warfarin users in excess suggests increase risk of ICH
174	1	a	warfarin associated ICH of risk increase suggests excess in users with ICH
175	1	a	warfarin associated ICH
176	0	a	warfarin users in users in range to increased were IS
177	0	a	warfarin users in users in range to increased were TIA IS
178	0	a	warfarin users in was CI none in users with CI TIA IS
179	0	a	warfarin users with CI TIA IS
180	0	a	warfarin users in users in range to increased were IS TIA
181	0	a	warfarin users in users in range to increased were TIA
182	0	a	warfarin users in was CI none in users with CI TIA
183	0	a	warfarin users with CI TIA
184	0	a	warfarin users in users in range to increased were MB
185	0	a	warfarin users in was excess of MB
186	0	a	warfarin users in none CI was excess of MB
187	0	a	warfarin users in excess of MB
188	0	a	warfarin users in excess suggests increase MB
189	0	a	warfarin associated ICH of risk increase suggests excess of MB
190	0	a	warfarin associated ICH of risk increase MB
191	0	a	platinum of combination with Treatment of cancer
192	0	a	cisplatinum of combination with treated patients with cancer
193	0	a	adriamycin platinum of combination with Treatment of cancer
194	0	a	adriamycin m2 cisplatinum of combination with treated patients with cancer
195	0	a	cyclophosphamide adriamycin platinum of combination with Treatment of cancer
196	0	a	cyclophosphamide m2 adriamycin m2 cisplatinum of combination with treated patients with cancer
197	0	a	hexamethylmelamine cyclophosphamide adriamycin platinum of combination with Treatment of cancer
198	0	a	hexamethylmelamine treated patients with cancer
199	0	a	HMM hexamethylmelamine treated patients with cancer
200	0	a	CPDD cisplatinum of combination with treated patients with cancer
201	0	a	HMM necessitated toxicity
202	0	a	Flurothyl thresholds seizure
203	0	a	Flurothyl thresholds treated with injection of glutamate evaluation in testing seizure
204	0	a	flurothyl testing in evaluation glutamate of injection with treated thresholds seizure
205	0	a	flurothyl testing seizure
206	0	a	flurothyl ether technique screening seizure
207	0	a	flurothyl ether technique used evaluate susceptibility seizure
208	0	a	Flurothyl ether produced was relationship to induction seizure
209	0	a	flurothyl exposure of duration with correlated hypothermia produced was relationship to induction seizure
210	0	a	Flurothyl testing seizure
211	0	a	Flurothyl testing proved be technique evaluate susceptibility seizure
212	0	a	glutamate of injection with treated thresholds seizure
213	0	a	glutamate evaluation in testing seizure
214	0	a	MSG glutamate of injection with treated thresholds seizure
215	0	a	MSG glutamate evaluation in testing seizure
216	0	a	glutamate produces convulsions
217	0	a	MSG administration glutamate produces convulsions
218	0	a	MSG of administration produced alterations in susceptibility seizure
219	0	a	MSG of injections received mice in susceptibility evaluate used technique screening seizure
220	0	a	MSG of injections received mice in susceptibility seizure
221	0	a	MSG treatment resulted alter threshold seizure
222	0	a	MSG treated mice of control of thresholds seizure
223	0	a	ether technique screening seizure
224	0	a	ether technique used evaluate susceptibility seizure
225	0	a	ether produced was relationship to induction seizure
226	0	a	naloxone was ineffective in altering thresholds seizure
227	1	a	Flurothyl ether produced hypothermia
228	1	a	Flurothyl ether produced was relationship of hypothermia
229	1	a	flurothyl exposure of duration with correlated hypothermia
230	1	a	flurothyl exposure of duration with correlated hypothermia produced was relationship of hypothermia
231	0	a	ether produced hypothermia
232	0	a	ether produced was relationship of hypothermia
233	0	a	Gemfibrozil lovastatin therapy for hyperlipoproteinemias
234	0	a	lovastatin therapy for hyperlipoproteinemias
235	0	a	gemfibrozil lovastatin label treatment in patients with hyperlipidemia
236	0	a	gemfibrozil lovastatin label treatment in patients with hyperlipidemia had disease
237	0	a	lovastatin label treatment in patients with hyperlipidemia
238	0	a	lovastatin label treatment in patients with hyperlipidemia had disease
239	0	a	creatine phosphokinase with % in had occurred Myositis
240	0	a	creatine phosphokinase with % in had rhabdomyolysis
241	0	a	creatine phosphokinase with % in had rhabdomyolysis myoglobinuria
242	0	a	Paclitaxel acid in cancer
243	0	a	paclitaxel acid are therapies for patients cancer
244	0	a	Taxol are therapies for patients cancer
245	0	a	5-fluorouracil Paclitaxel acid in cancer
246	0	a	5-fluorouracil m2 days in women with cancer
247	0	a	acid in cancer
248	0	a	acid are therapies for patients cancer
249	0	a	Paclitaxel have cytotoxicity
250	0	a	5-fluorouracil Paclitaxel have cytotoxicity
251	0	a	factor required reported associated with neutropenia
252	0	a	factor due neutropenia
253	1	a	indinavir related nephrotoxicity
254	1	a	indinavir discontinued because nephrotoxicity
255	1	a	Indinavir associated nephrotoxicity
256	0	a	indinavir related nephrotoxicity monitor in cohort of type
257	0	a	creatinine ratio in increase with associated leukocyturia
258	0	a	creatinine levels had Children with leukocyturia
259	0	a	creatinine levels had without leukocyturia
260	0	a	creatinine levels decreased returned disappeared leukocyturia
261	0	a	creatinine ratios returned disappeared leukocyturia
262	0	a	creatinine levels in increase had Children with leukocyturia
263	0	a	creatinine ratio in increase with by hematuria
264	0	a	indinavir with treated Children have incidence of leukocyturia
265	0	a	Indinavir associated nephrotoxicity monitored in children with factors as leukocyturia
266	1	a	Heparin induced thrombocytopenia
267	1	a	heparin therapy of effects thromboembolism thrombocytopenia
268	1	a	heparin therapy including thrombocytopenia
269	1	a	heparin therapy of effects discussed thrombocytopenia
270	1	a	heparin induced thrombocytopenia
271	1	a	heparin induced thrombocytopenia including therapy of effects discussed thrombocytopenia
272	1	a	heparin associated osteoporosis thrombocytopenia
273	1	a	heparin associated osteoporosis thrombocytopenia including therapy of effects discussed thrombocytopenia
274	1	a	Heparin induced thrombocytopenia thromboembolism
275	1	a	heparin therapy of effects thromboembolism
276	1	a	heparin therapy including thrombocytopenia osteoporosis
277	1	a	heparin induced thrombocytopenia osteoporosis
278	1	a	heparin associated osteoporosis
279	1	a	heparin therapy including thrombocytopenia osteoporosis eosinophilia
280	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia
281	1	a	heparin associated osteoporosis eosinophilia
282	1	a	heparin therapy including thrombocytopenia osteoporosis eosinophilia reactions
283	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions
284	1	a	heparin associated osteoporosis eosinophilia reactions
285	1	a	heparin therapy including thrombocytopenia osteoporosis eosinophilia reactions reactions
286	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions
287	1	a	heparin associated osteoporosis eosinophilia reactions reactions
288	1	a	heparin therapy of effects discussed thrombocytopenia alopecia
289	1	a	heparin induced thrombocytopenia including therapy of effects discussed thrombocytopenia alopecia
290	1	a	heparin associated osteoporosis thrombocytopenia including therapy of effects discussed thrombocytopenia alopecia
291	0	a	tazobactam induced seizure
292	0	a	piperacillin neurotoxicity
293	0	a	piperacillin with associated neurotoxicity
294	0	a	tazobactam of doses given report woman with disease
295	1	a	tazobactam of doses given report woman developed speech tremor
296	1	a	tazobactam of doses given report woman developed speech tremor behavior confusion
297	1	a	tazobactam of doses given report woman developed speech tremor behavior confusion episodes of seizure
298	1	a	tazobactam of doses given report woman developed speech tremor behavior confusion episodes of seizure GTCS
299	1	a	tazobactam of dose after recurred episode GTCS
300	0	a	tazobactam of doses given for bronchiectasis
301	0	a	tazobactam of doses given for bronchiectasis with infection
302	0	a	ammonia levels electrolyte leukocytosis
303	0	a	Piperacillin induced encephalopathy
304	0	a	piperacillin removing in inefficient is terminate encephalopathy
305	0	a	piperacillin induced encephalopathy
306	0	a	Piperacillin induced encephalopathy considered in patients uremic
307	0	a	temsirolimus of effects in lymphoma
308	0	a	temsirolimus with treated reported in MCL
309	0	a	temsirolimus treatment after had MCL
310	0	a	temsirolimus of effect contribute to efficiency in MCL
311	0	a	temsirolimus treatment after had regression tumor
312	0	a	temsirolimus inhibited proliferation cell tumor
313	0	a	temsirolimus inhibited showed induce change in number of cells tumor
314	0	a	temsirolimus had effect with decrease of density microvessel tumor
315	0	a	temsirolimus reduced burden tumor
316	0	a	temsirolimus on tissue tumor
317	1	a	temsirolimus therapy after found areas compatible with repair necrotic
318	0	a	Chloroacetaldehyde as reagent role of groups in nephropathy
319	0	a	Chloroacetaldehyde is metabolite of agent ifosfamide responsible for damage
320	0	a	CAA Chloroacetaldehyde is metabolite of agent ifosfamide responsible for damage
321	0	a	sulfhydryl reagent role of groups in nephropathy
322	0	a	thiol groups in nephropathy
323	1	a	ifosfamide nephropathy
324	1	a	ifosfamide responsible for damage
325	1	a	IFO ifosfamide responsible for damage
326	1	a	IFO with therapy following damage
327	1	a	IFO nephropathy
328	0	a	Chloroacetaldehyde is metabolite of agent ifosfamide responsible for damage following therapy tumor
329	0	a	CAA Chloroacetaldehyde is metabolite of agent ifosfamide responsible for damage following therapy tumor
330	0	a	ifosfamide responsible for damage following therapy tumor
331	0	a	IFO ifosfamide responsible for damage following therapy tumor
332	0	a	IFO with therapy tumor
333	0	a	CAA of Toxicity
334	0	a	CAA reacts mediating toxicity
335	0	a	blue assay release number content by determined Toxicity
336	0	a	CAA reduced induced loss increase in markers necrosis
337	0	a	CAA of reaction slowed Acidification attenuate effects on markers necrosis
338	0	a	CAA of effects on markers necrosis
339	0	a	thiols in loss increase in markers necrosis
340	0	a	thiol donors with reaction slowed Acidification attenuate effects on markers necrosis
341	0	a	thiol depletion markers necrosis
342	0	a	cysteine protease inhibition depletion markers necrosis
343	0	a	thiols protein with reacts mediating toxicity
344	0	a	dehydroepiandrosterone of Effects in models schizophrenia
345	0	a	dehydroepiandrosterone of effects on models of schizophrenia
346	0	a	DHEA dehydroepiandrosterone of effects on models of schizophrenia
347	0	a	DHEA displays used in treatment of schizophrenia
348	1	a	amphetamine induced models schizophrenia
349	1	a	Amphetamine induced induced used as models of schizophrenia
350	0	a	Amphetamine induced locomotion hyper
351	0	a	Amphetamine induced induced used tests catalepsy
352	0	a	apomorphine locomotion hyper
353	0	a	apomorphine locomotion induced induced used tests catalepsy
354	1	a	apomorphine locomotion induced induced used as models of schizophrenia
355	0	a	haloperidol induced induced locomotion hyper
356	1	a	haloperidol induced used tests catalepsy
357	1	a	haloperidol induced test catalepsy
358	1	a	haloperidol induced used as models of schizophrenia
359	0	a	DHEA reduced catalepsy
360	0	a	danazol of safety in women with angioedema
361	0	a	danazol of safety investigated by performing review of patients with angioedema
362	0	a	danazol with treated review of patients with angioedema
363	1	a	Tacrolimus related seizure
364	1	a	TAC level was factor associated with seizures
365	1	a	TAC level was factor contributed to seizures
366	1	a	TAC related seizures
367	0	a	chloride channel function in defect by caused congenita
368	0	a	chloride channel function in defect by caused congenita MC
369	0	a	chloride channel function cause depolarisation
370	1	a	suxamethonium of injection following describe woman developed spasm
371	0	a	propylthiouracil with treated patients disease
372	0	a	propylthiouracil with treated disease
373	0	a	PTU propylthiouracil with treated disease
374	0	a	PTU therapy during studies been on incidence of ANCA in patients disease
375	0	a	PTU therapy starting after investigated with hyperthyroidism due to disease
376	0	a	propylthiouracil with treated disease with patients in reported vasculitis
377	0	a	PTU propylthiouracil with treated disease with patients in reported vasculitis
378	0	a	PTU therapy during studies vasculitis
379	0	a	PTU therapy starting after investigated for vasculitis
380	0	a	PTU therapy related appear be related to vasculitis
381	0	a	PTU therapy starting after investigated with hyperthyroidism
382	0	a	PTU therapy despite increased developed disorders
383	1	a	PTU therapy stopping after resolved developed fever
384	1	a	PTU discontinuing after decreased resolved developed fever
385	1	a	PTU therapy stopping after resolved developed fever ulcers
386	1	a	PTU discontinuing after decreased resolved developed fever ulcers
387	1	a	PTU therapy stopping after resolved developed fever ulcers polyarthralgia
388	1	a	PTU discontinuing after decreased resolved developed fever ulcers polyarthralgia
389	1	a	contraceptives reported case of aneurysm
390	0	a	contraceptives reported case of aneurysm of artery in association with hypertension
391	0	a	contraceptives reported in patient with syndrome
392	1	a	metoprolol terbinafine combination induced bradycardia
393	1	a	terbinafine combination induced bradycardia
394	0	a	metoprolol by induced bradycardia
395	0	a	metoprolol between interaction bradycardia
396	0	a	metoprolol clearance decreased leading in accumulation resulted in bradycardia
397	0	a	metoprolol accumulation resulted in bradycardia
398	0	a	terbinafine interaction metoprolol by induced bradycardia
399	0	a	terbinafine metoprolol between interaction bradycardia
400	0	a	terbinafine decreased leading in accumulation resulted in bradycardia
401	0	a	metoprolol on man for disease
402	0	a	metoprolol on man prescribed for onychomycosis
403	0	a	terbinafine of course prescribed man for disease
404	0	a	terbinafine of course prescribed for onychomycosis
405	0	a	terbinafine therapy of day On brought for decrease of status confusion
406	0	a	metoprolol between interaction bradycardia between relationship indicates score on scale probability reaction
407	0	a	terbinafine metoprolol between interaction bradycardia between relationship indicates score on scale probability reaction
408	0	a	dipyridamole infusion after detection of disease
409	0	a	dipyridamole test is useful as test for assessment of disease
410	0	a	dipyridamole After observed depression ischemic
411	0	a	dipyridamole After observed depression
412	0	a	dipyridamole After observed in % of group MI
413	0	a	dipyridamole After observed in % % of group MI
414	0	a	dipyridamole After observed in % % % of group MI
415	1	a	dipyridamole induced ischemia
416	0	a	Nociceptin orphanin FQ on impairment
417	0	a	FQ on impairment
418	0	a	nociceptin modulate impairment of learning memory
419	0	a	FQ nociceptin modulate impairment of learning memory
420	0	a	Nociceptin orphanin FQ on impairment
421	0	a	FQ on impairment
422	0	a	nociceptin modulate impairment of learning memory
423	0	a	FQ nociceptin modulate impairment of learning memory
424	0	a	nocistatin FQ on impairment
425	0	a	nocistatin FQ nociceptin modulate impairment of learning memory
426	0	a	nocistatin FQ on impairment
427	0	a	nocistatin FQ nociceptin modulate impairment of learning memory
428	1	a	scopolamine by induced impairment
429	1	a	scopolamine by induced learning memory
430	1	a	scopolamine by induced impairment
431	1	a	scopolamine by induced learning memory
432	0	a	nocistatin isolated from precursor blocks allodynia
433	0	a	nocistatin isolated from precursor blocks allodynia hyperalgesia
434	0	a	nociceptin as precursor blocks allodynia
435	0	a	nociceptin as precursor blocks allodynia hyperalgesia
436	0	a	nociceptin induced allodynia
437	0	a	nociceptin induced allodynia hyperalgesia
438	1	a	propranolol loading by induced failure
439	0	a	propranolol loading by induced confirmed absence of MR
440	1	a	haloperidol induced hyperprolactinemia
441	1	a	haloperidol infusions of course During found hyperprolactinemia
442	0	a	cycloheximide with treated rats epileptic
443	1	a	pilocarpine by induced epilepticus
444	1	a	Pilo pilocarpine by induced epilepticus
445	0	a	cycloheximide with injected epilepticus
446	0	a	CHX cycloheximide with injected epilepticus
447	1	a	rifampicin due failure
448	0	a	Rifampicin administered time developed effects like nausea
449	0	a	Rifampicin administered time developed effects like nausea vomiting
450	0	a	Rifampicin administered time developed effects like nausea vomiting fever
451	1	a	dobutamine stress echocardiography during response Hypertensive
452	1	a	dobutamine stress studies Among occurred response hypertensive
453	1	a	dobutamine infusion before resting had had history of hypertension
454	0	a	levodopa induced dyskinesia without with characterize dynamics in patients PD
455	0	a	levodopa for role suggest confirm is predictor of alterations in PD
456	1	a	levodopa induced dyskinesia
457	1	a	levodopa dose of basis on explained function swallowing in performed patients dyskinetic
458	0	a	levodopa for role suggest confirm is dysphagia
459	0	a	Vasopressin as contributor to hypertension
460	0	a	vasopressin of role as agent to process hypertensive
461	0	a	Vasopressin plays in pathogenesis of hypertension
462	0	a	vasopressin of action appears be in development of model of hypertension
463	0	a	vasopressin of action appears observed in stage of hypertension
464	0	a	vasopressin of secretion promotes function as factor in hypertension
465	0	a	vasopressin of role remains determined in hypertension
466	0	a	Vasopressin plays was in rats with insipidus
467	1	a	DOCA salt hypertension
468	1	a	DOCA salt treatment after was plays in pathogenesis of hypertension
469	0	a	DOCA salt hypertension of pathogenesis in plays was in rats with insipidus
470	0	a	DOCA salt treatment after was in rats with insipidus
471	0	a	lithium treated insipidus with rats in was plays in pathogenesis of hypertension
472	1	a	lithium treated insipidus
473	1	a	sumatriptan use colitis
474	1	a	sumatriptan with treated report on development of cases of colitis
475	0	a	sumatriptan use after occurring published of vasospasm
476	0	a	sumatriptan use after occurring published of vasospasm ischemia
477	0	a	sumatriptan use after occurring published of vasospasm ischemia infarction
478	0	a	sumatriptan with treated report on development in patients with migraine
479	0	a	dobutamine stress of safety assess echocardiography in evaluation of pain
480	0	a	dobutamine of administration regarding concern Because conducted study assess safety in patients with pain
481	0	a	dobutamine administered to patients with pain
482	1	a	cocaine associated pain
483	1	a	cocaine use of setting in pain
484	1	a	cocaine use of setting in concern Because conducted study assess safety in patients with pain
485	1	a	cocaine associated pain
486	1	a	cocaine used preceding onset of pain
487	1	a	cocaine related pain
488	0	a	Dobutamine stress is test for evaluating ischemia
489	0	a	cocaine toxicity
490	1	a	dobutamine induced ischaemia occurs dysfunction
491	1	a	dobutamine induced results in dysfunction
492	0	a	dobutamine induced ischaemia occurs in patients with disease
493	0	a	dobutamine induced In patients with disease
494	0	a	Dobutamine induced used study in patients with disease
495	0	a	dobutamine induced ischaemia
496	0	a	dobutamine exercise induced ischaemia
497	0	a	dobutamine induced results ischaemia
498	0	a	Dobutamine induced used ischaemia
499	1	a	dobutamine induced results presumed be stunning
500	1	a	Zolmitriptan to secondary syndrome
501	1	a	Zolmitriptan to secondary syndrome syndrome
502	1	a	zolmitriptan to secondary revealed associated with TS
503	0	a	zolmitriptan took had migraines
504	0	a	zolmitriptan taking because headache
505	1	a	zolmitriptan to secondary revealed cases of vasospasm
506	1	a	epirubicin with chemotherapy of result as block
507	1	a	paclitaxel epirubicin with chemotherapy of result as block
508	0	a	Lindane is insecticide with effects neurotoxic
509	0	a	hexachlorocyclohexane Lindane is insecticide with effects neurotoxic
510	1	a	lindane of effect studied by measuring at onset of seizures
511	1	a	lindane administration after min at suffered convulsions
512	0	a	GABA of concentration measuring at onset of seizures
513	0	a	dopamine GABA of concentration measuring at onset of seizures
514	0	a	fumarate to exposed persons in injury
515	0	a	TDF related disease
516	0	a	TDF related disease for criteria had features of dysfunction
517	0	a	TDF related disease for criteria had found have features of dysfunction
518	1	a	TDF kidney effects for hospitalisation of incidence was amongst patients with features of syndrome
519	0	a	Cisplatin Receiving Patients in Toxicity
520	0	a	cisplatin use of complications of One is nephrotoxicity
521	0	a	cisplatin induced nephrotoxicity
522	0	a	cisplatin receiving patients in rates of nephrotoxicity
523	0	a	cisplatin are at risk of nephrotoxicity
524	0	a	Cisplatin Receiving Patients Cancer
525	0	a	cisplatin induced nephrotoxicity of rates in patients cancer
526	0	a	cisplatin receiving patients cancer
527	0	a	cisplatin receiving patients cancer
528	0	a	cisplatin received patients evaluated had as malignancy
529	0	a	mannitol of use including toxicity
530	0	a	mannitol without with receiving patients in rates of nephrotoxicity
531	0	a	mannitol receive Patients were likely develop nephrotoxicity
532	0	a	mannitol of quantities are given at risk of nephrotoxicity
533	0	a	mannitol of addition from benefit are at risk of nephrotoxicity
534	0	a	mannitol without with receiving patients cancer
535	0	a	cisplatin received patients evaluated had cancer
536	0	a	cisplatin are those with hypertension
537	0	a	mannitol of addition from benefit are those with hypertension
538	0	a	busulfan of neurotoxicity
539	0	a	Busulfan known be neurotoxic
540	0	a	Busulfan known remains neurotoxicity
541	0	a	busulfan dose taken was difference in terms of incidence neurotoxicity
542	0	a	busulfan neurotoxicity
543	0	a	busulfan followed by neurotoxicity
544	0	a	busulfan followed by neurotoxicity observed close to incidence neurotoxicity
545	0	a	busulfan receiving before transplantation for tumors
546	0	a	busulfan receiving study excluded tumors
547	1	a	busulfan course of days during seizures
548	0	a	busulfan total dose given had symptoms
549	0	a	clonazepam of infusion with dose given had symptoms
550	0	a	Busulfan levels measured by assay without disease
551	0	a	busulfan under measured by assay without disease
552	0	a	clonazepam with measured by assay without disease
553	0	a	clonazepam by prevented is neurotoxicity
554	1	a	vincristine administration due myeloencephalopathy
555	1	a	Vincristine given producing dysfunction followed by encephalopathy
556	0	a	Vincristine given to child with leukaemia
557	1	a	Vincristine given producing dysfunction
558	1	a	gentamicin by induced nephritis
559	1	a	gentamicin by induced nephritis
560	0	a	gentamicin with treated Animals show areas of fibrosis
561	0	a	paclitaxel of trial phase in cohort with compared Toxicities
562	0	a	Carboplatin appear add to toxicities
563	0	a	carboplatin combination dosed appear add to toxicities
564	1	a	paclitaxel carboplatin combination dosed appear add to toxicities
565	1	a	biperiden due Bradycardia
566	1	a	biperiden by induced Bradycardia
567	0	a	lactate of application led In patient suffering from postzosteric
568	0	a	lactate of application led In patient suffering from postzosteric neuralgia
569	0	a	lactate of application led to reaction characterized by bradycardia
570	0	a	lactate of application led to reaction characterized by bradycardia dysarthria
571	0	a	lactate of application led to reaction characterized by bradycardia dysarthria dysphagia
572	0	a	atropine like drugs of effect to to attributed Bradycardia
573	0	a	muscarine receptors on effect to to attributed Bradycardia
574	1	a	pilocarpine induced status epilepticus
575	1	a	pilocarpine injection by induced epilepticus
576	1	a	pilocarpine injection by induced epilepticus SE
577	1	a	pilocarpine injection by induced SE
578	1	a	pilocarpine induced SE
579	0	a	glycopyrrolate with Treatment of hyperhidrosis
580	0	a	glycopyrrolate applying After was sweating
581	0	a	glycopyrrolate applying After was sweating
582	0	a	glycopyrrolate pad of application appeared method for moderate to symptoms of hyperhidrosis
583	0	a	glycopyrrolate patients in throat mouth
584	0	a	glycopyrrolate patient in headache patients in throat mouth
585	1	a	glycopyrrolate patients in throat
586	1	a	glycopyrrolate patient in headache patients in throat
587	1	a	glycopyrrolate patients headache
588	1	a	glycopyrrolate patient in headache
589	0	a	Viracept warning heartbeat
590	0	a	Viracept inhibitor cause beat
591	1	a	Viracept inhibitor cause beat known as bradycardia
592	1	a	Viracept was patient in occurred Bradycardia
593	1	a	cisplatin receiving patients in manifestation as Hypotension
594	1	a	cisplatin with treated developed hypotension
595	1	a	CDDP cisplatin with treated developed hypotension
596	0	a	cisplatin receiving patients in manifestation of cardiotoxicity
597	0	a	CDDP by influenced cardiotoxicity
598	1	a	5-fluorouracil . Hypotension
599	1	a	5-fluorouracil 5-FU CDDP cisplatin with treated developed hypotension
600	1	a	5-FU CDDP cisplatin with treated developed hypotension
601	0	a	5-fluorouracil . Hypotension as manifestation of cardiotoxicity
602	0	a	5-FU cardiotoxicity
603	0	a	cisplatin with treated developed in patients with carcinoma
604	0	a	CDDP cisplatin with treated developed in patients with carcinoma
605	0	a	5-fluorouracil 5-FU CDDP cisplatin with treated developed in patients with carcinoma
606	0	a	5-FU CDDP cisplatin with treated developed in patients with carcinoma
607	1	a	Sotalol induced spasm
608	1	a	sotalol of properties by induced vasospasm
609	0	a	Sotalol induced spasm in patient with cardiomyopathy
610	0	a	Sotalol induced spasm in patient with cardiomyopathy associated with tachycardia
611	0	a	sotalol agent was effective for prevention of VT
612	0	a	hydrochloride of administration terminated VT
613	0	a	phenylephrine induced hypertension of effect ischemia
614	1	a	phenylephrine induced hypertension
615	1	a	phenylephrine induced hypertension of effect determined After min of occlusion in rats hypertensive
616	1	a	phenylephrine induced hypertension
617	0	a	phenylephrine induced hypertension of effect determined After min of occlusion
618	0	a	phenylephrine induced hypertension on injury
619	0	a	chloride using tissue by evaluated A for rats in injury
620	0	a	chloride edema
621	0	a	Blue was in group HTN
622	0	a	Blue was in group versus group was in turn greater than group HTN
623	0	a	ethambutol overtreatment due Optochiasmatic neuropathy
624	1	a	Ethambutol known cause neuropathy
625	1	a	Ethambutol known cause polyneuropathy
626	1	a	ethambutol of dose to exposure of weeks after developed loss
627	1	a	ethambutol of dose to exposure of weeks after developed loss paresthesias
628	0	a	ethambutol toxicity
629	0	a	carbamazepine with associated nystagmus
630	0	a	carbamazepine therapy to related nystagmus
631	0	a	carbamazepine levels of reduction after resolved nystagmus
632	1	a	carbamazepine with associated nystagmus oscillopsia
633	0	a	Glucose in patients with schizophrenia
634	0	a	glucose tolerance test Glucose in patients with schizophrenia
635	0	a	glucose metabolism affecting remains increasing in patients with schizophrenia
636	0	a	glucose tolerance test using evaluated patients with schizophrenia
637	0	a	glucose metabolism affecting remains increasing mellitus
638	0	a	glucose metabolism increasing factors for diabetes
639	0	a	clozapine with treated matched subjects with schizophrenia
640	0	a	clozapine with treated matched subjects with schizophrenia disorder
641	0	a	olanzapine clozapine with treated matched subjects with schizophrenia
642	0	a	olanzapine clozapine with treated matched subjects with schizophrenia disorder
643	0	a	risperidone olanzapine clozapine with treated matched subjects with schizophrenia
644	0	a	risperidone olanzapine clozapine with treated matched subjects with schizophrenia disorder
645	0	a	glucose fasting levels index sensitivity
646	0	a	glucose fasting levels index assessment of resistance
647	0	a	glucose Fasting glucose fasting levels index sensitivity
648	0	a	glucose Fasting glucose fasting levels index assessment of resistance
649	0	a	glucose effectiveness of resistance
650	1	a	clozapine risperidone P<.001 with subjects received exhibiting resistance
651	1	a	clozapine received exhibiting resistance
652	1	a	clozapine risperidone with treated subjects with compared received exhibiting resistance
653	1	a	clozapine- nonobese groups displayed resistance
654	1	a	clozapine taking Patients examined for resistance
655	1	a	olanzapine risperidone P<.001 with subjects received exhibiting resistance
656	1	a	olanzapine clozapine received exhibiting resistance
657	1	a	olanzapine treated groups displayed resistance
658	1	a	olanzapine clozapine taking Patients examined for resistance
659	0	a	risperidone P<.001 with subjects received exhibiting resistance
660	0	a	risperidone with treated subjects with compared received exhibiting resistance
661	0	a	risperidone vs clozapine risperidone with treated subjects with compared received exhibiting resistance
662	0	a	risperidone treated subjects with compared displayed resistance
663	1	a	nicotine induced seizures
664	1	a	nicotine induced seizures
665	1	a	nicotine of effects to sensitive Mice had binding than mice seizure
666	0	a	dithiothreitol with treatment by affected sites from mice sensitive seizure
667	0	a	aminonucleoside nephrosis with rats in sclerosis
668	0	a	aminonucleoside model studied relationship between dysfunction
669	0	a	aminonucleoside model studied relationship between dysfunction of sclerosis
670	0	a	PAN model studied relationship between dysfunction
671	0	a	PAN model studied relationship between dysfunction of sclerosis
672	0	a	PAN rats of glomeruli of % in found sclerosis
673	0	a	PAN nephrosis in model to Similar related development of sclerosis
674	0	a	aminonucleoside nephrosis
675	0	a	PAN nephrosis
676	1	a	PAN rats were proteinuric
677	0	a	carbon given were proteinuric
678	0	a	PAN treatment during change conclude caused in areas develop sclerosis
679	1	a	melphalan after insufficiency
680	1	a	melphalan conditioning after development of insufficiency
681	1	a	melphalan after insufficiency
682	1	a	melphalan after insufficiency ARI
683	1	a	melphalan after developed ARI
684	1	a	melphalan after had ARI
685	1	a	melphalan suggests timing of injury
686	1	a	melphalan by injury
687	0	a	melphalan after insufficiency in patients with amyloidosis
688	0	a	creatinine level in increase by defined insufficiency
689	0	a	creatinine level in increase by defined insufficiency ARI
690	0	a	melphalan by injury for prerequisite be injury
691	0	a	Serotonin inhibitors paranoia
692	0	a	serotonin inhibitors with exacerbation paranoid
693	0	a	serotonin inhibitors with associated exacerbations paranoid
694	0	a	serotonin blockers with exacerbations paranoid
695	0	a	serotonin blockers with exacerbations to call raise considerations regarding paranoia
696	1	a	fluoxetine inhibitors with exacerbation paranoid
697	1	a	amitriptyline fluoxetine inhibitors with exacerbation paranoid
698	0	a	serotonin inhibitors with associated exacerbations to vulnerability present disorders
699	0	a	serotonin inhibitors with associated exacerbations to vulnerability present disorders including atypicality chronicity psychosis
700	0	a	serotonin inhibitors with associated exacerbations to vulnerability present disorders in course of psychosis
701	0	a	dopamine release including mechanisms remain pharmacology of paranoia
702	1	a	picrotoxin induced seizures
703	1	a	picrotoxin by induced seizures
704	1	a	picrotoxin induced seizures
705	0	a	cholecystokinin by antagonism of seizures
706	0	a	cholecystokinin of fragments cholecystokinin by antagonism of seizures
707	0	a	CCK-8-NS enhanced latency of seizures
708	0	a	diazepam drug of doses kg octapeptides to comparison in had prevented seizures
709	0	a	dexamethasone with mice of Treatment led loss of cells ganglion
710	1	a	dexamethasone with mice of Treatment led loss degeneration
711	1	a	dexamethasone with mice of Treatment led resembling glaucoma
712	1	a	dexamethasone induced hypertension
713	1	a	Dexamethasone induced reduced prevented hypertension
714	1	a	dexamethasone induced hypertension
715	1	a	dexamethasone induced hypertension
716	0	a	4-phenylbutyrate with reduction prevented hypertension
717	0	a	Levetiracetam as adjunct to treatment in cats with epilepsy
718	0	a	levetiracetam of efficacy pharmacokinetics assess administered as adjunct to treatment in cats with epilepsy
719	0	a	levetiracetam tolerated be useful as adjunct to treatment in cats with epilepsy
720	0	a	phenobarbital treatment in cats with epilepsy
721	0	a	phenobarbital treatment in cats with epilepsy
722	0	a	phenobarbital with controlled epilepsy
723	0	a	phenobarbital with treated had controlled epilepsy
724	0	a	phenobarbital treatment in cats with epilepsy
725	0	a	levetiracetam treatment of initiation after before frequencies Seizure
726	0	a	levetiracetam with treatment to prior frequency seizure
727	0	a	levetiracetam treatment of initiation after was seizures
728	0	a	levetiracetam treatment of initiation after was higher than frequency seizure
729	0	a	levetiracetam treatment of initiation after was seizures
730	0	a	levetiracetam treatment of initiation after was seizures reduction in frequency seizure
731	0	a	levetiracetam responded as classified seizures was seizures
732	0	a	levetiracetam responded as classified seizures was higher than frequency seizure
733	0	a	levetiracetam responded as classified seizures
734	0	a	levetiracetam responded as classified seizures reduction in frequency seizure
735	1	a	S-23121 are herbicides embryolethality
736	1	a	S-23121 of administration resulted in incidence of death
737	1	a	S-23121 to exposure following observed resulted in incidence of death
738	1	a	S-23121 are herbicides embryolethality teratogenicity
739	1	a	S-23121 were teratogenic
740	1	a	S-23121 are herbicides embryolethality teratogenicity defects
741	1	a	S-23121 of administration resulted in incidence of death defect
742	1	a	S-23121 to exposure following observed resulted in incidence of death defect
743	1	a	S-23121 are herbicides embryolethality teratogenicity defects retardation
744	0	a	S-23121 are herbicides embryolethality teratogenicity defects in rats in studies toxicity
745	0	a	S-53482 to exposure at patterns of toxicity
746	0	a	Salicylate nephropathy
747	0	a	prostaglandins of role nephropathy
748	0	a	prostaglandins of role in development of nephropathy
749	0	a	prostaglandin synthesis in changes accompanied by evidence of damage
750	0	a	prostaglandin synthesis contributes lead to lesions deterioration of function
751	0	a	prostaglandin synthesis of inhibition lead to lesions deterioration of function
752	0	a	glucuronyl transferase of absence due have hyperbilirubinemia
753	0	a	bilirubin deposition to leading have hyperbilirubinemia
754	0	a	prostaglandin synthesis in changes accompanied by evidence rats evidenced by incidence of hematuria
755	1	a	aspirin treated jj in damage
756	1	a	aspirin treated jJ jj to compared increase creatinine rats evidence of damage
757	0	a	aspirin treated jj in damage of evidence rats evidenced by incidence of hematuria
758	0	a	aspirin treated jJ jj to compared increase creatinine rats evidenced by incidence of hematuria
759	0	a	creatinine rats evidence of damage
760	0	a	creatinine rats evidenced by incidence of hematuria
761	0	a	prostaglandin synthesis contributes lead to lesions
762	0	a	prostaglandin synthesis of inhibition lead to lesions
763	1	a	Heparin induced thrombocytopenia
764	1	a	Heparin induced thrombocytopenia
765	1	a	Heparin induced thrombocytopenia HIT
766	1	a	heparin exposure after occurs suspected acknowledged HIT
767	1	a	heparin exposure of cessation treatment of mandates HIT
768	1	a	heparin in patients with history of HIT
769	1	a	heparin remains with potential for HIT
770	1	a	heparin exposure with HIT
771	1	a	heparin initiated practiced remains with potential for HIT
772	1	a	heparin exposure after occurs suspected acknowledged for predilection for thrombosis
773	1	a	heparin exposure after occurs thrombosis
774	0	a	inhibitor using cessation treatment of mandates HIT
775	0	a	inhibitors are alternatives heparin in patients with history of HIT
776	1	a	X group had incidence of nausea
777	1	a	X group had incidence of nausea dizziness
778	1	a	Endografine group had incidence of pain
779	0	a	Hexabrix polyvidone considered preferred because Hexabrix toxicity
780	0	a	Hexabrix toxicity
781	0	a	polyvidone considered preferred because Hexabrix toxicity
782	0	a	media considered preferred because Hexabrix toxicity
783	1	a	contrast induced nephropathy
784	1	a	contrast induced nephropathy
785	1	a	Contrast induced nephropathy
786	0	a	contrast induced nephropathy in patients with cancer
787	0	a	contrast induced nephropathy to related in patients with cancer
788	0	a	bevacizumab irinotecan with treatment after in patients with hypertension
789	0	a	bevacizumab irinotecan of combination Hypertension
790	0	a	bevacizumab with treatment Hypertension
791	0	a	irinotecan with treatment after in patients with hypertension
792	0	a	irinotecan of combination Hypertension
793	1	a	Penicillamine related dermatitis
794	1	a	penicillamine interrupted after appearance of dermatitis
795	0	a	Penicillamine related dermatitis in patient disease
796	0	a	penicillamine related effects appeared patient disease
797	0	a	penicillamine treated patients disease
798	0	a	Penicillamine related dermatitis in patient with presentation abnormalities anxiety
799	0	a	acetate of utility dermatitis
800	0	a	acetate permitted interrupted after appearance of dermatitis
801	0	a	acetate of utility dermatitis in patient disease
802	0	a	acetate with therapy represented treatment for patient disease
803	0	a	acetate of safety allowed is in line with evidence on efficacy in treatment of disease
804	0	a	acetate of utility dermatitis in patient with presentation abnormalities anxiety
805	0	a	copper metabolism of disorder is disease
806	0	a	copper accumulation with disorder is disease
807	0	a	copper metabolism of disorder with accumulation toxicity
808	0	a	copper accumulation toxicity
809	0	a	copper metabolism of disorder in tissues disorders
810	0	a	copper accumulation with disorder in tissues disorders
811	0	a	copper metabolism of disorder in tissues disorders
812	0	a	copper accumulation with disorder in tissues disorders
813	0	a	copper metabolism of disorder in tissues disorders
814	0	a	copper accumulation with disorder in tissues disorders
815	0	a	penicillamine treated patients of most seem develop lesion
816	0	a	guanethidine of injection by reduced hexamethonium potentiated inhibited enlargement of pressure
817	0	a	guanethidine of injection by reduced hexamethonium potentiated inhibited enlargement tachycardia
818	0	a	hexamethonium potentiated inhibited enlargement of pressure
819	0	a	hexamethonium potentiated inhibited enlargement tachycardia
820	0	a	phentolamine hexamethonium potentiated inhibited enlargement of pressure
821	0	a	phentolamine hexamethonium potentiated inhibited enlargement tachycardia
822	1	a	desmethylimipramine by potentiated inhibited enlargement of pressure
823	0	a	desmethylimipramine by potentiated inhibited enlargement tachycardia
824	0	a	propranolol inhibited enlargement of pressure
825	0	a	propranolol inhibited enlargement tachycardia
826	1	a	carbachol following inhibited enlargement of pressure
827	1	a	carbachol following inhibited enlargement tachycardia
828	0	a	carbamazepine therapy by induced Asterixis
829	0	a	carbamazepine adding by triggered asterixis
830	0	a	CBZ carbamazepine adding by triggered asterixis
831	0	a	CBZ with combination in used consider be asterixis
832	1	a	lithium as drugs used consider be asterixis
833	0	a	lithium as drugs used consider be sign of neurotoxicity
834	1	a	clozapine lithium as drugs used consider be asterixis
835	0	a	clozapine lithium as drugs used consider be sign of neurotoxicity
836	0	a	CBZ with combination in used consider be sign of neurotoxicity
837	0	a	salbutamol in asthmatics
838	0	a	salbutamol of doses produce improvements in response in patients with asthma
839	0	a	salbutamol with treatment given predicted patients asthmatic
840	0	a	salbutamol treatment given predicted patients asthmatic
841	0	a	K Glu ) metabolic tremor
842	0	a	Glu ) metabolic tremor
843	0	a	propofol remifentanil anesthesia by induced anesthesia maintaining in using compare conditions including amount of bleeding
844	1	a	propofol remifentanil anesthesia by induced anesthesia hypotension
845	1	a	propofol remifentanil TIVA by caused anesthesia hypotension
846	0	a	remifentanil anesthesia by induced anesthesia maintaining in using compare conditions including amount of bleeding
847	1	a	remifentanil anesthesia by induced anesthesia hypotension
848	1	a	remifentanil TIVA by caused anesthesia hypotension
849	1	a	remifentanil infusion of rates using using period within achieved hypotension
850	1	a	remifentanil of dose infusion of rates using using period within achieved hypotension
851	1	a	remifentanil of doses with hypotension for allowed provided anesthesia hypotension
852	1	a	remifentanil of doses with hypotension
853	1	a	misoprostol of administration with associated woman in Delirium
854	1	a	misoprostol discontinued improved delirium
855	1	a	misoprostol therapy from resulted delirium
856	0	a	Misoprostol associated with reactions including symptoms problems headache
857	0	a	denopamine of failure
858	0	a	TA-064 ) denopamine of failure
859	0	a	denopamine of efficacy in improving failure
860	0	a	denopamine of trials warrant in treatment of failure
861	1	a	pentobarbital induced failure
862	0	a	denopamine of doses by induced arrhythmias
863	0	a	isoproterenol of effect cardiotoxic
864	0	a	isoproterenol of doses of effect cardiotoxic
865	0	a	ISO isoproterenol of doses of effect cardiotoxic
866	0	a	isoproterenol in rats diabetic
867	0	a	isoproterenol of doses of effect against diabetes
868	0	a	ISO isoproterenol of doses of effect against diabetes
869	0	a	ISO resistance towards effect on sensitivity in rats diabetic
870	0	a	streptozotocin rats in isoproterenol of effect cardiotoxic
871	0	a	streptozotocin diabetes against effect cardiotoxic
872	1	a	streptozotocin rats diabetic
873	1	a	streptozotocin diabetes
874	1	a	streptozotocin causes resistance towards effect on sensitivity in rats diabetic
875	1	a	isoproterenol of study induced fibrosis
876	1	a	ISO given analyzed fibrosis
877	1	a	ISO induced analyzed fibrosis
878	0	a	glucose in fall of slope to correlation analyzed fibrosis
879	0	a	catecholamines of content estimated in rats diabetic
880	0	a	catecholamine sensitivity in rats diabetic
881	0	a	bepridil administration for fibrillation flutter
882	0	a	hydrochloride attracted as drug for fibrillation
883	0	a	hydrochloride attracted as drug for fibrillation AF
884	0	a	Bpd hydrochloride attracted as drug for fibrillation
885	0	a	Bpd hydrochloride attracted as drug for fibrillation AF
886	0	a	Bpd administered to patients comprising AF
887	0	a	bepridil administration for fibrillation flutter
888	0	a	hydrochloride attracted as drug flutter
889	0	a	hydrochloride attracted as drug flutter AFL
890	0	a	Bpd hydrochloride attracted as drug flutter
891	0	a	Bpd hydrochloride attracted as drug flutter AFL
892	0	a	Bpd administered to patients comprising AF cases AFL
893	1	a	Indomethacin induced hypotension
894	0	a	sodium in hypotension
895	0	a	ketoconazole by induced syndrome
896	0	a	ketoconazole to sensitivity included history on based syndrome
897	0	a	ketoconazole induced syndrome
898	1	a	ketoconazole using after presented with eruption
899	1	a	fenfluramines had association with PPH
900	1	a	fenfluramines for specificity increase magnitude of association with PPH
901	1	a	fenfluramines for specificity increase magnitude are consistent with studies indicating are related to PPH
902	1	a	fenfluramines are indicating studies with consistent are magnitude of association with PPH
903	1	a	fenfluramines are related to PPH
904	0	a	organophosphate diazinon to exposed applicators among tumours
905	0	a	organophosphate insecticide Diazinon associated examined risk cancer
906	0	a	diazinon to exposed applicators among tumours
907	0	a	Diazinon associated examined risk cancer
908	0	a	diazinon associated risk cancer
909	0	a	diazinon exposure information incidence cancer
910	0	a	diazinon exposure used evaluate risk tumour
911	0	a	diazinon use reported assessed incidence cancer
912	1	a	Diazinon associated with cancer
913	1	a	diazinon associated risk examined associated with cancer
914	1	a	diazinon use of days observed risks cancer
915	1	a	diazinon of evaluation provides evidence of association with risk cancer
916	0	a	organophosphate insecticide Diazinon associated with cancer
917	1	a	dobutamine treatment during tachycardia pointes
918	1	a	dobutamine of cycle during developed prolongation tachycardia ventricular pointes
919	1	a	dobutamine during report of tachycardia pointes
920	0	a	dobutamine treatment during tachycardia
921	0	a	dobutamine of cycle during developed prolongation tachycardia
922	0	a	dobutamine during report of tachycardia
923	0	a	dobutamine treatment in patient with cardiomyopathy
924	0	a	dobutamine of cycle during developed arrhythmias of absence cardiomyopathy
925	0	a	dobutamine treatment in patient with cardiomyopathy failure
926	0	a	dobutamine of cycle during developed arrhythmias of absence cardiomyopathy to secondary failure
927	0	a	dobutamine of cycle during developed arrhythmias
928	0	a	dobutamine during report supports hypothesis occur arrhythmias
929	0	a	dobutamine of cycle during developed prolongation
930	0	a	asparaginase including chemotherapy after encephalopathy
931	1	a	asparaginase including chemotherapy after encephalopathy vasospasm
932	0	a	asparaginase including chemotherapy for treatment of leukemia
933	0	a	cytarabine asparaginase including chemotherapy after encephalopathy
934	0	a	cytarabine of administration after evidenced encephalopathy
935	1	a	cytarabine asparaginase including chemotherapy after encephalopathy vasospasm
936	1	a	cytarabine of administration after evidenced with vasospasm
937	0	a	cytarabine asparaginase including chemotherapy for treatment of leukemia
938	1	a	cytarabine of administration after evidenced by changes aphasia
939	1	a	cytarabine of administration after evidenced by changes aphasia incontinence
940	1	a	cytarabine of administration after evidenced by changes aphasia incontinence hallucinations
941	1	a	cytarabine of administration after evidenced by changes aphasia incontinence hallucinations weakness
942	1	a	Ozone Concentrations With Disease
943	1	a	ozone matter of associations with disease
944	1	a	ozone with disease
945	1	a	matter of associations with disease
946	1	a	matter CI associations of disease
947	0	a	chloride of effects in prevention of nephropathy
948	0	a	diltiazem with effects in prevention of nephropathy
949	0	a	contrast induced nephropathy
950	0	a	Contrast induced nephropathy
951	1	a	contrast material injected day on developed failure
952	1	a	contrast material injected day on developed failure ARF
953	0	a	alkylxanthines on failure
954	0	a	alkylxanthines of effects examined in rats developing failure
955	0	a	alkylxanthines with noted indicates plays role in ARF
956	1	a	gentamicin induced failure
957	1	a	gentamicin of injections after examined in rats developing failure
958	1	a	gentamicin induced ARF
959	0	a	Adenosine antagonists shown be in models ischaemic
960	0	a	Adenosine antagonists shown be in models ischaemic nephrotoxic
961	0	a	Adenosine antagonists shown be in models of failure
962	0	a	Adenosine antagonists shown be in models of failure ARF
963	0	a	adenosine antagonists as potencies with alkylxanthines of effects examined in rats developing failure
964	0	a	adenosine plays role in ARF
965	0	a	8-phenyltheophylline antagonists as potencies with alkylxanthines of effects examined in rats developing failure
966	0	a	theophylline 8-phenyltheophylline antagonists as potencies with alkylxanthines of effects examined in rats developing failure
967	0	a	enprofylline theophylline 8-phenyltheophylline antagonists as potencies with alkylxanthines of effects examined in rats developing failure
968	0	a	urea by assessed function analysis degree of indices necrosis
969	0	a	creatinine urea by assessed function analysis degree of indices necrosis
970	0	a	acid clearances 3H]inulin analysis degree of indices necrosis
971	1	a	Propylthiouracil induced damage
972	1	a	propylthiouracil induced damage
973	1	a	cocaine associated pain
974	1	a	cocaine associated pain
975	1	a	cocaine associated pain
976	1	a	cocaine associated pain
977	1	a	cocaine associated pain
978	1	a	cocaine associated ischemia result discharged patients with pain
979	1	a	cocaine pain
980	0	a	cocaine associated pain with presenting patients admitted receive protocol syndrome
981	0	a	cocaine associated pain in efficacious be account vasospasm
982	0	a	cocaine associated pain in efficacious be account for some of ischemia
983	0	a	cocaine associated ischemia result discharged patients with pain ECG ischemic
984	0	a	cocaine pain ECG ischemic
985	1	a	cocaine associated ischemia
986	1	a	cocaine pain with patients discharged result ischemia
987	1	a	cocaine exposure findings in infants
988	1	a	cocaine exposure increases incidence in infants
989	1	a	cocaine to exposed infants
990	0	a	cocaine exposure linked with hemorrhage
991	1	a	cocaine exposure linked with hemorrhage formation of cysts
992	1	a	cocaine exposure increases incidence of cysts
993	1	a	cocaine to exposed infants in cysts
994	1	a	cocaine to exposed infants in formation cyst
995	1	a	cocaine exposure increases incidence of cysts
996	1	a	cocaine to exposed infants in cysts
997	1	a	cocaine to exposed infants in formation cyst
998	0	a	cocaine exposed group to assigned was history of abuse
999	0	a	acetate on seizures
1000	0	a	093 acetate on seizures
1001	0	a	acetate on model elicited seizures
1002	0	a	acetate on model elicited without changes in patterns threshold seizure
1003	1	a	picrotoxin of microperfusion by induced seizures
1004	1	a	picrotoxin of doses with treated animals In was number of seizures
1005	1	a	picrotoxin of doses with treated animals In was was duration seizure
1006	1	a	picrotoxin microperfusion prevented seizures
1007	1	a	levodopa of effect hypotensive
1008	1	a	levodopa of effect hypotensive
1009	1	a	levodopa with competing amino Phenylalanine reduced effects hypotensive
1010	1	a	levodopa of effects hypotensive
1011	1	a	levodopa has action hypotensive
1012	0	a	levodopa of effect in patients parkinsonian
1013	0	a	levodopa of effects examined in patients parkinsonian
1014	0	a	levodopa to responses with examined in patients parkinsonian
1015	0	a	Phenylalanine reduced effects hypotensive
1016	0	a	acid amino Phenylalanine reduced effects hypotensive
1017	1	a	phenobarbital administration after ablation in results in proliferation hepatomegaly
1018	0	a	Temocapril modulates injury
1019	0	a	Temocapril modulates injury in nephrosis
1020	0	a	temocapril was effective in retarding protected function in rats neprotic
1021	0	a	angiotensin Temocapril modulates injury
1022	0	a	angiotensin Temocapril modulates injury in nephrosis
1023	0	a	aminonucleoside nephrosis in injury
1024	1	a	aminonucleoside nephrosis
1025	1	a	PAN of injection by induced Nephrosis
1026	1	a	PAN rats neprotic
1027	0	a	temocapril of administration inhibitor proteinuria
1028	0	a	Temocapril attenuate proteinuria
1029	0	a	temocapril of administration inhibitor proteinuria hypertrophy
1030	0	a	temocapril of administration prevented glomerulosclerosis
1031	0	a	temocapril of administration prevented rats nephrotic
1032	0	a	angiotensin acting inhibitor proteinuria
1033	0	a	angiotensin acting inhibitor proteinuria hypertrophy
1034	0	a	angiotensin acting inhibitor administration prevented glomerulosclerosis
1035	0	a	angiotensin acting inhibitor administration prevented rats nephrotic
1036	1	a	aminonucleoside rats prevented administration inhibitor proteinuria
1037	1	a	PAN induced rats prevented administration inhibitor proteinuria
1038	0	a	aminonucleoside rats prevented administration inhibitor proteinuria hypertrophy
1039	0	a	PAN induced rats prevented administration inhibitor proteinuria hypertrophy
1040	0	a	aminonucleoside rats prevented glomerulosclerosis
1041	0	a	PAN induced rats prevented glomerulosclerosis
1042	0	a	PAN group in weeks at was index glomerulosclerosis
1043	0	a	aminonucleoside rats nephrotic
1044	0	a	PAN induced rats nephrotic
1045	1	a	oxide deficiency by induced Mechanisms of hypertension
1046	1	a	NO deficiency by induced Mechanisms of hypertension
1047	1	a	oxide of Loss in hypertension
1048	1	a	NO Loss in hypertension
1049	1	a	NO of removal by created hypertension
1050	1	a	NO deficiency increases make contribution to form of hypertension
1051	0	a	oxide of Loss is hallmark of dysfunction
1052	0	a	NO Loss is hallmark of dysfunction
1053	0	a	arginine hypertension
1054	0	a	LNNA hypertension
1055	0	a	LNNA hypertension
1056	0	a	LNNA after elevated in hypertension
1057	0	a	LNNA rats hypertensive
1058	0	a	hexamethonium with blockade caused fall in rats hypertensive
1059	0	a	Nelarabine neurotoxicity
1060	0	a	nelarabine neurotoxicity
1061	0	a	nelarabine by caused neurotoxicity
1062	0	a	levobupivacaine of administration following toxicity
1063	1	a	levobupivacaine of injection following describe cases of seizures
1064	1	a	levobupivacaine of administration after developed seizures
1065	0	a	epinephrine with levobupivacaine of administration after developed seizures
1066	0	a	epinephrine administration of signs aspiration despite developed seizures
1067	0	a	thiopental with treated seizures
1068	0	a	succinylcholine to addition in treated seizures
1069	0	a	levobupivacaine have profile toxicity
1070	0	a	levobupivacaine of amounts reach result have profile toxicity
1071	0	a	levobupivacaine have result in convulsions
1072	0	a	levobupivacaine of amounts reach result in convulsions
1073	0	a	bupivacaine than profile toxicity
1074	0	a	bupivacaine than profile have result in convulsions
1075	0	a	dopa treatment in patients parkinsonian
1076	0	a	dopa treated patients parkinsonian
1077	1	a	dopa treated patients in observed Hypokalemia
1078	1	a	dopa of influence studied with hypokalemia
1079	0	a	potassium of excretion on influence studied with hypokalemia
1080	0	a	potassium of concentration rate influence studied with hypokalemia
1081	0	a	potassium of excretion concentration rate influence studied with hypokalemia
1082	0	a	sodium potassium of concentration rate influence studied with hypokalemia
1083	0	a	sodium potassium of excretion concentration rate influence studied with hypokalemia
1084	0	a	aldosterone sodium potassium of excretion concentration rate influence studied with hypokalemia
1085	1	a	Meloxicam induced toxicity
1086	1	a	meloxicam to due developed hepatitis
1087	1	a	meloxicam administration after occurred hepatitis
1088	1	a	meloxicam toxicity
1089	1	a	meloxicam toxicity of case demonstrates induce damage
1090	0	a	meloxicam to due developed patient with arthritis
1091	1	a	meloxicam administration after occurred associated with development of antibodies suggesting mechanism hypersensitivity
1092	1	a	clopidogrel with associated hepatitis
1093	1	a	clopidogrel related hepatitis
1094	1	a	clopidogrel due hepatotoxicity
1095	1	a	clopidogrel prescribed injury
1096	1	a	pilocarpine by produced seizures
1097	1	a	pilocarpine induces in seizures
1098	1	a	pilocarpine by produced seizures
1099	1	a	pilocarpine by produced seizures
1100	1	a	pilocarpine by induced damage from protected prevented seizures
1101	1	a	pilocarpine by induced damage related seizure
1102	1	a	pilocarpine induced seizures
1103	1	a	pilocarpine induces epilepticus
1104	1	a	salicylate drugs of effect investigate on seizures
1105	1	a	phenylbutazone salicylate drugs of effect investigate on seizures
1106	0	a	indomethacin phenylbutazone salicylate drugs of effect investigate on seizures
1107	0	a	Indomethacin failed modulate seizures
1108	0	a	ibuprofen indomethacin phenylbutazone salicylate drugs of effect investigate on seizures
1109	0	a	ibuprofen failed modulate seizures
1110	0	a	acid ibuprofen indomethacin phenylbutazone salicylate drugs of effect investigate on seizures
1111	0	a	acid prevented seizures
1112	0	a	acid prevented protected from damage related seizure
1113	0	a	acid prevented protected from damage
1114	0	a	pilocarpine by induced damage
1115	1	a	doxorubicin of doses with treatment after stress on cardiotoxicity
1116	1	a	doxorubicin of mechanism remains cardiotoxicity
1117	1	a	DOX)-induced cardiotoxicity
1118	1	a	DOX of dose by induced cardiotoxicity
1119	0	a	DOX of dose associated with disarrangement
1120	1	a	DOX of dose associated with disarrangement necrosis
1121	1	a	suxamethonium pains
1122	1	a	scoline pain
1123	1	a	scoline pain
1124	1	a	scoline pain
1125	1	a	suxamethonium of preparation type affected incidence of pain
1126	1	a	scoline pain
1127	0	a	Fazadinium of dose by abolition of fasciculations
1128	0	a	Fazadinium of dose by abolition influence occurrence of pain
1129	1	a	scoline pain of occurrence influence abolition of fasciculations
1130	0	a	Althesin agent of type affected incidence of pain
1131	0	a	Thiopentone Althesin agent of type affected incidence of pain
1132	0	a	chloride suxamethonium of preparation type affected incidence of pain
1133	0	a	bromide chloride suxamethonium of preparation type affected incidence of pain
1134	0	a	aminophenol of role in nephrotoxicity
1135	0	a	aminophenol of role effect of phosphate nephrotoxicity
1136	0	a	aminophenol nephrotoxicity phosphate of effect role in nephrotoxicity
1137	0	a	aminophenol nephrotoxicity
1138	0	a	PAP formation is step in nephrotoxicity
1139	0	a	PAP nephrotoxicity
1140	0	a	PAP administration APAP to prior Pretreatment resulted in reduction of APAP nephrotoxicity
1141	0	a	PAP administration APAP to prior Pretreatment resulted in reduction of APAP nephrotoxicity nephrotoxicity
1142	0	a	PAP nephrotoxicity nephrotoxicity
1143	0	a	PAP nephrotoxicity
1144	0	a	acetaminophen induced nephrotoxicity
1145	0	a	acetaminophen induced nephrotoxicity in role effect of phosphate nephrotoxicity
1146	0	a	acetaminophen on phosphate of effect role in nephrotoxicity
1147	0	a	acetaminophen on phosphate nephrotoxicity
1148	0	a	APAP induced nephrotoxicity
1149	0	a	APAP nephrotoxicity
1150	0	a	APAP to prior Pretreatment resulted in reduction of APAP nephrotoxicity
1151	0	a	APAP to prior Pretreatment resulted in reduction of APAP nephrotoxicity nephrotoxicity
1152	0	a	APAP nephrotoxicity
1153	0	a	APAP nephrotoxicity nephrotoxicity
1154	0	a	APAP induced nephrotoxicity
1155	0	a	APAP deacetylation of inhibition to due be appears reduction in nephrotoxicity
1156	0	a	phosphate of effect role in nephrotoxicity
1157	0	a	phosphate nephrotoxicity
1158	0	a	phosphate on APAP nephrotoxicity
1159	0	a	BNPP phosphate on APAP nephrotoxicity
1160	0	a	BNPP with animals of Pretreatment resulted in reduction of APAP nephrotoxicity
1161	0	a	BNPP with animals of Pretreatment resulted in reduction of APAP nephrotoxicity nephrotoxicity
1162	0	a	BNPP induced reduction in nephrotoxicity
1163	1	a	Acetaminophen produces necrosis
1164	1	a	APAP Acetaminophen produces necrosis
1165	1	a	APAP induced necrosis
1166	1	a	PAP formation accounts for necrosis
1167	1	a	tetrabenazine with therapy by induced syndrome
1168	1	a	tetrabenazine initiation after occurred woman with syndrome
1169	1	a	tetrabenazine with therapy due occurrence of syndrome
1170	0	a	tetrabenazine with therapy by induced in patient with disease
1171	0	a	tetrabenazine initiation for disease
1172	0	a	tetrabenazine with therapy by induced in patient with disease at stage of cancer
1173	1	a	tiapride tetrabenazine with therapy by induced syndrome
1174	1	a	tiapride with therapy of initiation after occurred woman with syndrome
1175	1	a	tiapride tetrabenazine with therapy due occurrence of syndrome
1176	0	a	tiapride tetrabenazine with therapy by induced in patient with disease
1177	0	a	tiapride with therapy of initiation for disease
1178	0	a	tiapride tetrabenazine with therapy by induced in patient with disease at stage of cancer
1179	0	a	thiabendazole administration after injury
1180	0	a	thiabendazole to exposure after developed jaundice
1181	0	a	levodopa effects in patients disease
1182	0	a	Levodopa is therapy for disease
1183	1	a	Levodopa is lead to outcomes as fluctuations dyskinesia
1184	1	a	Levodopa is lead to outcomes as fluctuations dyskinesia hallucinations
1185	0	a	HA with alteration to leading changes are factor in cardiotoxicity
1186	1	a	doxorubicin cardiotoxicity
1187	0	a	metformin with treatment suppresses attenuates dysfunction
1188	0	a	metformin of kg with treated groups in was dysfunction
1189	0	a	metformin with treatment suppresses attenuates dysfunction following infarction
1190	0	a	metformin with treatment has effect in infarction
1191	0	a	metformin with treatment of effect activities following infarction
1192	0	a	metformin with treatment reduces dysfunction infarction
1193	0	a	AMP activated kinase of activation due has effect in infarction
1194	0	a	metformin with treatment on dysfunction
1195	1	a	Isoproterenol injected induce infarction
1196	0	a	isoproterenol induced elevation protein factor necrosis tumor
1197	0	a	isoproterenol induced elevation protein factor necrosis
1198	1	a	ibuprofen prophylaxis after hypertension
1199	1	a	ibuprofen administration after report cases of hypoxaemia
1200	1	a	ibuprofen with trial during administration after report cases of hypoxaemia
1201	1	a	ibuprofen of administration after occurs hypoxaemia
1202	0	a	ibuprofen administration during trial of treatment of arteriosus
1203	0	a	ibuprofen with trial of treatment of arteriosus
1204	0	a	oxide therapy on resolved Hypoxaemia
1205	1	a	Linezolid induced neuropathy
1206	0	a	linezolid therapy with associated vision
1207	0	a	linezolid including drugs with treatment on was patient presented with loss of vision
1208	0	a	linezolid ethambutol for tuberculosis
1209	0	a	linezolid ethambutol for tuberculosis TB
1210	0	a	ethambutol for tuberculosis
1211	0	a	ethambutol for tuberculosis TB
1212	0	a	ethambutol linezolid including drugs with treatment on was patient presented with loss of vision
1213	0	a	Ethambutol induced neuropathy
1214	0	a	ethambutol withdrawn suspected neuropathy
1215	0	a	ethambutol of withdrawal despite occurred Deterioration of vision
1216	0	a	adriamycin nephropathy
1217	0	a	adriamycin with slowing progression disease
1218	0	a	adriamycin nephropathy
1219	0	a	ADR nephropathy adriamycin with slowing progression disease
1220	0	a	ADR nephropathy
1221	0	a	ADR nephropathy
1222	0	a	ADR nephropathy
1223	0	a	adriamycin nephropathy of progression in rats hypertensive
1224	0	a	adriamycin with slowing in rats hypertensive
1225	0	a	ADR nephropathy adriamycin with slowing in rats hypertensive
1226	0	a	losartan by treated rats in progression of nephropathy
1227	0	a	losartan potential in slowing progression disease
1228	0	a	losartan potential in slowing with adriamycin nephropathy
1229	0	a	Losartan reduced clearance in nephropathy
1230	0	a	losartan prevent atrophy infiltration in nephropathy
1231	0	a	losartan by treated rats hypertensive
1232	0	a	losartan potential in slowing in rats hypertensive
1233	0	a	II type-1 blocker losartan potential in slowing progression disease
1234	0	a	II type-1 blocker losartan potential in slowing with adriamycin nephropathy
1235	0	a	II type-1 blocker losartan potential in slowing in rats hypertensive
1236	0	a	losartan treatment improved ameliorated glomerulosclerosis
1237	0	a	losartan with treatment showed reduction of glomerulosclerosis
1238	0	a	losartan treatment improved ameliorated glomerulosclerosis resulting in proteinuria
1239	0	a	losartan with treatment showed preventing proteinuria
1240	0	a	losartan with treatment showed reduction of glomerulosclerosis associated with progression of atrophy
1241	0	a	losartan prevent atrophy
1242	0	a	losartan with treatment showed reduction of glomerulosclerosis associated with progression of atrophy fibrosis
1243	0	a	losartan prevent atrophy infiltration fibrosis
1244	0	a	losartan with treatment showed preventing proteinuria failure
1245	0	a	Losartan reduces to disease
1246	0	a	Losartan reduced uraemia
1247	0	a	urea clearance reduced uraemia
1248	0	a	urea clearance in nephropathy
1249	1	a	ADR nephropathy in clearance reduced uraemia
1250	0	a	ADR nephropathy in infiltration atrophy
1251	0	a	ADR nephropathy in infiltration fibrosis
1252	0	a	Losartan reduces rate of progression of glomerulosclerosis
1253	1	a	ADR induced glomerulosclerosis
1254	0	a	ADR induced glomerulosclerosis of progression of rate reduces to disease
1255	1	a	Vigabatrin defects
1256	1	a	Vigabatrin associated changes have known patients of group in defects
1257	1	a	Vigabatrin therapy to due be presumed defects
1258	1	a	Vigabatrin associated defects
1259	0	a	Vigabatrin associated changes elected because control seizure
1260	0	a	Vigabatrin associated defects of pathogenesis be reaction toxicity
1261	1	a	ecstasy users in consolidation memory
1262	1	a	Ecstasy users demonstrated consolidation memory
1263	1	a	ecstasy associated dysfunction underlie impairments
1264	1	a	ecstasy users in impairments
1265	1	a	ecstasy users marked impairments
1266	0	a	estrogen induced tumor in separation of growth tumor
1267	0	a	estrogen induced tumor
1268	0	a	estrogen induced tumor in separation of growth phenotypes hemorrhagic
1269	0	a	estrogen of administration induces growth of tumors hemorrhagic
1270	0	a	estrogen of administration induces growth of tumors
1271	0	a	diethylstilbestrol treatment of weeks caused grow versus become hemorrhagic
1272	0	a	DES treatment of weeks caused grow versus become hemorrhagic
1273	0	a	DES induced growth exhibited exhibited phenotype hemorrhagic
1274	0	a	nicotine of effects on anxiety
1275	0	a	Nicotine blocked anxiety
1276	0	a	nicotine of effect on anxiety
1277	1	a	caffeine by induced anxiety
1278	1	a	caffeine- anxiety
1279	1	a	caffeine induced anxiety
1280	1	a	caffeine to specific is effect on anxiety
1281	1	a	pentylenetetrazole drug caffeine by induced anxiety
1282	1	a	pentylenetetrazole induced anxiety
1283	0	a	histamine receptors of Blockade reduce mortality in encephalopathy pertussis
1284	0	a	histamine receptors of Blockade reduce mortality in encephalopathy
1285	1	a	acetaminophen induced failure
1286	1	a	Acetaminophen induced hepatotoxicity is cause of failure
1287	1	a	Acetaminophen induced hepatotoxicity is cause of failure ALF
1288	1	a	acetaminophen induced ALF
1289	1	a	acetaminophen induced ALF with undergoing for ALF
1290	1	a	acetaminophen induced ALF for undergoing with ALF
1291	1	a	acetaminophen induced ALF
1292	1	a	Acetaminophen induced patients ALF
1293	1	a	acetaminophen induced patients ALF
1294	1	a	acetaminophen induced patients had before ALF=0/35
1295	1	a	acetaminophen induced ALF=0/35 before had patients ALF
1296	1	a	acetaminophen induced ALF=0/35
1297	1	a	acetaminophen induced ALF
1298	1	a	acetaminophen induced ALF groups ALF
1299	1	a	acetaminophen induced ALF groups ALF
1300	1	a	acetaminophen induced ALF
1301	1	a	acetaminophen induced patients ALF
1302	1	a	acetaminophen induced ALF
1303	1	a	acetaminophen induced ALF for transplanted patients for outcomes were comparable to those transplanted for ALF
1304	1	a	acetaminophen induced ALF for transplanted those to comparable were outcomes for patients transplanted for ALF
1305	1	a	acetaminophen induced ALF
1306	1	a	Acetaminophen induced hepatotoxicity
1307	0	a	acetaminophen induced ALF with undergoing for ALF LT for disease
1308	0	a	acetaminophen induced ALF with undergoing for ALF LT CLD
1309	0	a	acetaminophen induced ALF LT for disease
1310	0	a	acetaminophen induced ALF LT CLD
1311	0	a	acetaminophen induced patients had before ALF=0/35 CLD=2/34
1312	0	a	acetaminophen induced ALF=0/35 CLD=2/34
1313	0	a	acetaminophen induced ALF groups between failure were CLD
1314	0	a	acetaminophen induced ALF groups between failure were CLD
1315	0	a	acetaminophen induced ALF for transplanted patients for outcomes were comparable to those transplanted electively for CLD
1316	0	a	acetaminophen induced ALF for transplanted electively for CLD
1317	0	a	Cocaine induced hyperactivity
1318	0	a	Cocaine induced hyperactivity influenced than hyperactivity
1319	0	a	cocaine hyperactivity
1320	0	a	cocaine induced hyperactivity in active were those than doses at decreased hyperactivity
1321	0	a	cocaine induced hyperactivity
1322	0	a	cocaine- and amphetamine induced activity reduce adenosine indicate influenced hyperactivity
1323	0	a	cocaine- and amphetamine induced activity reduce adenosine indicate influenced by agonists than hyperactivity
1324	0	a	cocaine induced hyperactivity
1325	0	a	cocaine induced hyperactivity influenced by agonists than hyperactivity
1326	0	a	adenosine agonists by influenced hyperactivity
1327	0	a	adenosine agonists by influenced than hyperactivity
1328	0	a	adenosine agonists antagonists on hyperactivity
1329	0	a	adenosine agonists decreased hyperactivity
1330	0	a	adenosine agonists decreased at doses than those were active in hyperactivity
1331	0	a	adenosine indicate influenced hyperactivity
1332	0	a	adenosine indicate influenced by agonists than hyperactivity
1333	0	a	adenosine agonists by influenced hyperactivity
1334	0	a	adenosine agonists than hyperactivity
1335	0	a	amphetamine induced hyperactivity than influenced hyperactivity
1336	0	a	amphetamine induced hyperactivity
1337	0	a	amphetamine induced hyperactivity
1338	0	a	amphetamine induced hyperactivity
1339	0	a	amphetamine induced hyperactivity decreased at doses than those were active in hyperactivity
1340	0	a	amphetamine induced activity reduce adenosine indicate influenced hyperactivity
1341	0	a	amphetamine induced activity reduce adenosine indicate influenced by agonists than hyperactivity
1342	0	a	amphetamine induced hyperactivity than agonists by influenced hyperactivity
1343	0	a	amphetamine induced hyperactivity
1344	0	a	adenosine agonists decreased activity
1345	1	a	amino compounds of effect Hyperglycemic
1346	1	a	amino derivatives of amounts of feeding resulted in hyperglycemia
1347	0	a	caproate to related compounds of effect Hyperglycemic
1348	0	a	caproate of derivatives of amounts of feeding resulted in hyperglycemia
1349	0	a	amino derivatives of amounts of feeding resulted glucosuria
1350	0	a	caproate of derivatives of amounts of feeding resulted glucosuria
1351	0	a	glucose tolerance curve hyperglycemia
1352	0	a	glucose tolerance curve hyperglycemia in resulted glucosuria
1353	1	a	bupivacaine determining AD50 concentration caused beating become arrhythmic
1354	1	a	bupivacaine of concentration caused beating become arrhythmic
1355	1	a	bupivacaine arrhythmia
1356	1	a	progesterone HCl exposure of effect determined After determining AD50 concentration caused beating become arrhythmic
1357	0	a	HCl exposure of effect determined After determining AD50 concentration caused beating become arrhythmic
1358	1	a	Trimethoprim induced anemia
1359	1	a	disulfiram by induced hepatitis
1360	1	a	disulfiram with treated woman in observed damage
1361	0	a	amisulpride overdose
1362	1	a	amisulpride overdose of cases cause for syndrome
1363	0	a	amisulpride of g poisoning
1364	0	a	gluconate of administration to respond appeared prolongation
1365	0	a	MIP synthase inhibition replicate augment effects in model seizures
1366	0	a	lithium of effects in model seizures
1367	0	a	inositol model seizures
1368	1	a	pilocarpine induced seizures
1369	1	a	caffeine doses at scored characteristics righting ability induction seizure
1370	0	a	alkylxanthines of testing toxicity
1371	0	a	methoxamine of Effect on pressure in women with incontinence
1372	0	a	methoxamine of doses administered with incontinence
1373	1	a	Methoxamine evoked caused rise in pressure
1374	1	a	methotrexate following Paraplegia
1375	1	a	methotrexate of instillation following developed paraplegia
1376	0	a	methothexate concentration leakage leukemia
1377	0	a	methotrexate doses to concentration leakage leukemia
1378	0	a	methotrexate preparations in presence concentration leakage leukemia
1379	0	a	methotrexate diluents of use presence concentration leakage leukemia
1380	0	a	methotrexate of doses employing in presence of leukemia
1381	0	a	methothexate concentration presence of preservatives neurotoxic
1382	0	a	methotrexate doses to concentration presence of preservatives neurotoxic
1383	0	a	methotrexate preparations in presence of preservatives neurotoxic
1384	0	a	methotrexate diluents of use presence of preservatives neurotoxic
1385	0	a	methotrexate of doses employing by reduced incidence of neurotoxicity
1386	0	a	methotrexate levels of monitoring be predictive of development of neurotoxicity
1387	0	a	methotrexate contaminants deficiency
1388	0	a	methotrexate toxicity of pathogenesis in irradiation deficiency
1389	0	a	methotrexate contaminants deficiency irradiation in pathogenesis of toxicity
1390	0	a	methotrexate toxicity
1391	1	a	sirolimus of role anemia
1392	1	a	Sirolimus implicated as playing in anemia
1393	1	a	rapamycin inhibitor of target Sirolimus implicated as playing in anemia
1394	1	a	sirolimus with associated anemia
1395	1	a	droperidol due case of anxiety
1396	1	a	droperidol induced disturbance
1397	0	a	thalidomide of study in cancer
1398	0	a	androgen independent cancer
1399	0	a	androgen independent cancer
1400	0	a	thalidomide of effects assessed in trials in patients with malignancies
1401	1	a	thalidomide on months completed men In found evidence of neuropathy
1402	1	a	thalidomide be maintained for development of neuropathy
1403	0	a	epinephrine lipid with Resuscitation in toxicity
1404	0	a	levobupivacaine induced toxicity
1405	0	a	epinephrine emulsion of regimens are determined in cases of toxicity
1406	1	a	levobupivacaine received occurred collapse
1407	0	a	CCK-8 alleviated amnesia
1408	1	a	morphine induced amnesia
1409	1	a	morphine treated animals in decreases reversed alleviated amnesia
1410	0	a	CCK-8 attenuates suggest function on impairment
1411	0	a	CCK-8 of function on impairment
1412	0	a	morphine of effect attenuates suggest function on impairment
1413	0	a	morphine induced impairment
1414	1	a	tropicamide with dilation
1415	1	a	tropicamide performed before after dilation
1416	0	a	CO2 of pulses of means by applied pain
1417	0	a	CO2 stimuli to response in obtained CSSEPs as correlates of pain
1418	1	a	ibuprofen of administration followed by decrease in pain
1419	1	a	ibuprofen of effect indicating increase in correlates of pain
1420	1	a	ibuprofen of effect on interaction between stimuli pain
1421	0	a	galantamine of trial in disorder
1422	0	a	galantamine of use in treatment of interfering with autism
1423	0	a	galantamine of trial in participated children with autism
1424	0	a	galantamine was appeared be beneficial for treatment of interfering behaviors in children with autism
1425	1	a	galantamine was with effects apart from headaches
1426	0	a	galantamine was appeared be beneficial for treatment of aggression
1427	0	a	galantamine was appeared be beneficial for treatment of aggression dyscontrol
1428	0	a	galantamine was appeared be beneficial for treatment of aggression dyscontrol inattention
1429	0	a	Bortezomib as therapy in patients with myeloma
1430	0	a	Bortezomib is therapy for myeloma
1431	0	a	Bortezomib is therapy for myeloma MM
1432	0	a	bort)-dexamethasone dex Bortezomib is therapy for myeloma
1433	0	a	bort)-dexamethasone dex Bortezomib is therapy for myeloma MM
1434	0	a	bort of combination investigated 11 dex mg on day day as treatment in patients with MM
1435	0	a	bort after day as treatment in patients with MM
1436	0	a	Bort dex was treatment for patients MM
1437	0	a	dexamethasone Bortezomib as therapy in patients with myeloma
1438	0	a	bort)-dexamethasone dex Bortezomib is therapy for myeloma
1439	0	a	bort)-dexamethasone dex Bortezomib is therapy for myeloma MM
1440	0	a	dex Bortezomib is therapy for myeloma
1441	0	a	dex Bortezomib is therapy for myeloma MM
1442	0	a	dex mg on day day as treatment in patients with MM
1443	0	a	dex was treatment for patients MM
1444	0	a	doxorubicin cardiomyopathy disease cardiomyopathy cardiomyopathy
1445	0	a	doxorubicin cardiomyopathy disease cardiomyopathy cardiomyopathy disease
1446	0	a	doxorubicin cardiomyopathy disease cardiomyopathy
1447	0	a	doxorubicin cardiomyopathy disease
1448	1	a	doxorubicin cardiomyopathy
1449	0	a	ganciclovir with treated infections
1450	1	a	methotrexate therapy after failure
1451	1	a	MTX therapy after case of failure
1452	1	a	MTX therapy caused failure
1453	0	a	methotrexate is treatment for lymphoma
1454	0	a	MTX methotrexate is treatment for lymphoma
1455	0	a	methotrexate is cause toxicity
1456	0	a	MTX methotrexate is cause toxicity
1457	0	a	methotrexate is cause toxicity
1458	0	a	MTX methotrexate is cause toxicity
1459	0	a	MTX therapy after case report was boy received for atresia
1460	0	a	dronedarone of effects with infarction
1461	0	a	dronedarone of effects compared with those at during stimulation in dogs with infarction
1462	0	a	amiodarone dronedarone of effects with infarction
1463	0	a	amiodarone to related compound dronedarone of effects compared with those at during stimulation in dogs with infarction
1464	0	a	amiodarone of those at during stimulation in dogs with infarction
1465	0	a	dronedarone reduced tachycardia
1466	0	a	dronedarone reduced decreased tachycardia
1467	0	a	amiodarone dronedarone reduced tachycardia
1468	0	a	amiodarone dronedarone reduced decreased tachycardia
1469	1	a	isoproterenol induced tachycardia decreased reduced tachycardia
1470	1	a	isoproterenol induced tachycardia
1471	0	a	dronedarone be suitable for treatment of arrhythmias
1472	1	a	isoproterenol induced hypertrophy
1473	1	a	Iso treatment by induced hypertrophy
1474	0	a	ondansetron following depression
1475	0	a	ondansetron prophylaxis used anaesthetic after woman with history of nausea vomiting
1476	0	a	serotonin antagonist of use to related developed disorder
1477	0	a	propofol infusion with Anaesthesia provided course free nausea
1478	0	a	propofol infusion with Anaesthesia provided without exacerbation of disorder
1479	0	a	serotonin antagonists of infusion with Anaesthesia provided course free nausea
1480	0	a	serotonin antagonists of infusion with Anaesthesia provided without exacerbation of disorder
1481	0	a	fluorescein angiography following Convulsion
1482	1	a	fluorescein injection followed seizures
1483	1	a	Ethambutol neuropathy
1484	1	a	ethambutol neuropathy
1485	1	a	ethambutol with treated after developed neuropathy
1486	1	a	ethambutol therapy starting after had neuropathy
1487	1	a	ethambutol therapy with patients in considered recognition of neuropathy
1488	0	a	ethambutol with treated for tuberculosis of node
1489	0	a	ethambutol with treated for tuberculosis of node
1490	0	a	carboplatin of study doxorubicin in patients with carcinoma of cervix
1491	0	a	carboplatin of combination administered to patients with carcinoma
1492	0	a	carboplatin of study doxorubicin in patients with carcinoma of cervix
1493	0	a	carboplatin of combination of activity tested in study of patients with carcinoma
1494	0	a	carboplatin of combination administered to patients with carcinoma
1495	0	a	carboplatin of combination has in patients with carcinoma
1496	0	a	doxorubicin in patients with carcinoma of cervix
1497	0	a	doxorubicin carboplatin of combination administered to patients with carcinoma
1498	0	a	Doxil doxorubicin carboplatin of combination administered to patients with carcinoma
1499	0	a	doxorubicin in patients with carcinoma of cervix
1500	0	a	doxorubicin carboplatin of combination of activity tested in study of patients with carcinoma
1501	0	a	doxorubicin carboplatin of combination administered to patients with carcinoma
1502	0	a	Doxil doxorubicin carboplatin of combination administered to patients with carcinoma
1503	0	a	doxorubicin carboplatin of combination has in patients with carcinoma
1504	0	a	carboplatin of combination administered determine activity profile toxicity
1505	0	a	doxorubicin carboplatin of combination administered determine activity profile toxicity
1506	0	a	Doxil doxorubicin carboplatin of combination administered determine activity profile toxicity
1507	1	a	triphosphate by induced hypotension
1508	1	a	triphosphate administered induce hypotension
1509	1	a	ATP triphosphate administered induce hypotension
1510	1	a	ATP by induced Hypotension
1511	1	a	ATP stopped returned left accompanied Hypotension
1512	1	a	nitroprusside triphosphate by induced hypotension
1513	1	a	nitroprusside triphosphate administered induce hypotension
1514	1	a	SNP nitroprusside triphosphate administered induce hypotension
1515	1	a	SNP decreases by produced hypotension
1516	0	a	oxygen consumption , left accompanied Hypotension
1517	0	a	oxygen content difference resistance , observed During hypotension
1518	0	a	oxide in convulsions
1519	0	a	NO plays role in model of seizures
1520	1	a	lindane by induced convulsions
1521	1	a	lindane dose by elicited convulsion to time increased incidence convulsion
1522	1	a	lindane dose by elicited convulsion
1523	1	a	lindane of dose with decreased incidence convulsion
1524	1	a	lindane of dose with decreased to convulsion
1525	1	a	lindane of dose convulsive
1526	1	a	lindane seizures
1527	0	a	GABA(A of blockage trough evokes convulsions
1528	0	a	oxide has observed in models epilepsy
1529	0	a	NO oxide has observed in models epilepsy
1530	0	a	NO syntheses of precursor has observed in models epilepsy
1531	0	a	NO of effects on characteristics of epilepsy
1532	0	a	arginine of effects due has observed in models epilepsy
1533	0	a	NAME observed in models epilepsy
1534	0	a	lindane induced epilepsy
1535	0	a	arginine of administration increased incidence convulsion
1536	0	a	arginine of administration increased time to convulsion
1537	0	a	NAME with pretreatment decreased incidence convulsion
1538	0	a	NAME with pretreatment decreased to convulsion
1539	0	a	NAME with pretreatment decreased with dose convulsive
1540	1	a	cromakalim by induced vessels hypotension
1541	1	a	cromakalim by induced vessels of Vasodilation affected by blockade tachycardia
1542	1	a	pinacidil cromakalim by induced vessels hypotension
1543	1	a	pinacidil cromakalim by induced vessels of Vasodilation affected by blockade tachycardia
1544	0	a	blockade by affected Vasodilation of vessels hypotension
1545	0	a	blockade by affected Vasodilation of vessels hypotension
1546	0	a	blockade tachycardia
1547	0	a	blockade tachycardia
1548	0	a	anthraquinones containing pills of intake with associated failure
1549	0	a	anthraquinone derivatives contained pill of use following developed failure
1550	0	a	anthraquinone containing agent injury
1551	0	a	herbs by caused Nephropathy
1552	0	a	acids of use involving reported Nephropathy
1553	1	a	herbal slimming pill of use following developed failure
1554	1	a	diclofenac drug of intake by aggravated injury
1555	0	a	anthraquinone containing agent of use between relationship remains considered nephropathy
1556	0	a	anthraquinone containing agent of use between relationship remains considered in patients present with failure
1557	1	a	bortezomib after fasciitis
1558	1	a	bortezomib with treatment after suffered fasciitis
1559	0	a	bortezomib in patient of macroglobulinaemia
1560	0	a	bortezomib with treatment after suffered man with macroglobulinaemia
1561	1	a	dexamethasone containing regimen bortezomib after fasciitis
1562	1	a	dexamethasone bortezomib with treatment after suffered fasciitis
1563	0	a	dexamethasone containing regimen bortezomib in patient of macroglobulinaemia
1564	0	a	dexamethasone bortezomib with treatment after suffered man with macroglobulinaemia
1565	0	a	Bortezomib considered be tolerable with infections
1566	0	a	bortezomib to related infections
1567	0	a	Bortezomib considered be tolerable with infections in patients with malignancies
1568	0	a	dexamethasone containing regimens Bortezomib considered be tolerable with infections
1569	0	a	dexamethasone bortezomib to related infections
1570	0	a	dexamethasone containing regimens Bortezomib considered be tolerable with infections in patients with malignancies
1571	0	a	bortezomib with treatment after suffered without neutropenia
1572	0	a	dexamethasone bortezomib with treatment after suffered without neutropenia
1573	1	a	coumadin therapy to secondary hematomyelia
1574	0	a	trinitrate for treatment of dysmenorrhea
1575	0	a	trinitrate of efficacy in resolution of dysmenorrhea
1576	0	a	GTN trinitrate of efficacy in resolution of dysmenorrhea
1577	0	a	GTN has efficacy by comparison in treatment of dysmenorrhea
1578	0	a	diclofenac with trinitrate for treatment of dysmenorrhea
1579	0	a	diclofenac DCF with comparison in resolution of dysmenorrhea
1580	0	a	DCF with comparison in resolution of dysmenorrhea
1581	0	a	DCF with comparison in treatment of dysmenorrhea
1582	0	a	prostaglandins of hypersecretion by caused contractility by characterized syndrome is dysmenorrhea
1583	0	a	NO donor trinitrate of efficacy in resolution of dysmenorrhea
1584	0	a	DCF continued be effective in reducing pain
1585	0	a	GTN scores remained continued be effective in reducing pain
1586	0	a	GTN continued be effective in reducing pain
1587	1	a	GTN by increased Headache
1588	1	a	GTN using stopped became headache
1589	0	a	DCF by increased Headache
1590	1	a	clavulanate stands as drug related to DILI
1591	1	a	cocaine users in recognition
1592	1	a	cocaine of effects by explained deficit in accuracy recognition
1593	0	a	ecstasy cocaine of effects by explained deficit in accuracy recognition
1594	0	a	albuterol nebulized in exacerbations of asthma
1595	0	a	albuterol received exacerbations of asthma
1596	0	a	albuterol treatments versus received exacerbations of asthma
1597	0	a	Ecstasy is drug associated with dysfunction
1598	0	a	MDMA Ecstasy is drug associated with dysfunction
1599	0	a	ecstasy polydrug users in observations with line in are increases in anxiety
1600	1	a	ecstasy polydrug users in observations with line in are increases in anxiety depression
1601	0	a	lidocaine of safety in patients with infarction
1602	0	a	lidocaine of safety evaluate in setting of infarction
1603	0	a	lidocaine of safety evaluate in setting of infarction MI
1604	0	a	lidocaine received MI
1605	0	a	lidocaine received in setting of MI
1606	0	a	lidocaine of administration after seizures exhibited died Of patients received in setting of MI
1607	0	a	lidocaine enhance concerns Despite associated use in patients with MI
1608	0	a	lidocaine of use in patients with MI
1609	1	a	cocaine associated infarction
1610	1	a	cocaine induced infarction
1611	1	a	cocaine induced infarction MI
1612	1	a	cocaine associated MI
1613	1	a	cocaine associated MI
1614	1	a	cocaine toxicity enhance concerns Despite associated use in patients with MI
1615	1	a	cocaine associated MI
1616	0	a	lidocaine received patients Of died exhibited bradydysrhythmias
1617	0	a	lidocaine of administration after seizures exhibited bradydysrhythmias
1618	0	a	lidocaine received patients Of died exhibited bradydysrhythmias tachycardia
1619	0	a	lidocaine of administration after seizures exhibited bradydysrhythmias tachycardia
1620	0	a	lidocaine received patients Of died exhibited bradydysrhythmias tachycardia fibrillation
1621	0	a	lidocaine of administration after seizures exhibited bradydysrhythmias tachycardia fibrillation
1622	0	a	lidocaine received patients Of died exhibited seizures
1623	0	a	lidocaine of administration after seizures
1624	0	a	cocaine associated MI of setting in received patients Of died exhibited bradydysrhythmias
1625	0	a	cocaine associated MI of setting in received patients Of died exhibited bradydysrhythmias tachycardia
1626	0	a	cocaine associated MI of setting in received patients Of died exhibited bradydysrhythmias tachycardia fibrillation
1627	0	a	cocaine associated MI of setting in received patients Of died exhibited seizures
1628	0	a	lidocaine enhance toxicity
1629	0	a	lidocaine of use associated Despite concerns enhance toxicity
1630	0	a	lidocaine enhance concerns Despite associated with toxicity
1631	0	a	lidocaine of use associated with toxicity
1632	0	a	lidocaine enhance concerns Despite associated with toxicity
1633	0	a	lidocaine of use associated with toxicity
1634	0	a	cocaine toxicity
1635	0	a	cocaine associated MI with patients in use associated Despite concerns enhance toxicity
1636	0	a	cocaine toxicity enhance concerns Despite associated with toxicity
1637	0	a	cocaine associated MI with patients in use associated with toxicity
1638	0	a	cocaine toxicity enhance concerns Despite associated with toxicity
1639	0	a	cocaine associated MI with patients in use associated with toxicity
1640	1	a	AVP of effects in normotensive hypertensive
1641	1	a	vasopressin of influence in rats hypertensive
1642	1	a	AVP vasopressin of influence in rats hypertensive
1643	1	a	phenylephrine hypertension
1644	1	a	Phe)-induced hypertension
1645	0	a	phenylephrine hypotension
1646	0	a	Phe)-induced hypertension phenylephrine hypotension
1647	0	a	nitroprusside hypertension
1648	0	a	SN)-induced hypotension phenylephrine hypertension
1649	1	a	nitroprusside hypertension phenylephrine hypotension
1650	1	a	SN)-induced hypotension
1651	1	a	SN induced hypotension
1652	0	a	AVP of administration during hypotension
1653	1	a	bepridil by induced bradycardia
1654	1	a	Bepridil induced bradycardia
1655	0	a	Bepridil compound for treatment of attacks
1656	0	a	Bepridil induced bradycardia effect tachycardial
1657	1	a	Succimer chelation improves produces impairment
1658	0	a	succimer treatment exposed produced dysfunction
1659	0	a	lead exposed rats in learning improves produces impairment
1660	0	a	lead exposure of absence in produces impairment
1661	0	a	Pb to exposed produced dysfunction
1662	0	a	Pb exposure regimen by produced that to magnitude in comparable dysfunction
1663	0	a	Pb exposure to due deficits
1664	0	a	Pb exposure with succimer agent for treatment of poisoning
1665	0	a	succimer agent for treatment of poisoning
1666	1	a	Pb exposure produced impairments in learning attention control regulation
1667	1	a	Pb exposed children in seen dysfunction of areas paralleling produced impairments in learning attention control regulation
1668	1	a	Pb exposure produced impairments in learning attention control regulation
1669	1	a	Pb exposed children in seen dysfunction of areas paralleling produced impairments in learning attention control regulation
1670	0	a	succimer treatment exposed produced dysfunction
1671	0	a	Pb to exposed produced dysfunction
1672	0	a	Pb exposure regimen by produced that to magnitude in comparable dysfunction
1673	0	a	alcohol use with progression disease
1674	0	a	alcohol consumption of association evaluated effects on progression disease
1675	1	a	alcohol consumption depression
1676	1	a	alcohol use assessment had examination extraction determination measurement of symptoms depression
1677	1	a	alcohol use assessment had using Center for Scale Depression
1678	1	a	alcohol consumption depression
1679	1	a	alcohol consumption has association with depression
1680	1	a	adrenaline hypertension
1681	1	a	adrenaline infusion after effect Support for hypothesis hypertension
1682	1	a	adrenaline hypertension
1683	0	a	betaine by Regulation attenuates injury
1684	0	a	betaine on damage
1685	0	a	isoproterenol induced injury
1686	0	a	betaine of effects investigate on ischemia
1687	0	a	betaine pretreatment attenuated ischemia
1688	1	a	isoproterenol of injection by induced injury
1689	1	a	isoproterenol induced ischemia
1690	0	a	betaine of administration reduced prevented left remodeling
1691	1	a	isoproterenol induced hypertrophy
1692	0	a	Na ATPase of Expression in Nephropathy
1693	0	a	Na(+)/K(+)-ATPase of expression with related nephropathy
1694	0	a	K ATPase of Expression in Nephropathy
1695	0	a	Na(+)/K(+)-ATPase of expression with related nephropathy
1696	1	a	Gentamicin induced Nephropathy
1697	1	a	gentamicin induced nephropathy
1698	1	a	Gentamicin induced nephropathy
1699	0	a	Glucarates of Effect on damage
1700	0	a	Glucarates were effective against damage
1701	0	a	glucarate With obtained against damages
1702	0	a	Glucarates had ability prevent damage
1703	0	a	glucarates of effect against nephrotoxicity
1704	0	a	aminoglycoside antibiotics of injection following develop rats Dehydrated
1705	1	a	aminoglycoside antibiotics of injection following develop failure
1706	0	a	6,3-dilactone D rats against failure
1707	0	a	kanamycin dextran by induced failure
1708	0	a	aminoglycoside antibitocis antibiotics by induced damage
1709	0	a	monosaccharides by lesions
1710	0	a	Procaterol terbutaline in asthma
1711	0	a	Procaterol studied in trial in patients with asthma
1712	0	a	procaterol of effects asthmatic
1713	0	a	terbutaline in asthma
1714	1	a	procaterol of effects asthmatic tremorgenic
1715	1	a	cisplatin induced injury
1716	1	a	Cisplatin treatment adopted induce injury
1717	1	a	cisplatin induced injury
1718	1	a	cisplatin with challenged examine role of receptor in injury
1719	1	a	cisplatin induced injury
1720	1	a	Cisplatin treatment adopted induce augment increase score necrosis
1721	0	a	creatinine of levels augment induce injury
1722	0	a	creatinine of levels augment increase score necrosis
1723	0	a	urea creatinine of levels augment induce injury
1724	0	a	urea creatinine of levels augment increase score necrosis
1725	0	a	cisplatin induced injury in involved by mediating process necrotic
1726	0	a	cisplatin therapy by induced nephrotoxicity
1727	0	a	daptomycin of penetration in meningitis
1728	0	a	daptomycin with treated case of aureus bacteremia with meningitis
1729	0	a	daptomycin initiated for meningitis
1730	0	a	methicillin sensitive aureus bacteremia
1731	0	a	methicillin sensitive aureus bacteremia with meningitis
1732	0	a	daptomycin with treated case of aureus bacteremia
1733	0	a	Daptomycin initiated secondary to nephritis bacteremia
1734	0	a	daptomycin be option for bacteremia
1735	0	a	creatinine failure
1736	0	a	Nafcillin was discontinued initiated for meningitis
1737	0	a	Daptomycin initiated secondary to nephritis
1738	1	a	nafcillin induced nephritis
1739	0	a	nafcillin induced nephritis bacteremia
1740	0	a	cocaine dependent man became manic
1741	1	a	diethylpropion of efficacy evaluating study in subject was man became manic
1742	1	a	DEP diethylpropion of efficacy evaluating study in subject was man became manic
1743	1	a	DEP on changes changes were different than those observed in subjects become manic
1744	0	a	DEP on changes changes in power of oscillation
1745	1	a	scopolamine induced amnesia
1746	1	a	Scopolamine induced amnesia
1747	1	a	scopolamine induced amnesia
1748	0	a	naloxone by avoidance of amnesia
1749	0	a	naloxone of administration attenuated amnesia
1750	0	a	naloxone of role on deficit
1751	0	a	Naloxone attenuated deficit
1752	0	a	naloxone sensitivity in increase appear be responsible for influence on deficit
1753	0	a	naloxone state increase appear be responsible for influence on deficit
1754	0	a	naloxone of influence on deficit
1755	0	a	scopolamine induced deficit
1756	0	a	scopolamine induced deficit
1757	0	a	scopolamine Scopolamine induced amnesia
1758	0	a	naloxone sensitivity pain
1759	0	a	naloxone state increase in sensitivity pain
1760	0	a	naloxone of influence for responsible be appear increase in sensitivity pain
1761	0	a	scopolamine induced deficit on influence for responsible be appear increase in sensitivity pain
1762	0	a	Crocin reduced inhibition of activation hyperlipemia
1763	0	a	Crocin considered as agent in hyperlipemia
1764	1	a	diazinon induced hyperlipemia
1765	1	a	diazinon induced hyperlipemia
1766	0	a	carboline of mg/kg reduced increase of binding convulsions
1767	0	a	35S]TBPS binding convulsions
1768	1	a	isoniazid by induced convulsions
1769	0	a	caffeine of effects in disorders
1770	0	a	caffeine of administration of effects determined in subjects patients meeting with attacks
1771	0	a	caffeine of administration of effects determined in subjects patients meeting with attacks disorder
1772	0	a	caffeine of effects were similar to those experienced during attacks
1773	0	a	caffeine is suggest have patients disorder
1774	0	a	caffeine of administration of effects determined in subjects patients meeting criteria for agoraphobia
1775	0	a	3-methoxy-4-hydroxyphenethyleneglycol MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting criteria for agoraphobia
1776	0	a	MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting criteria for agoraphobia
1777	0	a	3-methoxy-4-hydroxyphenethyleneglycol MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting with attacks
1778	0	a	3-methoxy-4-hydroxyphenethyleneglycol MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting with attacks disorder
1779	0	a	MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting with attacks
1780	0	a	MHPG of levels pressure symptoms ratings on effects determined in subjects patients meeting with attacks disorder
1781	0	a	cortisol pressure symptoms ratings on effects determined in subjects patients meeting criteria for agoraphobia
1782	0	a	cortisol pressure symptoms ratings on effects determined in subjects patients meeting with attacks
1783	0	a	cortisol pressure symptoms ratings on effects determined in subjects patients meeting with attacks disorder
1784	1	a	Caffeine produced increases in fear anxiety
1785	1	a	caffeine containing foods avoiding by benefit Patients with disorders
1786	1	a	Caffeine produced increases in fear nausea
1787	0	a	Caffeine produced increases in fear nausea palpitations
1788	0	a	Caffeine produced increases in fear nausea palpitations restlessness
1789	1	a	Caffeine produced increases in fear nausea palpitations restlessness tremors
1790	0	a	caffeine is suggest have abnormalities in systems
1791	0	a	adenosine receptor antagonist is suggest have patients disorder
1792	0	a	adenosine involving systems in abnormalities have patients disorder
1793	0	a	adenosine receptor antagonist is suggest have abnormalities in systems
1794	0	a	adenosine involving systems
1795	0	a	apigenin prevent amnesia
1796	1	a	scopolamine by induced amnesia
1797	0	a	rifampicin associated failure
1798	0	a	rifampicin of reintroduction by induced 3 patients with failure
1799	1	a	rifampicin of reintroduction by induced 3 with thrombopenia
1800	1	a	rifampicin of reintroduction by induced 3 with thrombopenia hemolysis
1801	1	a	Carbimazole induced vasculitis
1802	0	a	drugs prescribed for treatment of hyperthyroidism
1803	0	a	carbimazole like drugs prescribed for treatment of hyperthyroidism
1804	0	a	propylthiouracil carbimazole like drugs prescribed for treatment of hyperthyroidism
1805	0	a	PTU propylthiouracil carbimazole like drugs prescribed for treatment of hyperthyroidism
1806	1	a	antithyroidmedications of effect is antibody vasculitis
1807	0	a	carbimazole induced vasculitis developed patient with disease
1808	0	a	carbimazole induced vasculitis
1809	0	a	carbimazole induced case vasculitis
1810	0	a	Cyclophosphamide cardiotoxicity
1811	0	a	CYA of doses At occur cardiotoxicity
1812	0	a	CYA of doses At occur described factors for development of cardiotoxicity
1813	0	a	CYA of dose in patients transplanted determine correlated incidence of cardiotoxicity
1814	0	a	CYA cardiotoxicity
1815	0	a	CYA cardiotoxicity
1816	0	a	CYA of doses receiving of days within had symptoms signs consistent with cardiotoxicity
1817	0	a	CYA to related thought Cardiotoxicity
1818	0	a	CYA cardiotoxicity
1819	0	a	CYA cardiotoxicity correlates prepared for grafting with incidence of cardiotoxicity
1820	0	a	CYA dosage with correlates cardiotoxicity
1821	0	a	CYA dosage with correlates prepared for grafting with incidence of cardiotoxicity
1822	0	a	CYA dose at grafting for prepared correlates cardiotoxicity
1823	0	a	CYA dose at grafting with incidence of cardiotoxicity
1824	0	a	CYA dosage calculated patients than incidence with grafting for prepared correlates cardiotoxicity
1825	0	a	CYA dosage calculated patients than incidence of cardiotoxicity
1826	0	a	CYA of dose calculated correlates toxicity
1827	0	a	CYA cardiotoxicity of incidence correlated determine transplanted patients in dose calculated correlates toxicity
1828	0	a	CYA receive were patients underwent total of transplants for anemia
1829	0	a	CYA cardiotoxicity correlates prepared patients with anemia
1830	0	a	CYA dosage with correlates prepared patients with anemia
1831	0	a	CYA dose at grafting for prepared patients with anemia
1832	0	a	CYA dosage calculated patients than incidence with grafting for prepared patients with anemia
1833	0	a	CYA receive were patients underwent total syndrome
1834	0	a	CYA receive were patients underwent total syndrome syndrome
1835	0	a	CYA cardiotoxicity correlates prepared patients with anemia immunodeficiencies
1836	0	a	CYA dosage with correlates prepared patients with anemia immunodeficiencies
1837	0	a	CYA dose at grafting for prepared patients with anemia immunodeficiencies
1838	0	a	CYA dosage calculated patients than incidence with grafting for prepared patients with anemia immunodeficiencies
1839	1	a	3,4-methylenedioxymethamphetamine ecstasy of users in Depression
1840	1	a	MDMA ecstasy of users in Depression
1841	1	a	ecstasy of users in Depression
1842	1	a	ecstasy users of generation for prognosis is Given record of memory levels of depression
1843	1	a	3,4-methylenedioxymethamphetamine ecstasy of users in Depression impulsiveness
1844	1	a	MDMA ecstasy of users in Depression impulsiveness
1845	1	a	ecstasy of users in Depression impulsiveness
1846	1	a	ecstasy users of generation for prognosis is Given record of memory levels of depression impulsiveness
1847	0	a	ecstasy users of generation for prognosis is Given record of memory
1848	1	a	ecstasy users of generation for prognosis is Given record of memory levels of depression impulsiveness disturbance
1849	0	a	tacrolimus ointment with treatment during Induction of dermatitis
1850	0	a	tacrolimus ointment with treatment of complication as report on dermatitis
1851	0	a	tacrolimus ointment with treatment of complication as spectrum of dermatitis
1852	0	a	tacrolimus ointment with treatment of dermatoses
1853	0	a	tacrolimus ointment with treated patients with dermatoses
1854	1	a	Tacrolimus ointment used indicate is in rosacea
1855	0	a	Tacrolimus ointment used indicate is in rosacea dermatitis
1856	0	a	steroid aggravated rosacea
1857	0	a	steroid aggravated rosacea dermatitis
1858	0	a	acid therapy with associated hemorrhage
1859	0	a	acid therapy thrombosis
1860	1	a	acid used prevent rebleeding in patients with hemorrhage
1861	1	a	acid used prevent rebleeding in patients with hemorrhage SAH
1862	1	a	EACA acid used prevent rebleeding in patients with hemorrhage
1863	1	a	EACA acid used prevent rebleeding in patients with hemorrhage SAH
1864	1	a	EACA with treated patients in thrombi with SAH
1865	1	a	EACA therapy in patient with SAH
1866	1	a	EACA therapy in patient with SAH documentation of SAH
1867	1	a	EACA therapy of complications thrombotic
1868	1	a	EACA with treated patients in thrombi
1869	1	a	EACA implicated observed thrombi
1870	1	a	EACA implicated in pathogenesis of thrombi
1871	1	a	EACA with treated patients in thrombi with patients in deterioration thrombosis
1872	0	a	EACA phenomena
1873	0	a	EACA implicated in pathogenesis of thrombi in patients with coagulation
1874	0	a	EACA implicated in pathogenesis of thrombi in patients with coagulation coagulopathies
1875	0	a	rocuronium of dose decrease fasciculation
1876	0	a	rocuronium of dose identified prevent fasciculation
1877	0	a	rocuronium of influence evaluated prevent fasciculation
1878	0	a	rocuronium of dose of amount increasing with less was incidence of fasciculation
1879	0	a	rocuronium with Precurarization was dose considering reduction in incidence of fasciculation
1880	0	a	rocuronium of dose decrease fasciculation myalgia
1881	0	a	rocuronium of dose identified prevent fasciculation myalgia
1882	0	a	rocuronium of influence evaluated prevent fasciculation myalgia
1883	0	a	rocuronium of dose of amount increasing to according decrease tend Those of myalgia
1884	0	a	rocuronium with Precurarization was dose considering reduction in incidence of fasciculation myalgia
1885	1	a	succinylcholine administration following decrease fasciculation
1886	1	a	Succinylcholine produces effects including fasciculation
1887	1	a	succinylcholine induced fasciculation
1888	1	a	succinylcholine by produced onset of speed on evaluated prevent fasciculation
1889	1	a	succinylcholine received assessed incidence of fasciculations
1890	1	a	succinylcholine administration following decrease fasciculation myalgia
1891	1	a	Succinylcholine produces effects including fasciculation myalgia
1892	1	a	succinylcholine induced fasciculation myalgia
1893	1	a	succinylcholine by produced onset of speed on evaluated prevent fasciculation myalgia
1894	1	a	succinylcholine received assessed assessed myalgia
1895	1	a	Indomethacin induced hyperkalemia
1896	1	a	indomethacin with developed hyperkalemia
1897	0	a	Indomethacin induced hyperkalemia in patients with arthritis
1898	0	a	indomethacin with developed after treatment of arthritis
1899	1	a	indomethacin with developed hyperkalemia insufficiency
1900	0	a	prostaglandin synthesis hypoaidosteronism
1901	0	a	potassium balance function to attention in patients with mellitus
1902	0	a	potassium balance function to attention in patients with mellitus disease
1903	0	a	indomethacin receiving patients in function to attention in patients with mellitus
1904	0	a	indomethacin receiving patients in function to attention in patients with mellitus disease
1905	1	a	methadone receiving users in syndrome
1906	1	a	methadone treatment with prolongation
1907	1	a	methadone to addition In considered as factors for prolongation
1908	1	a	methadone maintenance patients in prolongation
1909	1	a	Methadone dose contribute to prolongation
1910	1	a	methadone of doses with occur syndrome
1911	0	a	methadone group in patients presented pointes
1912	0	a	methadone dose attribution interactions hypokalemia
1913	0	a	potassium level inhibitors of presence contribute to prolongation
1914	0	a	anthracycline cardiotoxicity
1915	0	a	Doxorubicin is therapeutic cancer
1916	0	a	DOX Doxorubicin is therapeutic cancer
1917	0	a	Doxorubicin is associated with cardiotoxicity
1918	0	a	DOX Doxorubicin is associated with cardiotoxicity
1919	0	a	DOX cardiotoxicity
1920	1	a	DOX induced failure
1921	1	a	pilocarpine induced status during Damage of reticulata
1922	1	a	pilocarpine induced status during Damage epilepticus
1923	1	a	pilocarpine of injection by induced epilepticus
1924	0	a	calcium binding protein against antibodies staining served detect damage
1925	0	a	carboplatin chemotherapy for retinoblastoma
1926	0	a	carboplatin injections used as adjunct to chemotherapy for retinoblastoma
1927	0	a	carboplatin received retinoblastoma
1928	0	a	carboplatin of injections with treated for retinoblastoma
1929	0	a	carboplatin injections used as adjunct free toxicity
1930	0	a	carboplatin is free of toxicity
1931	1	a	carboplatin chemotherapy with treated patients in motility
1932	1	a	carboplatin received retinoblastoma with patients in motility
1933	1	a	carboplatin chemotherapy associated with fibrosis
1934	1	a	MK-801 augments seizure
1935	1	a	MK-801 on model seizure
1936	1	a	MK-801 ( development of seizure
1937	1	a	MK-801 seizure
1938	1	a	MK-801 seizure augmented seizure
1939	0	a	MK-801 augments protects against damage
1940	0	a	MK-801 scopolamine Pentobarbital protected damage
1941	0	a	MK-801-treated group in appeared protected damage
1942	1	a	pilocarpine induced seizure
1943	1	a	pilocarpine induced model seizure
1944	1	a	pilocarpine tonic seizure
1945	1	a	pilocarpine induced seizure
1946	1	a	pilocarpine treated group in appeared seizure
1947	1	a	pilocarpine induced seizure
1948	1	a	pilocarpine induced seizure augmented seizure
1949	1	a	pilocarpine by induced seizure augmented seizure
1950	1	a	pilocarpine by induced seizure
1951	0	a	pilocarpine induced seizure augments protects against damage
1952	0	a	pilocarpine by damage
1953	0	a	pilocarpine by induced epilepticus initiated indicate cause damage
1954	0	a	Scopolamine prevented development of seizure
1955	0	a	Scopolamine blocked seizure
1956	0	a	Scopolamine blocked seizure augmented seizure
1957	0	a	pentobarbital Scopolamine prevented development of seizure
1958	0	a	pentobarbital Scopolamine blocked seizure
1959	0	a	pentobarbital Scopolamine blocked seizure augmented seizure
1960	1	a	Pilocarpine produced death
1961	0	a	Pentobarbital protected damage
1962	0	a	scopolamine Pentobarbital protected damage
1963	1	a	pilocarpine by induced epilepticus
1964	0	a	NMDA mechanism through damage cause indicate initiated epilepticus
1965	0	a	NMDA mechanism through damage
1966	1	a	Vincristine of use with reported Hyponatremia
1967	1	a	vincristine treated patients among secretion of hyponatremia
1968	1	a	vincristine of use during reported Lilly searched for cases of hyponatremia
1969	1	a	vincristine use with associated SIADH cases of hyponatremia
1970	1	a	vincristine use with associated SIADH hyponatremia
1971	1	a	Vincristine of use with reported Hyponatremia of hormone
1972	1	a	vincristine treated patients among secretion of hormone
1973	1	a	vincristine treated patients among secretion of hormone SIADH
1974	1	a	vincristine of use during reported Lilly searched for cases of hyponatremia SIADH
1975	1	a	vincristine use with associated SIADH
1976	1	a	vincristine use with associated SIADH
1977	1	a	vincristine with associated SIADH
1978	1	a	Fluvastatin Therapy After Hours Within Injury
1979	1	a	fluvastatin with treatment beginning after appeared damage
1980	0	a	statins are reported cases of injury
1981	1	a	thiotepa combination chemotherapy after polyneuropathy
1982	1	a	thiotepa including chemotherapy of administration to related toxicity
1983	1	a	TSPA thiotepa including chemotherapy of administration to related toxicity
1984	1	a	TSPA arabinoside methotrexate with described toxicities
1985	1	a	TSPA is fact of spite In cause neurotoxicity
1986	1	a	methotrexate with described toxicities
1987	1	a	MTX with combination cause neurotoxicity
1988	1	a	arabinoside methotrexate with described toxicities
1989	1	a	C MTX with combination cause neurotoxicity
1990	0	a	DOPA induced dyskinesias rigidity bradykinesia of treatment for underwent patients with disease
1991	0	a	DOPA induced dyskinesias rigidity bradykinesia
1992	0	a	DOPA induced dyskinesias rigidity
1993	1	a	DOPA induced dyskinesias
1994	1	a	Cotrimoxazole involved episodes manic
1995	1	a	metronidazole Cotrimoxazole involved episodes manic
1996	1	a	erythromycin metronidazole Cotrimoxazole involved episodes manic
1997	1	a	clarithromycin showed be associated with development of mania
1998	1	a	ciprofloxacin clarithromycin showed be associated with development of mania
1999	0	a	Hydroxytyrosol ameliorates stress dysfunction
2000	0	a	Hydroxytyrosol ameliorates stress in cardiotoxicity
2001	0	a	hydroxytyrosol with ameliorated toxicity
2002	0	a	Hydroxytyrosol ameliorates stress in rats with cancer
2003	0	a	hydroxytyrosol in rats with cancer
2004	0	a	hydroxytyrosol control groups into divided rats bearing tumors
2005	0	a	hydroxytyrosol doxorubicin doxorubicin divided rats bearing tumors
2006	0	a	doxorubicin induced cardiotoxicity in stress dysfunction
2007	0	a	Doxorubicin causes cardiotoxicity characterized by increases in stress dysfunction
2008	0	a	doxorubicin induced cardiotoxicity
2009	0	a	Doxorubicin causes cardiotoxicity
2010	0	a	doxorubicin associated toxicity
2011	0	a	doxorubicin induced cardiotoxicity in stress in rats with cancer
2012	0	a	doxorubicin associated toxicity ameliorated with hydroxytyrosol in rats with cancer
2013	0	a	doxorubicin divided rats bearing tumors
2014	0	a	doxorubicin doxorubicin divided rats bearing tumors
2015	0	a	doxorubicin as drugs of effect potentiate shown involved in processes including cancer
2016	0	a	doxorubicin as drugs of effect potentiate shown involved in processes including cancer disease
2017	0	a	Hydroxytyrosol improved disturbances
2018	0	a	hydroxytyrosol protect that damage
2019	1	a	doxorubicin by enhanced disturbances
2020	1	a	doxorubicin by provoked damage
2021	1	a	Adrenaline induced hypertension
2022	1	a	adrenaline giving after evaluated BBB destroy used hypertension
2023	0	a	triphenyltetrazolium using evaluated BBB destroy used hypertension
2024	0	a	TTC triphenyltetrazolium using evaluated BBB destroy used hypertension
2025	0	a	lithium therapy receiving patient bipolar
2026	0	a	lithium therapy receiving patient in findings prompted conduct study of patients bipolar
2027	0	a	lithium associated hypercalcemia with patients of study conduct prompted findings in patient bipolar
2028	0	a	lithium associated hypercalcemia with patients bipolar
2029	0	a	lithium treated patients normocalcemic bipolar
2030	0	a	lithium treated patients age- included C1 C2 included patients bipolar
2031	0	a	lithium associated hypercalcemia with diseases patients bipolar
2032	1	a	lithium therapy receiving patient developed hypercalcemia
2033	1	a	lithium therapy receiving patient in findings prompted conduct study of patients with hypercalcemia
2034	1	a	lithium associated hypercalcemia with patients of study conduct prompted findings in patient developed hypercalcemia
2035	1	a	lithium associated hypercalcemia
2036	1	a	lithium treated patients identified After eliminating hypercalcemias
2037	1	a	lithium treated patients with hypercalcemias
2038	1	a	lithium treated patients patients with hypercalcemia
2039	1	a	lithium associated hypercalcemia with patients patients identified After eliminating hypercalcemias
2040	1	a	lithium associated hypercalcemia with patients patients with hypercalcemias
2041	1	a	lithium associated hypercalcemia
2042	1	a	lithium associated hypercalcemia with diseases from resulting hypercalcemia
2043	1	a	lithium associated hypercalcemia
2044	0	a	lithium therapy receiving patient developed hypercalcemia bradyarrhythmia
2045	0	a	lithium associated hypercalcemia with patients of study conduct prompted findings in patient developed hypercalcemia bradyarrhythmia
2046	0	a	lithium treated patients with hypercalcemias related to malignancies
2047	0	a	lithium associated hypercalcemia with patients patients with hypercalcemias related to malignancies
2048	1	a	androgen with treated carcinoma
2049	0	a	androgen with treated carcinoma in anemia
2050	0	a	androgens with treated known have anemia
2051	0	a	androgen- and treated anemia
2052	1	a	corticosteroid androgen with treated carcinoma
2053	0	a	corticosteroid androgen with treated carcinoma in anemia
2054	0	a	corticosteroids androgens with treated known have anemia
2055	0	a	corticosteroid treated anemia
2056	0	a	androgen- and treated anemia observations develop neoplasms
2057	1	a	androgen- and treated anemia observations develop neoplasms peliosis
2058	0	a	corticosteroid treated anemia observations develop neoplasms
2059	1	a	corticosteroid treated anemia observations develop neoplasms peliosis
2060	1	a	GTN administration following drop in pressure
2061	1	a	GTN experienced drop in pressure
2062	0	a	sulphate by rectified minutes after GTN experienced drop in pressure
2063	1	a	Amiodarone induced pointes
2064	1	a	amiodarone therapy with associated torsade pointes
2065	1	a	amiodarone therapy with associated torsade pointes TdP
2066	1	a	amiodarone therapy of context in resulted speculate TdP.
2067	1	a	amiodarone induced proarrhythmia in resulted speculate TdP.
2068	1	a	amiodarone therapy of absence In induce TdP
2069	0	a	digoxin hypokalemia including factors of context in occurred case of TdP
2070	0	a	digoxin hypokalemia
2071	0	a	amiodarone therapy of context in resulted in proarrhythmia
2072	0	a	amiodarone induced proarrhythmia
2073	0	a	amiodarone therapy of absence In induce despite hypokalemia
2074	0	a	amiodarone therapy of absence In induce despite hypokalemia hypomagnesemia
2075	0	a	propranolol of effects on hypertrophy
2076	1	a	isoproterenol induced hypertrophy
2077	1	a	isoproterenol induced hypertrophy
2078	1	a	isoproterenol prevent from producing hypertrophy
2079	0	a	ornithine decarboxylase activity suppress with blockers in hearts
2080	0	a	propranolol stop changes in pattern of heart hypertrophied
2081	1	a	heparin induced thrombocytopenia
2082	1	a	heparin therapy of effects thrombosis thrombocytopenia
2083	1	a	heparin therapy of effects include thrombocytopenia
2084	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia
2085	1	a	heparin induced thrombocytopenia
2086	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia
2087	1	a	heparin associated osteoporosis thrombocytopenia
2088	1	a	heparin associated osteoporosis eosinophilia reactions reactions other than thrombocytopenia
2089	0	a	heparin of use given are common HITT
2090	0	a	heparin induced thrombocytopenia thrombosis
2091	0	a	heparin therapy of effects thrombosis
2092	0	a	Heparin used treat thrombosis
2093	0	a	heparin remains treat episodes thrombotic
2094	0	a	heparin of use given are common HITT
2095	0	a	heparin of effect is Bleeding
2096	0	a	heparin therapy receiving patients in concern of is bleeding
2097	1	a	heparin therapy of effects include thrombocytopenia osteoporosis
2098	1	a	heparin induced thrombocytopenia osteoporosis
2099	1	a	heparin associated osteoporosis
2100	1	a	heparin of use given are common HITT osteoporosis
2101	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia
2102	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia
2103	1	a	heparin associated osteoporosis eosinophilia
2104	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions
2105	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions
2106	1	a	heparin associated osteoporosis eosinophilia reactions
2107	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions
2108	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions
2109	1	a	heparin associated osteoporosis eosinophilia reactions reactions
2110	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia
2111	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia
2112	1	a	heparin associated osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia
2113	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia
2114	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia
2115	1	a	heparin associated osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia
2116	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism
2117	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism
2118	1	a	heparin associated osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism
2119	1	a	heparin therapy of effects include thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism priapism
2120	1	a	heparin induced thrombocytopenia osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism priapism
2121	1	a	heparin associated osteoporosis eosinophilia reactions reactions other than thrombocytopenia alopecia transaminasemia hyperkalemia hypoaldosteronism priapism
2122	1	a	everolimus with treated proteinuria
2123	1	a	everolimus to conversion after developed proteinuria
2124	1	a	everolimus with treated proteinuria with patient in diagnosis amyloidosis AL
2125	1	a	everolimus with treated proteinuria with patient in diagnosis amyloidosis
2126	1	a	everolimus to conversion after developed significance of gammapathy with patient in report diagnosis of amyloidosis
2127	0	a	rapamycin inhibitors of target with treated complication is Proteinuria
2128	0	a	tacrolimus from conversion after developed significance of gammapathy with patient in report diagnosis of amyloidosis
2129	0	a	tacrolimus from conversion after developed proteinuria
2130	1	a	fluoxetine treatment during Delirium
2131	1	a	fluoxetine with connected delirium
2132	1	a	fluoxetine concentration fluoxetine with connected delirium
2133	0	a	citalopram of concentration associated with difficulties somnolence
2134	0	a	citalopram of concentration associated with difficulties
2135	1	a	fluoxetine with connected delirium hyperkinetic
2136	1	a	fluoxetine concentration fluoxetine with connected delirium hyperkinetic
2137	0	a	desmethylfluoxetine fluoxetine concentration fluoxetine with connected delirium hyperkinetic
2138	0	a	desmethylfluoxetine fluoxetine concentration fluoxetine with connected delirium
2139	1	a	doxorubicin of cardiotoxicity
2140	1	a	doxorubicin toxicity cardiotoxicity
2141	1	a	DOX doxorubicin toxicity cardiotoxicity
2142	1	a	DOX received animals in observed deaths related to cardiotoxicity
2143	1	a	DOX received animals in observed revealed marked changes in heart were consistent with cardiotoxicity
2144	1	a	DOX copolymer of mixture DOX received animals in observed deaths related to cardiotoxicity
2145	1	a	DOX copolymer of mixture DOX received animals in observed revealed marked changes in heart were consistent with cardiotoxicity
2146	1	a	DOX induced cardiotoxicity with consistent were heart in changes marked revealed observed deaths related to cardiotoxicity
2147	1	a	DOX induced cardiotoxicity
2148	0	a	N-(2-hydroxypropyl)methacrylamide conjugates of form in given cardiotoxicity
2149	0	a	N-(2-hydroxypropyl)methacrylamide of form in as given evaluate toxicity cardiotoxicity
2150	0	a	HPMA copolymer of mixture DOX received animals in observed deaths related to cardiotoxicity
2151	0	a	HPMA copolymer of mixture DOX received animals in observed revealed marked changes in heart were consistent with cardiotoxicity
2152	0	a	doxorubicin toxicity
2153	0	a	DOX doxorubicin toxicity
2154	0	a	N-(2-hydroxypropyl)methacrylamide of form in as given evaluate toxicity
2155	0	a	methamphetamine of dose neurotoxic
2156	1	a	methamphetamine of dose induces behaviour like depressive
2157	1	a	METH of dosage causes phenotype depressive
2158	1	a	METH dose following assessed behaviour like depressive
2159	1	a	METH by induced profile like depressive
2160	1	a	METH of dose induces behaviour like depressive
2161	0	a	dopamine of levels in reduction by indicated accompanied profile like depressive
2162	0	a	DOPAC dopamine of levels in reduction by indicated accompanied profile like depressive
2163	0	a	HVA DOPAC dopamine of levels in reduction by indicated accompanied profile like depressive
2164	0	a	tyrosine hydroxylase dopamine of levels in reduction by indicated accompanied profile like depressive
2165	0	a	serotonin hydroxylase dopamine of levels in reduction by indicated accompanied profile like depressive
2166	0	a	desferrioxamine therapy during occurring failure
2167	0	a	desferrioxamine by caused failure
2168	0	a	desferrioxamine treatment undergoing patient with thalassemia
2169	0	a	DFX desferrioxamine treatment undergoing patient with thalassemia
2170	1	a	methotrexate with treated patients with leukoencephalopathy
2171	0	a	methotrexate with treated patients with leukoencephalopathy developed from leukemia
2172	1	a	lithium induced diabetes insipidus
2173	1	a	Lithium induces insipidus
2174	1	a	Lithium induces insipidus NDI
2175	1	a	lithium induced NDI
2176	1	a	lithium therapy with associated polyuria of development prevents preserves expression in NDI
2177	1	a	lithium induced polyuria
2178	1	a	lithium induced NDI in expression preserves prevents development of polyuria
2179	1	a	lithium therapy with associated polyuria
2180	1	a	lithium induced diabetes insipidus by precipitated coma
2181	1	a	lithium with treated depression of history with man admitted with coma
2182	1	a	lithium induced diabetes insipidus
2183	1	a	lithium induced be likely indicated insipidus
2184	0	a	lithium with treated depression
2185	0	a	glucose for negative been history of polyuria
2186	0	a	glucose concentrations despite remained polyuric
2187	0	a	glucose for negative been history of polyuria polydipsia
2188	0	a	glucose concentrations despite remained After recovery from hyperglycaemia
2189	0	a	glucose concentrations despite remained indicated insipidus
2190	0	a	lithium induced be likely indicated remained After recovery from hyperglycaemia
2191	1	a	lithium induced be likely indicated remained polyuric
2192	1	a	suxamethonium with apnea
2193	1	a	suxamethonium relaxants of use after characterized by apnea
2194	1	a	suxamethonium relaxants of use after characterized deficiency
2195	1	a	mivacurium suxamethonium relaxants of use after characterized deficiency
2196	1	a	mivacurium suxamethonium relaxants of use after characterized by apnea
2197	0	a	cocaine associated pain
2198	0	a	cocaine associated pain
2199	0	a	cocaine chest pain
2200	0	a	cocaine associated pain
2201	0	a	cocaine associated pain with patients in difficult make abnormalities associated with necrosis
2202	1	a	cocaine associated pain with patients in difficult make diagnosis of infarction
2203	1	a	cocaine associated pain with patients in difficult make diagnosis of infarction MI
2204	1	a	cocaine chest pain with patients in positivity admitted for exclusion of MI
2205	1	a	cocaine use after admitted for MI
2206	1	a	cocaine associated pain MI
2207	0	a	cocaine associated pain with patients in necrosis
2208	1	a	labetalol by induced hypotension
2209	1	a	labetalol using of feasibility as agent hypotensive
2210	1	a	labetalol induces hypotension
2211	1	a	halothane with induced hypotension
2212	1	a	halothane anaesthetics with combination in agent hypotensive
2213	1	a	H concentration during hypotension
2214	1	a	enflurane halothane with induced hypotension
2215	1	a	enflurane halothane anaesthetics with combination in agent hypotensive
2216	1	a	isoflurane enflurane halothane with induced hypotension
2217	1	a	isoflurane enflurane halothane anaesthetics with combination in agent hypotensive
2218	1	a	isoflurane group except level to returned rose During hypotension
2219	1	a	isoflurane group except level to returned rose before hypotension
2220	0	a	creatinine concentration rose During hypotension
2221	0	a	creatinine concentration rose before hypotension
2222	0	a	labetalol induces without tachycardia
2223	0	a	labetalol induces rebound hypertension
2224	0	a	pethidine of infusion by induced dysfunction
2225	0	a	pethidine of infusion by induced dysfunction
2226	0	a	Pethidine is opioid gains for control pain
2227	0	a	pethidine cause In those need control pain
2228	0	a	pethidine cause In patients with function
2229	0	a	pethidine cause In patients with function
2230	0	a	pethidine cause effects through metabolite neurotoxic
2231	0	a	pethidine cause effects resulting in irritability
2232	0	a	pethidine cause effects resulting in irritability attack seizure
2233	0	a	norpethidine metabolite through effects cause In patients with function
2234	0	a	norpethidine metabolite through effects cause In patients with function
2235	0	a	norpethidine metabolite through effects cause In those need control pain
2236	0	a	norpethidine metabolite neurotoxic
2237	0	a	norpethidine metabolite through effects resulting in irritability
2238	1	a	norpethidine metabolite through effects resulting in irritability attack seizure
2239	1	a	inhibitors with risk of infarction
2240	1	a	inhibitors with risk of infarction AMI
2241	1	a	inhibitors using bleeding AMI
2242	1	a	drugs with compared offset risk of infarction
2243	1	a	drugs with compared offset risk of infarction AMI
2244	0	a	inhibitors using bleeding
2245	0	a	acetaminophen NSAIDs inhibitors using bleeding AMI
2246	0	a	acetaminophen vs GI AMI
2247	0	a	acetaminophen of that to similar was toxicity GI AMI
2248	0	a	acetaminophen NSAIDs inhibitors using bleeding
2249	0	a	aspirin of users Among were ratios of hospitalization for GI AMI
2250	0	a	aspirin group with ratios of hospitalization for GI AMI
2251	0	a	aspirin of users Among seemed carry risk for bleeding GI AMI
2252	1	a	rofecoxib were ratios of hospitalization for GI AMI
2253	1	a	rofecoxib of those than better be seemed was toxicity GI AMI
2254	0	a	celecoxib rofecoxib were ratios of hospitalization for GI AMI
2255	0	a	celecoxib of toxicity GI AMI
2256	1	a	naproxen celecoxib rofecoxib were ratios of hospitalization for GI AMI
2257	1	a	naproxen seemed carry risk for bleeding GI AMI
2258	0	a	diclofenac rofecoxib were ratios of hospitalization for GI AMI
2259	0	a	ibuprofen diclofenac rofecoxib were ratios of hospitalization for GI AMI
2260	0	a	aspirin of users Among seemed carry risk for bleeding
2261	1	a	naproxen seemed carry risk for bleeding
2262	0	a	celecoxib of toxicity
2263	0	a	acetaminophen of that to similar was toxicity
2264	0	a	rofecoxib of those than better be seemed was toxicity
2265	1	a	desvenlafaxine with associated secretion hormone
2266	1	a	desvenlafaxine with associated secretion hormone
2267	1	a	desvenlafaxine with associated secretion SIADH
2268	1	a	desvenlafaxine included included nausea
2269	1	a	desvenlafaxine included included nausea anxiety
2270	1	a	desvenlafaxine included included nausea anxiety confusion
2271	0	a	sodium L consistent with diagnosis of SIADH
2272	1	a	desvenlafaxine cause hyponatremia
2273	0	a	Carvedilol protects against cardiomyopathy
2274	0	a	carvedilol by protection afford in minimizing dysfunction cardiomyopathy
2275	1	a	doxorubicin induced cardiomyopathy
2276	1	a	doxorubicin by caused cardiomyopathy
2277	1	a	doxorubicin therapy accompanies dysfunction cardiomyopathy
2278	0	a	carvedilol protects against dysfunction associated with toxicity
2279	0	a	doxorubicin toxicity
2280	0	a	carvedilol by protection afford in minimizing dysfunction
2281	0	a	carvedilol by protection afford in minimizing dysfunction accompanies therapy in patients cancer
2282	0	a	doxorubicin therapy accompanies dysfunction
2283	0	a	doxorubicin therapy in patients cancer
2284	1	a	tetracycline by induced liver
2285	1	a	tetracycline by induced liver
2286	1	a	tetracycline to response in involved in production of liver
2287	0	a	acid of provision With observed between dose accumulation of triglyceride in liver depression
2288	0	a	tetracycline of dose accumulation of triglyceride in liver depression
2289	0	a	tetracycline of effects on depression
2290	0	a	triglyceride in liver depression
2291	0	a	triglyceride of output of liver depression
2292	0	a	triglyceride of output of depression
2293	0	a	triglyceride of secretion accounted indicating involved in production of liver
2294	0	a	triglyceride of % for accounted indicating involved in production of liver
2295	0	a	triglyceride rich liver
2296	1	a	vigabatrin to specific are defects
2297	1	a	vigabatrin with associated defects
2298	1	a	VGB vigabatrin with associated defects
2299	0	a	VGB to exposure previous current therapy of basis on grouped people with epilepsy
2300	1	a	VGB with associated toxicity
2301	0	a	Nefiracetam reverses amnesia
2302	0	a	DM-9384 Nefiracetam reverses amnesia
2303	0	a	nefiracetam of ability evaluated attenuate amnesia
2304	0	a	nefiracetam of administration reversed amnesia
2305	1	a	apomorphine induced amnesia
2306	1	a	apomorphine inhibits evaluated attenuate amnesia
2307	1	a	apomorphine by induced amnesia
2308	0	a	Nefiracetam is derivative attenuates deficits
2309	0	a	pyrrolidone derivative attenuates deficits
2310	1	a	scopolamine induced learning deficits
2311	0	a	melatonin of effects upon cortex in model of dysplasia
2312	0	a	melatonin of effects upon dysplasia
2313	1	a	BCNU induced dysplasia
2314	1	a	carmustine-[1,3-bis to exposure by induced cerebellum in alterations evaluate investigate effects upon dysplasia
2315	1	a	2-chloroethyl)-1-nitrosoure carmustine-[1,3-bis to exposure by induced cerebellum in alterations evaluate investigate effects upon dysplasia
2316	1	a	BCNU alterations evaluate investigate effects upon dysplasia
2317	1	a	BCNU induced dysplasia
2318	1	a	BCNU exposed group dysplasia
2319	0	a	oxide synthesis of inhibition modifies catalepsy
2320	0	a	oxide synthase of inhibitor arginine induces catalepsy
2321	1	a	haloperidol induced catalepsy
2322	1	a	haloperidol as drugs cause catalepsy
2323	1	a	haloperidol induced catalepsy
2324	1	a	haloperidol induced catalepsy
2325	0	a	NADPH diaphorase neurons of number catalepsy
2326	0	a	arginine induces catalepsy
2327	0	a	NOARG arginine induces catalepsy
2328	0	a	NOARG treatment of effects in catalepsy
2329	0	a	NOARG administration produced tolerance of of catalepsy
2330	0	a	NOARG of of catalepsy
2331	0	a	dopamine receptors block haloperidol as drugs cause catalepsy
2332	0	a	Testosterone ameliorates impairment
2333	0	a	testosterone of effects on streptozotocin impairment
2334	0	a	testosterone replacement attenuated impaired memory
2335	0	a	testosterone replacement impairment
2336	0	a	Testosterone administration ameliorates impairment
2337	1	a	streptozotocin induced impairment
2338	1	a	streptozotocin impairment
2339	1	a	STZ)-induced impairment
2340	1	a	STZ- improving in replacement attenuated impaired memory
2341	1	a	STZ- improving in replacement impairment
2342	1	a	STZ- impairment
2343	1	a	flutamide of Administration impaired memory
2344	1	a	flutamide of Administration impaired attenuated replacement impairment
2345	1	a	letrozole flutamide of Administration impaired memory
2346	1	a	letrozole flutamide of Administration impaired attenuated replacement impairment
2347	1	a	tamoxifen letrozole flutamide of Administration impaired memory
2348	1	a	tamoxifen letrozole flutamide of Administration impaired attenuated replacement impairment
2349	1	a	timolol with associated bradycardia
2350	1	a	maleate drops with treated man developed bradycardia
2351	1	a	timolol with associated bradycardia hypotension
2352	1	a	maleate drops with treated man developed became hypotensive
2353	1	a	pilocarpine drops timolol with associated bradycardia
2354	1	a	nitrate drops with treated man developed bradycardia
2355	1	a	pilocarpine drops timolol with associated bradycardia hypotension
2356	1	a	nitrate drops with treated man developed became hypotensive
2357	0	a	halothane anaesthesia during became developed bradycardia
2358	0	a	halothane anaesthesia with bradycardia
2359	0	a	halothane anaesthesia during became hypotensive
2360	0	a	halothane anaesthesia with bradycardia hypotension
2361	1	a	ethinylestradiol associated cholestasis
2362	1	a	EE)-induced cholestasis
2363	0	a	salt synthesis of pathway of inhibition with associated cholestasis
2364	0	a	BS synthesis of pathway of inhibition with associated cholestasis
2365	1	a	Fluconazole agranulocytosis
2366	1	a	fluconazole agranulocytosis
2367	1	a	fluconazole with therapy of result as occurred agranulocytosis
2368	1	a	Fluconazole agranulocytosis thrombocytopenia
2369	1	a	fluconazole agranulocytosis with thrombocytopenia
2370	1	a	fluconazole with therapy of result as occurred agranulocytosis thrombocytopenia
2371	0	a	fluconazole of initiation to relationship of suppression
2372	1	a	carbamazepine with treated patient in anemia
2373	1	a	carbamazepine treatment due case of anemia
2374	0	a	carbamazepine treatment in woman epileptic
2375	0	a	carbamazepine to due concerns of toxicity
2376	0	a	ethanol extract of rhizomes on infarction
2377	1	a	isoproterenol induced infarction
2378	1	a	isoproterenol induced infarction
2379	1	a	fluoxetine occlusion
2380	1	a	fluoxetine induced hypertension with associated occlusion
2381	1	a	fluoxetine induced hypertension
2382	0	a	serotonin therapy of complication Although is are aware cause hypertension
2383	0	a	argatroban thrombolysis
2384	0	a	argatroban thrombolysis
2385	0	a	argatroban thrombolysis of Use in patient with thrombocytopenia
2386	0	a	argatroban thrombolysis with treated developed thrombocytopenia
2387	0	a	argatroban thrombolysis with treated developed with thrombosis HITT
2388	0	a	argatroban with treated man secondary to HITT
2389	0	a	argatroban thrombolysis of Use with thrombosis
2390	0	a	argatroban thrombolysis with treated developed with thrombosis
2391	0	a	argatroban thrombolysis with treated developed with thrombosis HITT
2392	0	a	argatroban with treated man secondary to HITT
2393	0	a	heparin induced thrombocytopenia with patient in Use of thrombolysis
2394	0	a	heparin induced thrombocytopenia developed treated with thrombolysis
2395	1	a	heparin induced thrombocytopenia
2396	1	a	heparin induced thrombocytopenia
2397	1	a	heparin induced thrombocytopenia
2398	0	a	heparin induced thrombocytopenia developed with thrombosis HITT
2399	0	a	heparin induced thrombocytopenia with patient in Use with thrombosis
2400	0	a	heparin induced thrombocytopenia developed with thrombosis
2401	0	a	heparin induced thrombocytopenia developed with thrombosis HITT
2402	0	a	argatroban on restarted resolved epistaxis
2403	0	a	argatroban with treated man with amyloidosis
2404	0	a	argatroban with treated man with amyloidosis syndrome
2405	1	a	hydrochloride ingesting heart involving thrombosis
2406	1	a	hydrochloride had have thrombosis
2407	0	a	hydrochloride had thrombosis
2408	0	a	nitrite hydrochloride had thrombosis
2409	0	a	nitrite hydrochloride had have thrombosis
2410	0	a	MT induction on carmustine dysfunction
2411	1	a	carmustine dysfunction
2412	1	a	BCNU)-induced carmustine dysfunction
2413	1	a	BCNU administration resulted in deterioration of learning memory
2414	1	a	BCNU administration resulted in deterioration of learning memory
2415	0	a	glutathione GR activity with accompanied resulted in deterioration of learning memory
2416	0	a	glutathione content activity with accompanied resulted in deterioration of learning memory
2417	0	a	GSH content activity with accompanied resulted in deterioration of learning memory
2418	0	a	glutathione GR activity with accompanied resulted in deterioration of learning memory
2419	0	a	glutathione content activity with accompanied resulted in deterioration of learning memory
2420	0	a	GSH content activity with accompanied resulted in deterioration of learning memory
2421	0	a	BCNU administration increased contents factor necrosis tumor
2422	0	a	BCNU administration increased contents factor necrosis
2423	0	a	MT factor necrosis tumor
2424	0	a	MT factor necrosis
2425	0	a	malondialdehyde MT factor necrosis tumor
2426	0	a	MDA contents factor necrosis tumor
2427	0	a	malondialdehyde MT factor necrosis
2428	0	a	MDA contents factor necrosis
2429	0	a	MT induction halts toxicity
2430	0	a	BCNU induced toxicity
2431	0	a	GSH depletion inhibition prevented halts toxicity
2432	0	a	MDA TNFalpha of levels counteracted prevented halts toxicity
2433	0	a	lamivudine untreated patients with infection
2434	0	a	Lamivudine used for treatment of patients B
2435	0	a	lamivudine untreated patients B
2436	0	a	lamivudine untreated patients B
2437	0	a	lamivudine with treated patients B
2438	0	a	lamivudine untreated patients with B
2439	0	a	lamivudine untreated patients in mutants of occurrence reported detected in patients B
2440	0	a	lamivudine untreated patients in detected reported occurrence of mutants in patients with B
2441	0	a	lamivudine untreated patients B
2442	0	a	lamivudine untreated patients in variability as occur mutants virus B
2443	0	a	argatroban therapy in thrombocytopenia
2444	0	a	Argatroban is direct thrombin inhibitor used in thrombocytopenia
2445	0	a	Argatroban is direct thrombin inhibitor used in thrombocytopenia HIT
2446	0	a	Argatroban is direct thrombin inhibitor used for patients with at risk of HIT
2447	0	a	argatroban therapy in HIT
2448	0	a	argatroban dose in HIT
2449	0	a	argatroban therapy in HIT
2450	0	a	argatroban therapy with familiarity facilitate reduction of harm associated with thromboses HIT
2451	0	a	argatroban errors treatment reduction facilitate familiarity with therapy in HIT
2452	0	a	argatroban errors treatment reduction of harm associated with thromboses HIT
2453	0	a	heparin induced thrombocytopenia
2454	0	a	heparin induced thrombocytopenia
2455	0	a	heparin induced thrombocytopenia HIT
2456	0	a	heparin induced thrombocytopenia in used for patients with at risk of HIT
2457	0	a	Argatroban is direct thrombin inhibitor used for prophylaxis of thrombosis
2458	0	a	heparin induced thrombocytopenia in used for prophylaxis of thrombosis
2459	0	a	argatroban investigated is be age sex ethnicity obesity
2460	1	a	argatroban with bleeding
2461	1	a	norepinephrine by induced spasm
2462	0	a	norepinephrine by induced vasoconstriction produced hernias
2463	0	a	levodopa induced dyskinesias rigidity bradykinesia Stages patients suffering from disease
2464	0	a	levodopa induced dyskinesias rigidity bradykinesia
2465	0	a	levodopa induced dyskinesias rigidity
2466	1	a	levodopa induced dyskinesias
2467	1	a	levodopa dose in reduction is useful in controlling dyskinesias
2468	1	a	Methyldopa induced anemia
2469	1	a	methyldopa induced anemia
2470	0	a	Methyldopa induced anemia presenting as syncope
2471	0	a	methyldopa induced anemia of case in boy presented with syncope
2472	0	a	Methyldopa causes anemia
2473	0	a	methyldopa induced anemia of case in boy presented to department
2474	0	a	methyldopa with treated during admission trauma
2475	1	a	medium nephrotoxicity
2476	1	a	medium administration by induced dysfunction
2477	1	a	CM administration by induced dysfunction
2478	1	a	CM of effect nephrotoxic
2479	1	a	CM administration by induced damage
2480	0	a	CM toxicity
2481	0	a	domperidone potentiate syndrome
2482	0	a	domperidone induce aggravate symptoms of RLS
2483	0	a	domperidone therapy to added report comorbid with dyspepsia developed RLS
2484	0	a	domperione of effect support relationship between use of mirtazapine symptoms of RLS
2485	0	a	domperione on RLS
2486	1	a	mirtazapine associated syndrome
2487	1	a	Mirtazapine associated with RLS
2488	1	a	mirtazapine after developed RLS
2489	1	a	mirtazapine with treated have symptoms of RLS
2490	1	a	mirtazapine with treated have started resolved symptoms RLS
2491	1	a	mirtazapine of discontinuation upon resolved started have symptoms of RLS
2492	1	a	mirtazapine of discontinuation upon resolved symptoms RLS
2493	1	a	mirtazapine symptoms of RLS
2494	1	a	mirtazapine of use between relationship support effect of domperione on RLS
2495	1	a	mirtazapine associated RLS on domperione of effect support relationship between use of mirtazapine symptoms of RLS
2496	1	a	mirtazapine associated RLS
2497	1	a	mirtazapine associated with RLS
2498	0	a	levodopa agonists by improved symptoms of RLS
2499	0	a	levodopa agonists by improved induce aggravate symptoms RLS
2500	0	a	dopamine levodopa agonists by improved symptoms of RLS
2501	0	a	dopamine levodopa agonists by improved induce aggravate symptoms RLS
2502	0	a	dopamine D2 antagonists induce improved symptoms of RLS
2503	0	a	dopamine D2 antagonists induce aggravate symptoms RLS
2504	0	a	dopamine D2 antagonist domperidone induce aggravate symptoms of RLS
2505	0	a	dopamine D2 antagonists receiving those individuals in associated with RLS
2506	0	a	mirtazapine after developed dyspepsia
2507	0	a	domperidone therapy to added report comorbid with dyspepsia
2508	1	a	cyclophosphamide induced cystitis
2509	1	a	cyclophosphamide by induced inflammation
2510	1	a	CYP cyclophosphamide by induced inflammation
2511	1	a	CYP induced cystitis
2512	1	a	CYP induced cystitis
2513	1	a	CYP induced cystitis
2514	0	a	tyrosine receptors of expression in reflexes with inflammation
2515	0	a	CPA treatment on period After found affected by disease
2516	1	a	CPA therapy by caused arteriosclerosis
2517	1	a	CPA therapy by caused arteriosclerosis mediated through changes in cholesterol I les other than effect
2518	0	a	cholesterol in changes through mediated arteriosclerosis
2519	0	a	cholesterol I les other than effect
2520	0	a	estrogen by caused effect than other les I cholesterol in changes through mediated arteriosclerosis
2521	0	a	estrogen by caused effect
2522	1	a	Aconitine induced causes arrhythmia
2523	1	a	aconitine aggravates overload causes arrhythmia
2524	0	a	Ca2 causes arrhythmia
2525	0	a	Ca(2 overload lead caused arrhythmia
2526	0	a	Ca(2 overload causes arrhythmia
2527	0	a	Na(+ ) channels have in cardiotoxicity
2528	1	a	aconitine of cardiotoxicity
2529	0	a	Ca(2 of role on available are in poisoning
2530	0	a	Ca(2 of importance explored signaling in poisoning
2531	1	a	aconitine poisoning
2532	1	a	aconitine poisoning
2533	0	a	aconitine of effects on injury
2534	0	a	aconitine resulted in injury
2535	0	a	aconitine of effects investigate performed assay cytotoxicity
2536	0	a	lactate level performed investigate effects on injury
2537	0	a	lactate level performed assay cytotoxicity
2538	0	a	lovastatin is product approved for treatment of hypercholesterolemia
2539	0	a	lovastatin is product approved for treatment of hypercholesterolemia dyslipidemia
2540	0	a	lovastatin dyslipidemia
2541	0	a	creatine phosphokinase of increase occurred observed cases of myopathy
2542	1	a	veralipride of use after Worsening of Parkinsonism
2543	1	a	veralipride with symptoms of therapy following worsening shown disease
2544	1	a	acid seizures convulsive
2545	1	a	acid seizures
2546	1	a	acid clamp of duration arrest failure ascending of calcification redo included predictors of seizures
2547	1	a	acid was predictor of seizures
2548	1	a	acid is weighed against risk of seizures
2549	0	a	acid clamp of duration arrest failure
2550	0	a	acid clamp of duration arrest hypothermic
2551	1	a	nicergoline due nephritis
2552	1	a	Sermion nicergoline due nephritis
2553	1	a	nicergoline due case of nephritis
2554	1	a	nicergoline due case of nephritis AIN
2555	1	a	Sermion nicergoline due case of nephritis
2556	1	a	Sermion nicergoline due case of nephritis AIN
2557	1	a	nicergoline associated AIN
2558	0	a	nicergoline taking due occlusion
2559	0	a	lysine bendazac taking due occlusion
2560	1	a	C after edema
2561	1	a	C after edema shock
2562	1	a	C associated hypothesize thought involved in development of shock
2563	0	a	C for lymphoma
2564	0	a	C with treated for lymphomas
2565	0	a	C associated hypothesize thought involved in development of shock syndrome
2566	0	a	bupivacaine induced depression
2567	0	a	propofol of formulations using treatment of depression
2568	1	a	bupivacaine of doses increase shown alleviate cardiotoxicity
2569	1	a	bupivacaine induced cardiotoxicity
2570	1	a	bupivacaine induced cardiotoxicity
2571	1	a	bupivacaine levels were conclude delayed onset of effects cardiotoxic
2572	1	a	Bupivacaine levels in than lower were conclude delayed onset of effects cardiotoxic
2573	1	a	bupivacaine induced effects cardiotoxic
2574	1	a	bupivacaine levels effects cardiotoxic
2575	0	a	propofol of content alleviate cardiotoxicity
2576	0	a	propofol of effects in emulsions on cardiotoxicity
2577	0	a	propofol with treatment delayed onset of effects cardiotoxic
2578	0	a	propofol with compared delayed onset of effects cardiotoxic
2579	0	a	bupivacaine consumption of amount recorded to occurrence dysrhythmia
2580	1	a	bupivacaine consumption of amount mean pressure time asystole
2581	0	a	K(+)-channel blockers of neither affected hypoactivity
2582	0	a	K(+)-channel blockers prevented affected hypoactivity
2583	0	a	K(+)-channels of blockade is sufficient prevent hypoactivity
2584	0	a	K(+)-channel blockers of neither affected prevented hyperactivity
2585	0	a	K(+)-channel blockers prevented hyperactivity
2586	0	a	K(+)-channels of blockade is seems hyperactivity
2587	0	a	morphine induced hypoactivity
2588	0	a	morphine induced hyperactivity prevented affected hypoactivity
2589	0	a	morphine induced hypoactivity
2590	0	a	morphine induced hyperactivity seems is sufficient prevent hypoactivity
2591	1	a	morphine induced hypoactivity affected prevented hyperactivity
2592	1	a	morphine induced hyperactivity
2593	1	a	morphine induced hypoactivity prevent sufficient is seems hyperactivity
2594	1	a	morphine induced hyperactivity
2595	0	a	quinine- to connected seems is sufficient prevent hypoactivity
2596	0	a	quinine- to connected seems hyperactivity
2597	0	a	indinavir therapy undergoing obstruction
2598	0	a	indinavir crystals by caused obstruction
2599	0	a	indinavir therapy receive infection with patients in stones obstruction
2600	1	a	indinavir receiving patients in calculi
2601	0	a	indinavir therapy receive infection with patients in stones obstruction
2602	0	a	indinavir receiving patients infected
2603	0	a	indinavir therapy receive infection
2604	0	a	indinavir inhibitor associated with incidence of urolithiasis
2605	1	a	cocaine of amount causes deterioration of function
2606	1	a	cocaine of infusion causes deterioration of performance
2607	0	a	hydrochloride saline of infusion of minutes during before pressure rate measured referred for catheterization for evaluation of pain
2608	1	a	methylprednisolone therapy after Bradycardia
2609	0	a	methylprednisolone therapy received patients with arthritis
2610	0	a	MP therapy received patients with arthritis
2611	0	a	MP contraindicated in patients with disease
2612	1	a	Amlodipine of effect be Going Dysguesia
2613	1	a	amlodipine of effect is dysguesia
2614	1	a	amlodipine cause dysguesia
2615	1	a	amlodipine dysguesia
2616	0	a	amlodipine loss with hypertension
2617	0	a	amlodipine loss of sensation
2618	0	a	warfarin on aged over 75 in fibrillation
2619	0	a	warfarin on fibrillation
2620	0	a	warfarin on fibrillation
2621	1	a	warfarin on aged People rate of hemorrhage
2622	1	a	warfarin on fibrillation with aged people in incidence of hemorrhage
2623	1	a	warfarin use strokes episodes bleeding
2624	1	a	warfarin on rate was resulted was rate of hemorrhage
2625	1	a	warfarin treatment is demonstrating was resulted was rate of hemorrhage
2626	0	a	warfarin on aged People rate stroke
2627	0	a	warfarin on fibrillation with aged people in incidence of hemorrhage stroke
2628	0	a	warfarin use strokes
2629	0	a	warfarin of initiation after rate stroke
2630	0	a	warfarin on rate stroke
2631	0	a	warfarin treatment is demonstrating was rate stroke
2632	1	a	haloperidol induced catalepsy
2633	1	a	haloperidol blocker by induced catalepsy
2634	1	a	haloperidol induced catalepsy
2635	1	a	haloperidol by induced catalepsy
2636	1	a	haloperidol as neuroleptics by produced catalepsy
2637	0	a	neuroleptic induced catalepsy of expression for be need promotes catalepsy
2638	0	a	neuroleptic induced catalepsy
2639	0	a	neuroleptics by produced catalepsy
2640	1	a	pilocarpine doses induce catalepsy
2641	1	a	pilocarpine of doses caused enhancement of catalepsy
2642	0	a	atropine blocker disrupted catalepsy
2643	0	a	acetylcholine synthesis inhibitor of injection prevented catalepsy
2644	0	a	hemicholinium inhibitor of injection prevented catalepsy
2645	0	a	botox injection after paralysis
2646	0	a	Botox injections following report cases of paralysis
2647	0	a	Botox dose sex age paralysis
2648	0	a	Botox dose sex age paralysis with patients For noted course following paralysis
2649	0	a	Botox dose dose sex age paralysis
2650	0	a	Botox dose dose sex age paralysis with patients For noted course following paralysis
2651	0	a	Botox injection was incidence of paralysis
2652	0	a	Botox injections of complication is paralysis
2653	0	a	Botox of diffusion is mechanism of paralysis
2654	1	a	botox injection for dysphonia
2655	1	a	Botox injections toxin are standard for dysphonia
2656	1	a	Botox injections toxin are standard for dysphonia ADSD
2657	1	a	Botox injections for ADSD
2658	1	a	Botox receiving patients of database From diagnosed with ADSD
2659	1	a	Botox injection for ADSD
2660	1	a	Botox injections of complication for ADSD
2661	0	a	Botox injections received for dysphonia
2662	1	a	phosphorus poisoning of presentation Cholestatic
2663	1	a	phosphorus poisoning of case patient presented with features of cholestasis
2664	1	a	phosphorus poisoning of case patient highlighting fact be cholestasis
2665	1	a	phosphorus hepatotoxicity of feature be fact highlighting patient presented with features of cholestasis
2666	1	a	phosphorus hepatotoxicity of feature be cholestasis
2667	0	a	phosphorus poisoning
2668	0	a	phosphorus with Poisoning
2669	0	a	phosphorus poisoning
2670	0	a	phosphorus hepatotoxicity of feature be fact highlighting patient case of poisoning
2671	0	a	phosphorus is known cause hepatotoxicity
2672	0	a	phosphorus poisoning of case patient highlighting fact be feature of hepatotoxicity
2673	0	a	phosphorus hepatotoxicity
2674	1	a	phosphorus with Poisoning manifests with hepatitis
2675	1	a	phosphorus with Poisoning manifests with hepatitis leading to failure
2676	1	a	amphetamine by induced hyperactivity
2677	0	a	DSP4 pretreatment by reduced hyperactivity
2678	0	a	DSP4 by induced hyperactivity
2679	0	a	DSP4 of action prevents agent with pretreatment by blocked reduction of hyperactivity
2680	0	a	amphetamine induced stereotypies
2681	0	a	DSP4 with pretreatment by blocked rearings stereotypies
2682	0	a	amphetamine hyperactivity
2683	0	a	amphetamine hyperactivity of reduction blocked by pretreatment with agent prevents action neurotoxic
2684	0	a	DSP4 by induced hyperactivity of reduction blocked by pretreatment with agent prevents action neurotoxic
2685	0	a	DSP4 of action neurotoxic
2686	0	a	noradrenaline uptake agent with pretreatment by blocked reduction of hyperactivity
2687	0	a	noradrenaline uptake agent prevents action neurotoxic
2688	0	a	desipramine agent with pretreatment by blocked reduction of hyperactivity
2689	0	a	desipramine agent prevents action neurotoxic
2690	1	a	carbamazepine induced eosinophilic
2691	1	a	carbamazepine induced eosinophilic hypersensitivity
2692	1	a	carbamazepine induced myocarditis emphasis on characteristics mechanisms of hypersensitivity
2693	1	a	carbamazepine of effect necrotizing fatal eosinophilic myocarditis hypersensitivity
2694	1	a	carbamazepine of administration to secondary hypersensitivity
2695	1	a	carbamazepine induced myocarditis
2696	1	a	carbamazepine of effect necrotizing fatal eosinophilic myocarditis
2697	1	a	carbamazepine of administration to secondary myocarditis
2698	1	a	carbamazepine of case induced myocarditis
2699	0	a	5-fluorouracil / dose acid in combination in treatment of cancer
2700	0	a	5-fluorouracil of infusion as part of regimens in cancer
2701	0	a	5-fluorouracil of infusion as part of regimens in cancer AGC
2702	0	a	5-FU of infusion as part of regimens in cancer
2703	0	a	5-FU of infusion as part of regimens in cancer AGC
2704	0	a	5-FU 24-hour receive recruited patients with AGC
2705	0	a	5-FU FA MMC is regimen for AGC
2706	0	a	acid in combination in treatment of cancer
2707	0	a	acid infusion as part of regimens in cancer
2708	0	a	acid infusion as part of regimens in cancer AGC
2709	0	a	FA acid infusion as part of regimens in cancer
2710	0	a	FA acid infusion as part of regimens in cancer AGC
2711	0	a	FA mg by preceded recruited patients with AGC
2712	0	a	FA MMC is regimen for AGC
2713	0	a	C with combination in treatment of cancer
2714	0	a	MMC is regimen for AGC
2715	0	a	5-fluorouracil of infusion shown be with toxicity
2716	0	a	5-FU of infusion shown be with toxicity
2717	0	a	acid infusion shown be with toxicity
2718	0	a	FA acid infusion shown be with toxicity
2719	0	a	cisplatin containing regimens to alternative as serve has considered occur HUS
2720	0	a	lidocaine in phase of infarction
2721	0	a	lidocaine of trial entered patients with infarction
2722	0	a	lidocaine level plasma without infarction
2723	0	a	lidocaine of administration advocate in hours of infarction
2724	0	a	Lidocaine followed prevent tachycardia
2725	0	a	lidocaine of administration after minutes between warning with patients of number in reduction was prevent tachycardia
2726	0	a	Lidocaine followed prevent was reduction in number of patients with warning arrhythmias
2727	0	a	lidocaine of administration after minutes between warning arrhythmias
2728	0	a	lidocaine level plasma was for patients with infarction
2729	1	a	lidocaine group in was occurred hypotension
2730	1	a	lidocaine received patients in occurred hypotension
2731	1	a	lidocaine had asystole from died occurred hypotension
2732	0	a	lidocaine group in was occurred died from asystole
2733	0	a	lidocaine received patients in occurred died from asystole
2734	0	a	lidocaine had asystole
2735	0	a	copper dismutase of Overexpression protects from loss
2736	0	a	zinc superoxide dismutase of Overexpression protects from loss
2737	0	a	superoxide dismutase of Overexpression protects from loss
2738	1	a	kanamycin induced loss
2739	0	a	oxygen species in ototoxicity
2740	0	a	oxygen species of participation deduced from observations catalyze attenuate ototoxicity
2741	0	a	aminoglycoside induced ototoxicity
2742	0	a	aminoglycoside induced ototoxicity in species of participation deduced from observations catalyze attenuate ototoxicity
2743	0	a	aminoglycoside iron complexes catalyze observations from deduced participation of species in ototoxicity
2744	0	a	aminoglycoside iron complexes catalyze attenuate ototoxicity
2745	0	a	aminoglycoside induced ototoxicity
2746	0	a	iron complexes catalyze observations from deduced participation of species in ototoxicity
2747	0	a	iron complexes catalyze attenuate ototoxicity
2748	0	a	superoxide radicals of formation catalyze observations from deduced participation of species in ototoxicity
2749	0	a	superoxide radicals of formation catalyze attenuate ototoxicity
2750	0	a	superoxide dismutase of overexpression protect from ototoxicity
2751	0	a	superoxide dismutase of overexpression by protection supports hypothesis plays in ototoxicity
2752	0	a	Cu superoxide dismutase of overexpression protect from ototoxicity
2753	0	a	Zn superoxide dismutase of overexpression protect from ototoxicity
2754	1	a	acetaminophen edema from facility in female with FHF
2755	1	a	acetaminophen from confirmed FHF
2756	1	a	acetaminophen overdose from patients with FHF
2757	1	a	acetaminophen edema
2758	1	a	acetaminophen edema
2759	1	a	acetaminophen overdose from patients with FHF edema
2760	0	a	acetaminophen from toxicity
2761	0	a	acetaminophen overdose
2762	0	a	acetaminophen overdose from patients In used hypothermia
2763	1	a	haloperidol by induced catalepsy
2764	0	a	Minocycline induced vasculitis
2765	0	a	minocycline induced vasculitis
2766	1	a	Minocycline induced vasculitis fulfilling criteria of nodosa
2767	0	a	minocycline taking for fever pustulosis
2768	0	a	minocycline taking for fever
2769	0	a	minocycline taking man myalgias
2770	0	a	minocycline taking man myalgias polyneuropathy
2771	0	a	minocycline taking man myalgias polyneuropathy pain
2772	1	a	Amiodarone risk of bradyarrhythmia
2773	1	a	amiodarone of use increases risk of bradyarrhythmia
2774	1	a	amiodarone therapy during Reports of bradyarrhythmia
2775	1	a	amiodarone of use increases risk of bradyarrhythmia
2776	0	a	Amiodarone risk of bradyarrhythmia requiring in patients with fibrillation
2777	0	a	amiodarone in patients with fibrillation
2778	0	a	amiodarone in patients with fibrillation AF
2779	0	a	amiodarone of use with AF
2780	0	a	Amiodarone risk of bradyarrhythmia requiring in patients with fibrillation infarction
2781	0	a	amiodarone of use MI
2782	0	a	amiodarone therapy during Reports are infrequent limited to studies assessing use in management of patients with arrhythmias
2783	1	a	thiopentone of use associated with risk for delirium
2784	0	a	propofol to compared risk for delirium
2785	0	a	metolachlor use incidence Cancer
2786	0	a	metolachlor using reported applicators for evaluated incidence cancer
2787	0	a	metolachlor use of metrics days incidence cancer
2788	0	a	metolachlor use of cancers
2789	0	a	metolachlor use of cancers combined with lag cancers
2790	1	a	Metolachlor classified by Agency based on neoplasms
2791	1	a	metolachlor cancer
2792	1	a	metolachlor cancer between association of suggestion is echoes observation of neoplasms
2793	1	a	metolachlor use of effects differentiate findings for cancer
2794	0	a	metolachlor use of levels at suggestion of risk cancer
2795	0	a	metolachlor use of effects differentiate findings for cancer up warrant lymphoma
2796	0	a	ginsenosides on hyperalgesia
2797	0	a	ginsenosides Rg1 of effects on OIH
2798	0	a	Re inhibited OIH
2799	0	a	Re ginsenoside contribute toward reversal of OIH
2800	0	a	ginsenosides Rg1 of effects on OIH
2801	0	a	ginsenosides failed prevent OIH
2802	0	a	Rg1 showed tendency aggravate OIH
2803	0	a	Rg1 contribute toward reversal of OIH
2804	0	a	ginsenosides Rg1 of effects on OIH
2805	0	a	ginsenosides failed prevent OIH
2806	0	a	Rb1 Rg1 contribute toward reversal of OIH
2807	1	a	morphine of administration after achieved OIH
2808	0	a	acid induced test test in inhibited OIH
2809	0	a	acid induced test in aggravate OIH
2810	1	a	acid induced convulsions
2811	1	a	acid of injection dose convulsive
2812	1	a	acid induced convulsions
2813	0	a	5-hydroxytryptamine of turnover accelerated injection dose convulsive
2814	0	a	5-HT turnover accelerated injection dose convulsive
2815	0	a	acid of synthesis suppressed accelerated injection dose convulsive
2816	0	a	acetylcholine acid of synthesis suppressed accelerated injection dose convulsive
2817	0	a	misoprostol of effect on dysfunction
2818	0	a	Misoprostol shown counteract dysfunction
2819	0	a	misoprostol of effect on dysfunction in cirrhosis
2820	0	a	Misoprostol shown counteract dysfunction in patients cirrhotic
2821	0	a	misoprostol of doses indomethacin of mg of combination after before assessed in patients cirrhotic
2822	0	a	misoprostol of micrograms of ability confirmed be avoid therapy in patients with cirrhosis
2823	1	a	indomethacin induced dysfunction
2824	1	a	indomethacin induced dysfunction
2825	0	a	indomethacin induced dysfunction in cirrhosis
2826	0	a	indomethacin induced dysfunction in patients cirrhotic
2827	0	a	indomethacin of mg of combination after before assessed in patients cirrhotic
2828	0	a	indomethacin of effects prevent ability confirmed be avoid therapy in patients with cirrhosis
2829	0	a	sodium hemodynamics of Parameters assessed in patients cirrhotic
2830	1	a	methoxyflurane with anesthesia after Hepatitis
2831	1	a	methoxyflurane with anesthesia after Hepatitis acidosis
2832	1	a	methoxyflurane anesthesia under operated man developed syndrome acidosis
2833	0	a	methoxyflurane anesthesia under operated for cholecystitis
2834	0	a	methoxyflurane anesthesia under operated man developed syndrome
2835	1	a	levodopa induced dyskinesia
2836	1	a	levodopa therapy leads to development of fluctuations dyskinesia
2837	1	a	levodopa induced dyskinesia
2838	1	a	levodopa therapy with was Dyskinesia
2839	1	a	levodopa therapy of duration age had Patients with dyskinesia
2840	1	a	levodopa therapy of duration age duration dose scores than patients without dyskinesia
2841	1	a	levodopa dose duration age had Patients with dyskinesia
2842	1	a	levodopa dose scores than patients without dyskinesia
2843	1	a	levodopa therapy of duration were predictors of dyskinesia
2844	1	a	levodopa dose age therapy of duration were predictors of dyskinesia
2845	1	a	levodopa induced dyskinesia
2846	0	a	levodopa induced dyskinesia of predictors factors among Malaysians with disease
2847	0	a	levodopa therapy for disease
2848	0	a	levodopa therapy for disease PD
2849	0	a	levodopa induced dyskinesia of prevalence studied with PD
2850	0	a	levodopa therapy on involving patients with PD
2851	0	a	methotrexate consequence protocols leukemia
2852	0	a	methotrexate neurotoxicity about Concerns led to modifications in therapy rescue frequency of administration in children with leukemia
2853	0	a	MTX neurotoxicity about Concerns led to modifications in therapy rescue frequency of administration in children with leukemia
2854	0	a	MTX administration in children with leukemia
2855	0	a	methotrexate neurotoxicity
2856	0	a	MTX neurotoxicity
2857	0	a	MTX administration of frequency rescue therapy in modifications to led Concerns about neurotoxicity
2858	0	a	propranolol of Use in treatment of hypotension
2859	0	a	propranolol is drug in patients with hypotension
2860	0	a	catecholamines exhibited marked hypersensitivity
2861	0	a	norepinephrine of effects to marked hypersensitivity
2862	1	a	propranolol by induced hypertension
2863	1	a	clonidine induced hypotension
2864	1	a	clonidine induced hypotension
2865	1	a	clonidine induced hypotension
2866	1	a	clonidine induced hypotension bradycardia
2867	1	a	clonidine induced bradycardia
2868	1	a	clonidine reduced magnitude of vasodepressor responses bradycardiac
2869	1	a	clonidine induced hypotension bradycardia
2870	0	a	5-HT nerves of destruction reduced magnitude of vasodepressor responses bradycardiac
2871	0	a	5,7-dihydroxytryptamine of injection by produced destruction reduced magnitude of vasodepressor responses bradycardiac
2872	1	a	diethylcarbamazine with treatment during cases of encephalitis
2873	1	a	diethylcarbamazine with treatment following cases of encephalitis
2874	1	a	DEC diethylcarbamazine with treatment following cases of encephalitis
2875	0	a	diethylcarbamazine with treatment of loiasis
2876	0	a	diethylcarbamazine with treatment following cases observed in patients with filariasis
2877	0	a	DEC diethylcarbamazine with treatment following cases observed in patients with filariasis
2878	0	a	granisetron of Efficacy in prevention of nausea
2879	0	a	granisetron of doses of effects assess administered dose for prophylaxis of nausea
2880	0	a	Kytril granisetron of doses of effects assess administered dose for prophylaxis of nausea
2881	0	a	granisetron of Efficacy in prevention of nausea vomiting
2882	0	a	granisetron of doses of effects assess administered dose for prophylaxis of nausea vomiting
2883	0	a	Kytril granisetron of doses of effects assess administered dose for prophylaxis of nausea vomiting
2884	0	a	granisetron doses vomiting
2885	0	a	granisetron doses vomiting recorded % response vomiting
2886	0	a	granisetron of dose was effective in controlling vomiting
2887	0	a	granisetron of dose was effective in controlling in % of patients received prevented vomiting
2888	0	a	5-hydroxytryptamine-3 antagonist Efficacy in prevention of nausea
2889	0	a	5-hydroxytryptamine-3 antagonist Efficacy in prevention of nausea vomiting
2890	1	a	cisplatin by induced nausea
2891	1	a	cisplatin induced nausea
2892	1	a	cisplatin by induced nausea vomiting
2893	1	a	cisplatin induced nausea vomiting
2894	1	a	cisplatin received patients of % in controlling vomiting
2895	1	a	cisplatin received prevented vomiting
2896	1	a	Doxorubicin induced cardiotoxicity
2897	1	a	doxorubicin induced cardiotoxicity
2898	1	a	doxorubicin induced cardiotoxicity
2899	0	a	doxorubicin treated animals of hearts enlarged were hypertrophic
2900	0	a	ICRF-187 of protection determined exerted toxicity
2901	0	a	ICRF-187 of protection determined using with toxicity
2902	0	a	doxorubicin doses toxicity with using determined exerted toxicity
2903	0	a	doxorubicin doses toxicity
2904	0	a	ICRF-187 by provided protection by demonstrated testing against cardiotoxicity
2905	0	a	sirolimus to Conversion ameliorates nephropathy
2906	0	a	sirolimus to from conversion of Protocols used prevent nephropathy
2907	0	a	SRL sirolimus to from conversion of Protocols used prevent nephropathy
2908	0	a	SRL treated rats presented as markers of impairment
2909	0	a	SRL to Conversion prevented evolution damage
2910	0	a	SRL to replacement of biomarker be seems prevented evolution damage
2911	1	a	cyclosporine induced nephropathy
2912	1	a	A from conversion of Protocols used prevent nephropathy
2913	1	a	CsA A from conversion of Protocols used prevent nephropathy
2914	1	a	CsA induced nephropathy
2915	1	a	CsA treatment presented lesions
2916	1	a	CsA exposure aggravated damage
2917	1	a	CsA induced evolution damage
2918	1	a	CsA replacement of biomarker be seems prevented evolution damage
2919	0	a	hematoxylin in analyzed lesions
2920	0	a	eosin hematoxylin in analyzed lesions
2921	1	a	SRL treated rats presented proteinuria
2922	0	a	calcium of importance in pathogenesis of disease
2923	0	a	calcium of importance of recognition Increasing stimulated into use of blocking for treatment of variety of diseases
2924	0	a	agents blocking of use into stimulated Increasing recognition of importance in pathogenesis of disease
2925	0	a	agents blocking for treatment of variety of diseases
2926	0	a	dihydropyridine angina
2927	0	a	dihydropyridine angina hypertension
2928	0	a	nifedipine angina
2929	0	a	nifedipine angina hypertension
2930	0	a	nitrendipine offers schedule encourages compliance in therapy of hypertension
2931	0	a	nisoldipine nitrendipine offers schedule encourages compliance in therapy of hypertension
2932	0	a	nisoldipine of properties led to investigation for use in angina
2933	0	a	nimodipine useful in treatment of hemorrhage
2934	0	a	nimodipine useful in treatment of hemorrhage headache
2935	0	a	nimodipine useful in treatment of hemorrhage headache dementia
2936	0	a	nimodipine useful in treatment of hemorrhage headache dementia stroke
2937	0	a	dihydropyridine calcium channel blockers are with headache
2938	0	a	dihydropyridine calcium channel blockers are with headache flushing
2939	0	a	dihydropyridine calcium channel blockers are with headache flushing palpitations
2940	0	a	dihydropyridine calcium channel blockers are with headache flushing palpitations edema
2941	0	a	dihydropyridine calcium channel blockers are with headache flushing palpitations edema nausea
2942	0	a	dihydropyridine calcium channel blockers are with headache flushing palpitations edema nausea anorexia
2943	0	a	dihydropyridine calcium channel blockers are with headache flushing palpitations edema nausea anorexia dizziness
2944	1	a	blockers are with headache
2945	1	a	blockers are with headache flushing
2946	0	a	blockers are with headache flushing palpitations
2947	1	a	blockers are with headache flushing palpitations edema
2948	1	a	blockers are with headache flushing palpitations edema nausea
2949	1	a	blockers are with headache flushing palpitations edema nausea anorexia
2950	1	a	blockers are with headache flushing palpitations edema nausea anorexia dizziness
2951	1	a	Quetiapine induced neutropenia
2952	1	a	Quetiapine is derivative similar to clozapine has risk of causing dyscrasias neutropenia
2953	1	a	quetiapine with treatment after developed neutropenia
2954	1	a	quetiapine of effect is neutropenia
2955	0	a	Quetiapine induced neutropenia in patient bipolar
2956	0	a	Quetiapine induced neutropenia in patient with carcinoma
2957	0	a	quetiapine with treatment after developed carcinoma
2958	0	a	Quetiapine is derivative similar to clozapine has risk of causing dyscrasias
2959	0	a	clozapine has risk of causing dyscrasias
2960	0	a	clozapine has risk of causing dyscrasias neutropenia
2961	1	a	quetiapine with treated after developed leucopenia
2962	0	a	quetiapine to reaction for marker be be dysfunction
2963	1	a	quetiapine to reaction for marker be fever
2964	1	a	isotretinoin to exposure due report with anomalies anotia
2965	1	a	isotretinoin to exposure due report with anomalies anotia malformation
2966	1	a	iAs exposure relate in relationship to cancer
2967	1	a	iAs exposure with associated risk of development cancer
2968	1	a	iAs exposure elicits mechanisms are reprogramming imparts changes in expression development of cells cancer
2969	1	a	iAs exposure development cancer
2970	0	a	valsartan hydrochlorothiazide therapy of Comparison study followed by therapy in adults hypertensive
2971	0	a	hydrochlorothiazide therapy of Comparison study followed by therapy in adults hypertensive
2972	0	a	valsartan VAL hydrochlorothiazide combinations in patients with hypertension
2973	0	a	VAL hydrochlorothiazide combinations in patients with hypertension
2974	0	a	hydrochlorothiazide combinations in patients with hypertension
2975	0	a	HCTZ)-monotherapy combinations in patients with hypertension
2976	0	a	VAL HCTZ combinations with lower was incidence of hypokalemia
2977	0	a	VAL HCTZ with therapies associated were associated with hypokalemia
2978	1	a	HCTZ combinations with lower was incidence of hypokalemia
2979	1	a	HCTZ monotherapies with than lower was incidence of hypokalemia
2980	1	a	HCTZ with therapies associated were associated with hypokalemia
2981	1	a	HCTZ than hypokalemia
2982	1	a	imipramine by induced neuroblastoma in Hypertension
2983	1	a	Imipramine of discontinuation following none had believe caused hypertension
2984	0	a	imipramine by induced neuroblastoma
2985	0	a	Imipramine given neuroblastoma
2986	0	a	Imipramine given control disorder
2987	1	a	inhibitor with therapy to related frequency severity of oedema
2988	1	a	inhibitors of introduction after reported bouts of oedema
2989	1	a	inhibitors to reactions after in patients with oedema
2990	0	a	inhibitors enzyme used treat hypertension
2991	0	a	inhibitors enzyme used treat hypertension failure
2992	0	a	celecoxib of Safety in patients with reactions
2993	0	a	CE of tolerability evaluated in group of patients with history of reactions
2994	1	a	acetaminophen to reactions
2995	1	a	paracetamol acetaminophen to reactions
2996	1	a	P to reactions
2997	1	a	P reactions
2998	1	a	nimesulide paracetamol acetaminophen to reactions
2999	1	a	N P to reactions
3000	1	a	N - induced reactions
3001	0	a	P to hypersensitivity
3002	0	a	P patients among documented reaction hypersensitivity
3003	0	a	N P to hypersensitivity
3004	0	a	N - P patients among documented reaction hypersensitivity
3005	0	a	CE to reaction hypersensitivity
3006	0	a	doxorubicin of nephrotoxicity cardiotoxicity
3007	0	a	doxorubicin by induced nephrotoxicity cardiotoxicity
3008	0	a	doxorubicin kg of dose at observed scored evidence of cardiotoxicity
3009	0	a	doxorubicin of nephrotoxicity
3010	0	a	doxorubicin by induced nephrotoxicity
3011	0	a	doxorubicin kg of dose above seen evidence of damage
3012	0	a	doxorubicin of nephrotoxicity cardiotoxicity effect in rat bearing immunocytoma
3013	0	a	doxorubicin by induced nephrotoxicity cardiotoxicity activity studied bearing immunocytoma
3014	0	a	doxorubicin of injections with treated Animals with tumor
3015	0	a	doxorubicin kg with observed regression Tumor
3016	0	a	doxorubicin kg with induced disappearance of tumor
3017	1	a	doxorubicin kg resulted in albuminuria
3018	0	a	cocaine users in disease
3019	0	a	cocaine users in disease
3020	0	a	cocaine users underwent determine prevalence of disease
3021	1	a	cocaine users in is disease
3022	1	a	cocaine users in is disease
3023	0	a	Cocaine ethanol cardiotoxity
3024	0	a	cocaine metabolite cocaethylene to due be be toxicity
3025	0	a	cocaine of cardiotoxicity
3026	0	a	Cocaine in model of cocaine abuse
3027	0	a	Cocaine in model of cocaine abuse
3028	0	a	ethanol cardiotoxity
3029	0	a	ethanol of presence in formed metabolite cocaethylene to due be be toxicity
3030	0	a	ethanol cocaine of cardiotoxicity
3031	0	a	ethanol Cocaine in model of cocaine abuse
3032	0	a	ethanol Cocaine in model of cocaine abuse
3033	0	a	cocaethylene ethanol cardiotoxity
3034	0	a	cocaethylene to due be be toxicity
3035	0	a	CE cocaethylene to due be be toxicity
3036	0	a	CE of role in cardiotoxicity
3037	0	a	cocaethylene ethanol Cocaine in model of cocaine abuse
3038	0	a	cocaethylene ethanol Cocaine in model of cocaine abuse
3039	0	a	cocaethylene concentrations associated with depression
3040	1	a	Nifedipine induced bradycardia
3041	0	a	Nifedipine induced in patient with neuropathy
3042	0	a	nifedipine slowed rate at have flutter
3043	1	a	nifedipine induces tachycardia
3044	0	a	estrogen sites in nuclei of diethylstilbesterol carcinomas
3045	0	a	Estrogen sites demonstrated induced carcinomas
3046	0	a	estrogen of binding in preferential documenting report is induced carcinomas
3047	0	a	estrogen in cells of nuclei to documenting report is induced carcinomas
3048	1	a	diethylstilbesterol carcinomas
3049	1	a	diethylstilbesterol induced carcinomas
3050	0	a	estradiol of injection in following Radiolabelling increased over nuclei of cells tumor
3051	0	a	silver grains of concentration revealed increased over nuclei of cells tumor
3052	0	a	steroid injection after neuropathy
3053	0	a	steroid injection after occurred neuropathy
3054	0	a	steroid injection after occurred treat epicondylitis
3055	0	a	steroid injection for treatment of epicondylitis
3056	1	a	steroid injection after occurred woman presented with sensation paresthesia
3057	1	a	steroid injection after occurred paresthesia
3058	1	a	trimethaphan induced hypotension
3059	0	a	trimethaphan induced hypotension accompanied by bradycardia
3060	0	a	ribose on cardiotoxicity
3061	0	a	ribose influence cardiotoxicity
3062	0	a	adriamycin evoked cardiotoxicity
3063	0	a	Adriamycin evoked toxicity
3064	0	a	ADR cardiotoxicity
3065	0	a	ribose on myocardiopathy
3066	1	a	adriamycin induced myocardiopathy
3067	1	a	lithium therapy leading to hyperparathyroidism
3068	1	a	lithium treated patient had hypercalcemia
3069	1	a	lithium treated patients of % become hypercalcemic
3070	0	a	lithium therapy of effect is hyperparathyroidism
3071	0	a	Mesna reduces genotoxicity
3072	0	a	IFO genotoxicity
3073	1	a	dipropionate with developed candidiasis
3074	1	a	beclomethasone on placed patients Of developed hoarseness thrush
3075	1	a	dipropionate with developed candidiasis hoarseness
3076	1	a	beclomethasone on placed patients Of developed hoarseness
3077	1	a	beclomethasone on restarted conclude challenged patients develop hoarseness
3078	1	a	beclomethasone prednisone of use increase risk of developing hoarseness
3079	0	a	beclomethasone on placed patients asthmatic
3080	0	a	prednisone of use increase risk of developing hoarseness
3081	0	a	prednisone of use increase risk of developing hoarseness candidiasis
3082	0	a	beclomethasone prednisone of use increase risk of developing hoarseness candidiasis
3083	0	a	Curcumin prevents nephrotoxicity
3084	0	a	curcumin of effect against injury
3085	0	a	curcumin is able attenuate in nephropathy
3086	1	a	maleate induced nephrotoxicity
3087	1	a	maleate by induced injury
3088	1	a	Maleate induced injury
3089	1	a	Maleate induced injury included increase in in excretion of protein glucose sodium lipocalin upregulation of molecule injury
3090	1	a	maleate induced nephropathy
3091	0	a	oxygen consumption stress alterations to relation nephrotoxicity
3092	1	a	maleate of injection by induced proteinuria
3093	1	a	Maleate induced injury included increase decrease determined expression besides of necrosis
3094	0	a	glucose protein of excretion in in increase included injury
3095	0	a	glucose sodium lipocalin upregulation of molecule injury
3096	0	a	glucose protein of excretion in in increase decrease determined expression besides of necrosis
3097	0	a	sodium glucose protein of excretion in in increase included injury
3098	0	a	sodium lipocalin upregulation of molecule injury
3099	0	a	sodium glucose protein of excretion in in increase decrease determined expression besides of necrosis
3100	1	a	acid therapy during complications Thrombotic
3101	0	a	acid therapy during complications in leukemia
3102	0	a	acid with treated due occlusion of vessels in patient with leukemia
3103	0	a	acid with treated due occlusion of vessels in patient with leukemia APL
3104	0	a	ATRA acid with treated due occlusion of vessels in patient with leukemia
3105	0	a	ATRA acid with treated due occlusion of vessels in patient with leukemia APL
3106	0	a	ATRA with treated patient APL
3107	0	a	ATRA therapy in patients APL
3108	0	a	ATRA with protocol in included presented signs of APL
3109	0	a	ATRA is choice for patients with APL
3110	1	a	acid with treated case of failure
3111	1	a	ATRA acid with treated case of failure
3112	1	a	ATRA with treated patient in failure
3113	0	a	acid with treated due occlusion of vessels
3114	0	a	ATRA acid with treated due occlusion of vessels
3115	0	a	acid described case of failure
3116	0	a	acid described case treated due occlusion of vessels
3117	0	a	acid described case treated due occlusion of vessels in patient with leukemia
3118	0	a	acid described case treated due occlusion of vessels in patient with leukemia APL
3119	0	a	ATRA therapy with associated complications thromboembolic
3120	0	a	heparin using by avoided events Thrombotic
3121	1	a	etomidate induced myoclonus
3122	1	a	etomidate induced myoclonus
3123	1	a	etomidate induced myoclonus
3124	0	a	Fentanyl Prevention of myoclonus
3125	0	a	fentanyl midazolam combination prevent myoclonus
3126	0	a	fentanyl of combination prevent myoclonus
3127	0	a	fentanyl with pretreatment was effective in preventing myoclonus
3128	0	a	fentanyl of fentanyl with pretreatment was effective in preventing myoclonus
3129	0	a	midazolam Fentanyl Prevention of myoclonus
3130	0	a	midazolam combination prevent myoclonus
3131	0	a	midazolam fentanyl of combination prevent myoclonus
3132	0	a	midazolam pretreatment was effective in preventing myoclonus
3133	0	a	etomidate injection after minutes during severity to according graded observed movements
3134	0	a	etomidate due severity of pain
3135	1	a	Levodopa induced dyskinesias
3136	1	a	Levodopa induced dyskinesias
3137	1	a	levodopa of effect during deviations with patient on report hypothesize needed for appearance of dyskinesias
3138	1	a	levodopa induce dyskinesias
3139	0	a	Levodopa induced dyskinesias in disease
3140	0	a	Phenytoin induced injury
3141	1	a	phenytoin administration after failure
3142	0	a	oestrogen therapy receiving women in disease
3143	0	a	oestrogen therapy receiving women among disease
3144	1	a	oestrogen therapy with associated hyperplasia
3145	1	a	oestrogen therapy difficulty in distinguishing hyperplasia
3146	0	a	progestagen without therapy with associated hyperplasia
3147	0	a	norethisterone daily of days of courses caused in cases of hyperplasia
3148	0	a	norethisterone daily of days of courses caused in cases 6 of cases of hyperplasia
3149	0	a	oestrogen therapy of problems demonstrated cases of carcinoma
3150	0	a	oestrogen therapy difficulty in distinguishing hyperplasia from malignancy
3151	0	a	oestrogen therapy seem increase risk of hyperplasia
3152	0	a	oestrogen therapy seem increase risk of hyperplasia carcinoma
3153	0	a	progestagen of days with therapy seem increase risk of hyperplasia
3154	0	a	progestagen of days with therapy seem increase risk of hyperplasia carcinoma
3155	0	a	cyclophosphamide therapy following pelvis
3156	0	a	cyclophosphamide treatment with association in reported carcinoma of pelvis
3157	0	a	cyclophosphamide wtih treated after had woman with hydroureteronephrosis
3158	0	a	cyclophosphamide to exposure that suggests association with hydroureteronephrosis
3159	1	a	cyclophosphamide wtih treated after had hematuria
3160	0	a	cyclophosphamide wtih for vasculitis
3161	0	a	cyclophosphamide of ability cause cystitis
3162	0	a	cyclophosphamide of ability cause cystitis
3163	1	a	cyclophosphamide of ability indistinguishable from carcinoma
3164	0	a	cyclophosphamide of ability is appreciated associated with carcinoma of tract
3165	0	a	cyclophosphamide treatment with association in reported cancer
3166	0	a	cyclophosphamide to exposure that suggests association of tumor
3167	0	a	cyclophosphamide treatment for candidates are Patients evaluated for uropathy
3168	1	a	sulfadiazine nephrotoxicity
3169	1	a	Sulfadiazine nephrotoxicity
3170	0	a	Sulfadiazine nephrotoxicity reviving because use in toxoplasmosis
3171	0	a	sulfadiazine with treatment Under developed oliguria
3172	0	a	sulfadiazine with treatment Under developed oliguria pain
3173	0	a	sulfadiazine with treatment Under developed oliguria pain failure
3174	1	a	sulfadiazine with treatment Under developed showed calculi
3175	1	a	tacrolimus therapy on patient in case of neuropathy
3176	1	a	FK506 therapy on patient in case of neuropathy
3177	1	a	tacrolimus receiving patient in case of neuropathy
3178	1	a	506 FK tacrolimus receiving patient in case of neuropathy
3179	1	a	Tacrolimus associated with toxicity
3180	0	a	tacrolimus of discontinuation despite occurred Deterioration of vision
3181	0	a	Lamivudine is effective in suppressing DNA virus B
3182	0	a	Lamivudine is analogue has effects on replication virus B
3183	0	a	cytosine analogue has effects on replication virus B
3184	0	a	lamivudine receiving patients had decrease in virus B
3185	1	a	antigen carriers in DNA virus B
3186	0	a	bortezomib of Combination as therapy after transplantation for myeloma
3187	0	a	bortezomib of regimen of safety analyzed as therapy in patients with MM
3188	0	a	thalidomide bortezomib of Combination as therapy after transplantation for myeloma
3189	0	a	thalidomide bortezomib of regimen of safety analyzed as therapy in patients with MM
3190	0	a	dexamethasone thalidomide bortezomib of Combination as therapy after transplantation for myeloma
3191	0	a	dexamethasone thalidomide bortezomib of regimen of safety analyzed as therapy in patients with MM
3192	1	a	adriamycin induced injury
3193	1	a	ADR induced showed at point as appeared injury
3194	0	a	oxygen resulted cardiotoxicity
3195	0	a	ROS)/nitrogen species reported oxygen resulted cardiotoxicity
3196	0	a	adriamycin in present be reported oxygen resulted cardiotoxicity
3197	0	a	ADR)-induced cardiotoxicity
3198	0	a	4HNE protein adducts induced showed at point as appeared injury
3199	1	a	Terfenadine blockers reported cause TdP Pointes
3200	1	a	Terfenadine blockers reported cause TdP
3201	1	a	Citalopram Terfenadine blockers reported cause TdP Pointes
3202	1	a	Citalopram Terfenadine blockers reported cause TdP
3203	0	a	FZP toxocity
3204	0	a	FZP toxocity of Signs included salivation
3205	0	a	FZP toxocity of Signs included salivation behavior retching tremors
3206	1	a	FZP toxocity of Signs included salivation behavior retching tremors convulsions
3207	1	a	FZP protected against convulsions
3208	1	a	FZP of doses were lower than those cause convulsions
3209	0	a	FZP of use in situations is excitability as epilepsy
3210	1	a	valproate therapy during disease
3211	1	a	VPA treatment during developed child in arising case of disease
3212	1	a	VPA treatment during developed child in arising case of disease NAFLD
3213	1	a	VPA with treatment resistance hyperinsulinemia obesity associated with development of NAFLD
3214	1	a	VPA withdrawal after is suggests associated with development of NAFLD
3215	0	a	acid is effective for treatment of types of epilepsy
3216	0	a	VPA acid is effective for treatment of types of epilepsy
3217	1	a	VPA treatment during developed obesity
3218	1	a	VPA with treatment resistance hyperinsulinemia obesity
3219	1	a	VPA withdrawal after is suggests associated obesity
3220	0	a	VPA therapy of withdrawal After showed loss
3221	1	a	VPA with treatment resistance hyperinsulinemia
3222	1	a	VPA withdrawal after is suggests associated obesity hyperinsulinemia
3223	1	a	VPA with treatment resistance
3224	1	a	VPA withdrawal after is suggests associated obesity hyperinsulinemia resistance
3225	0	a	Haloperidol failed prevent seizures
3226	0	a	Haloperidol decreased incidence of seizures
3227	0	a	haloperidol blocker for role without reducing incidence of seizures
3228	0	a	haloperidol demonstrated ability reduce seizures
3229	1	a	amphetamine induced seizures
3230	1	a	amphetamine exposure from death against role without reducing incidence of seizures
3231	1	a	cocaine induced seizures
3232	1	a	cocaine induced seizures
3233	0	a	dopamine blocker for role without reducing incidence of seizures
3234	0	a	Streptozotocin in events activation neurotoxicity
3235	0	a	STZ treatment showed remains indicating neurotoxicity
3236	0	a	STZ activation death post neurotoxicity
3237	0	a	STZ impairment in factors are activation post neurotoxicity
3238	1	a	Streptozotocin in events activation impairment
3239	1	a	Streptozotocin in toxicity induced rats impaired
3240	1	a	STZ Streptozotocin in toxicity induced rats impaired
3241	1	a	STZ after days on test in found deficit
3242	1	a	STZ impairment
3243	0	a	Streptozotocin in toxicity
3244	0	a	STZ Streptozotocin in toxicity
3245	0	a	STZ increased reduced in preparation illustrating generation excitotoxicity
3246	1	a	STZ causes expression of GFAP activation neuroinflammation
3247	0	a	nitrite ROS of level increased reduced in preparation illustrating generation excitotoxicity
3248	0	a	Ca(2 nitrite ROS of level increased reduced in preparation illustrating generation excitotoxicity
3249	0	a	Memantine with treatment attenuated activation death post neurotoxicity
3250	0	a	Ibuprofen Memantine with treatment attenuated activation death post neurotoxicity
3251	1	a	cobalt cardiomyopathy
3252	1	a	doxorubicin induced failure
3253	0	a	corticosteroid suspensions of injection following artery occlusion
3254	1	a	acetate with injection following blindness with occlusions
3255	0	a	acetate with injection following blindness
3256	0	a	lidocaine with combination in acetate with injection following blindness with occlusions
3257	0	a	lidocaine with combination in acetate with injection following blindness
3258	0	a	epinephrine lidocaine with combination in acetate with injection following blindness with occlusions
3259	0	a	epinephrine lidocaine with combination in acetate with injection following blindness
3260	0	a	penicillin epinephrine lidocaine with combination in acetate with injection following blindness with occlusions
3261	0	a	penicillin epinephrine lidocaine with combination in acetate with injection following blindness
3262	0	a	risperidone of administration after developed patient with failure
3263	0	a	risperidone of administration after developed CRF
3264	1	a	risperidone of administration after developed syndrome
3265	1	a	risperidone of administration after developed syndrome NMS
3266	0	a	levomepromazine risperidone of administration after developed patient with failure
3267	0	a	levomepromazine risperidone of administration after developed CRF
3268	1	a	levomepromazine risperidone of administration after developed syndrome
3269	1	a	levomepromazine risperidone of administration after developed syndrome NMS
3270	0	a	calcium antagonist on ischemia
3271	0	a	calcium antagonist on ischemia in dogs with stenosis
3272	0	a	CD-832 antagonist on ischemia
3273	0	a	CD-832 on Effects studied ischemia
3274	0	a	CD-832 improves ischemia
3275	0	a	CD-832 of property plays suggest improves ischemia
3276	0	a	CD-832 of effects in plays suggest improves ischemia
3277	0	a	CD-832 antagonist on ischemia in dogs with stenosis
3278	0	a	CD-832 on Effects studied in dogs with stenosis
3279	1	a	isoproterenol induced ischemia
3280	1	a	isoproterenol on Effects studied ischemia
3281	1	a	ISO)-induced ischemia
3282	1	a	ISO infusion during ischemia
3283	0	a	isoproterenol induced ischemia in dogs with stenosis
3284	0	a	isoproterenol on Effects studied in dogs with stenosis
3285	0	a	ISO)-induced ischemia studied in dogs with stenosis
3286	0	a	ISO infusion of periods increased In presence of stenosis
3287	0	a	nifedipine for those with compared Effects studied ischemia
3288	0	a	nifedipine for those with compared Effects studied in dogs with stenosis
3289	0	a	diltiazem nifedipine for those with compared Effects studied ischemia
3290	0	a	diltiazem nifedipine for those with compared Effects studied in dogs with stenosis
3291	0	a	ISO infusion with stenosis
3292	0	a	ISO infusion with stenosis
3293	0	a	ISO infusion with stenosis
3294	0	a	ISO infusion with stenosis
3295	0	a	CD-832 ( micrograms of doses performed infusion with stenosis
3296	0	a	CD-832 improves ischemia during infusion with stenosis
3297	0	a	CD-832 of property plays suggest improves ischemia during infusion with stenosis
3298	0	a	CD-832 of effects in plays suggest improves ischemia during infusion with stenosis
3299	1	a	Morphine induced seizures
3300	1	a	sulfate of course during suffered from seizures
3301	1	a	morphine received in doses larger than group of neonates received had seizures
3302	1	a	morphine of cessation after stopped ruled reasons for seizures
3303	1	a	morphine of cessation after stopped convulsions
3304	0	a	cocaine induced dysfunction to contributes impairment
3305	0	a	cocaine to exposure after was suggesting were abnormalities
3306	0	a	cocaine to response in event late were abnormalities
3307	0	a	cocaine induced dysfunction be due to defect
3308	1	a	cocaine induced dysfunction
3309	1	a	cocaine induced dysfunction
3310	1	a	cocaine induced dysfunction
3311	0	a	MitoQ. by Prevention contributes impairment
3312	0	a	MitoQ shown prevent abnormalities
3313	0	a	MitoQ. by Prevention contributes to dysfunction
3314	0	a	MitoQ shown prevent abnormalities dysfunction
3315	0	a	MitoQ shown prevent abnormalities dysfunction characterized by dysfunction
3316	0	a	Topotecan in combination in glioblastoma
3317	0	a	topotecan in adults with GBM
3318	0	a	Topotecan is exhibits inhibition of glioma
3319	0	a	olanzapine of Efficacy in mania
3320	0	a	olanzapine of efficacy for treatment of mania
3321	0	a	olanzapine to randomized total of patients with diagnosis of disorder
3322	0	a	olanzapine to randomized total of patients with diagnosis manic
3323	0	a	Olanzapine demonstrated efficacy than placebo in treatment of mania
3324	1	a	olanzapine treated patients had gain
3325	1	a	olanzapine treated patients had experienced somnolence
3326	0	a	digoxin fibrillation
3327	1	a	digoxin has effects as increasing causing arrhythmias
3328	0	a	digoxin increase after infarction
3329	0	a	digoxin increase after infarction MI
3330	1	a	Suxamethonium induced stiffness
3331	1	a	suxamethonium after occur rigidity
3332	1	a	Suxamethonium induced stiffness myalgia
3333	1	a	suxamethonium after occur rigidity myalgia
3334	0	a	pancuronium with pretreatment despite occur rigidity
3335	0	a	pancuronium with pretreatment despite occur rigidity myalgia
3336	0	a	MK-801 on actions epilepticus
3337	0	a	MK-801 30 of Administration reduced during epilepticus
3338	1	a	lithium pilocarpine model on actions epilepticus
3339	1	a	lithium by induced seizures block easy is is terminate epilepticus
3340	1	a	lithium pilocarpine model in damage epilepticus
3341	1	a	pilocarpine model on actions epilepticus
3342	1	a	pilocarpine lithium by induced seizures block easy is is terminate epilepticus
3343	1	a	pilocarpine to prior induced seizures block easy is is terminate epilepticus
3344	1	a	pilocarpine after min Administration reduced during epilepticus
3345	1	a	pilocarpine model in damage epilepticus
3346	1	a	pilocarpine NMDA of doses were resulting in epilepticus
3347	0	a	MK-801 , tested using models seizure
3348	0	a	MK-801 produced suggesting seizures
3349	0	a	MK-801 in effect occurred after periods of activity seizure
3350	0	a	MK-801 30 of Administration reduced activity seizure
3351	0	a	aspartate tested using models seizure
3352	0	a	NMDA aspartate tested using models seizure
3353	0	a	lithium of coadministration models seizure
3354	0	a	lithium pilocarpine model with action produced suggesting seizures
3355	0	a	lithium pilocarpine model in effect occurred after periods of activity seizure
3356	0	a	lithium by induced seizures
3357	0	a	lithium by induced seizures block easy is is terminate block lethality of seizures
3358	0	a	pilocarpine lithium of coadministration models seizure
3359	0	a	pilocarpine of dose of coadministration models seizure
3360	0	a	pilocarpine model with action produced suggesting seizures
3361	0	a	pilocarpine with treated rats with produced suggesting seizures
3362	0	a	pilocarpine model in effect occurred after periods of activity seizure
3363	0	a	pilocarpine lithium by induced seizures
3364	0	a	pilocarpine lithium by induced seizures block easy is is terminate block lethality of seizures
3365	0	a	pilocarpine to prior induced seizures
3366	0	a	pilocarpine to prior induced seizures block easy is is terminate block lethality of seizures
3367	0	a	pilocarpine after min Administration reduced activity seizure
3368	0	a	NMDA receptors of activation plays role in epilepticus
3369	0	a	NMDA of doses were resulting in epilepticus
3370	0	a	NMDA receptors of activation plays role in epilepticus damage
3371	0	a	lithium pilocarpine model in damage
3372	0	a	pilocarpine model in damage
3373	1	a	fluoxetine treatment with associated Mania
3374	1	a	fluoxetine reported induce mania
3375	1	a	fluoxetine with pharmacotherapy during developed mania
3376	1	a	fluoxetine pharmacotherapy during factors for development of mania
3377	1	a	fluoxetine pharmacotherapy during factors for development of mania hypomania
3378	1	a	fluoxetine pharmacotherapy during factors were depression history of disorder disorder
3379	1	a	fluoxetine pharmacotherapy during factors were depression history diagnosis of disorder
3380	1	a	fluoxetine mania
3381	0	a	Fluoxetine gaining acceptance in treatment of depression
3382	0	a	fluoxetine with pharmacotherapy during developed years cases of adolescents depressed
3383	0	a	fluoxetine pharmacotherapy during factors were depression
3384	0	a	serotonin Fluoxetine gaining acceptance in treatment of depression
3385	0	a	fluoxetine pharmacotherapy during factors were combination of disorder
3386	0	a	fluoxetine pharmacotherapy during factors were depression with features psychotic
3387	0	a	fluoxetine pharmacotherapy during factors were depression history of disorder
3388	1	a	Zidovudine induced hepatitis
3389	1	a	zidovudine by induced hepatitis
3390	0	a	zidovudine by induced in patient with AIDS
3391	1	a	pilocarpine induced status epilepticus
3392	1	a	pilocarpine induced status epilepticus
3393	1	a	pilocarpine model of epilepsy
3394	0	a	cyclophosphamide of toxicity
3395	0	a	CY toxicity
3396	0	a	CY of toxicity
3397	1	a	CY toxicity caused cystitis haemorrhagic
3398	1	a	CY toxicity caused cystitis
3399	1	a	CY ulcerous forms of cystitis
3400	1	a	streptozotocin induced nephropathy
3401	1	a	STZ induced nephropathy
3402	1	a	STZ induced nephropathy
3403	0	a	angiotensin system of blockade in patients with diabetes
3404	0	a	angiotensin system of blockade retard progression of nephropathy
3405	0	a	angiotensin system of blockade retard suggesting involved in pathogenesis of nephropathy
3406	0	a	angiotensin system of blockade retard suggesting involved in pathogenesis of nephropathy nephropathy
3407	0	a	streptozotocin with microalbuminuria of independently development of fibrosis
3408	0	a	STZ)-induced diabetes streptozotocin with microalbuminuria of independently development of fibrosis
3409	0	a	streptozotocin diabetes
3410	0	a	STZ)-induced diabetes
3411	1	a	chlorpromazine induced syndrome
3412	1	a	chlorpromazine induced EPS
3413	1	a	chlorpromazine with treated Ser311Cys in gene in inpatients 59 with EPS
3414	1	a	chlorpromazine with treated Ser311Cys without EPS
3415	0	a	chlorpromazine induced syndrome in patients schizophrenic
3416	0	a	chlorpromazine induced EPS in plays in patients schizophrenic
3417	0	a	chlorpromazine with treated Ser311Cys in gene in inpatients schizophrenic
3418	0	a	chlorpromazine by induced effect in patients with schizophrenia
3419	0	a	bupivacaine precipitate dysrhythmias
3420	0	a	bupivacaine circulating potentiate precipitate dysrhythmias
3421	0	a	Bupivacaine antagonizes in in dogs with dysrhythmias
3422	0	a	epinephrine bupivacaine precipitate dysrhythmias
3423	0	a	epinephrine of effects potentiate precipitate dysrhythmias
3424	0	a	epinephrine dysrhythmogenicity antagonizes in in dogs with dysrhythmias
3425	0	a	bupivacaine alters in in dogs with infarction
3426	0	a	epinephrine of administration of dysrhythmogenicity alters in in dogs with infarction
3427	0	a	epinephrine received after infarction
3428	0	a	halothane anesthetized dogs received after infarction
3429	0	a	halothane anesthetized dogs received appeared VT
3430	1	a	epinephrine received appeared VT
3431	1	a	epinephrine dysrhythmogenicity antagonizes in dogs susceptible to VT
3432	0	a	Bupivacaine antagonizes in dogs susceptible to VT
3433	0	a	doxorubicin induced cardiotoxicity
3434	1	a	doxorubicin cardiomyopathy
3435	1	a	DOX)-induced cardiomyopathy
3436	0	a	doxorubicin of model utilized applying provide characterization to date of timecourse of events underlying toxicity
3437	0	a	DOX)-induced cardiomyopathy doxorubicin of model utilized applying provide characterization to date of timecourse of events underlying toxicity
3438	0	a	gadolinium delayed enhancement grading dysfunction
3439	0	a	Fluoxetine improves deficits
3440	1	a	5-fluorouracil improves deficits
3441	0	a	artesunate with treatment after anemia
3442	1	a	artesunate with treatment after described Cases of anemia
3443	0	a	artesunate with treatment after described Organization drug for treatment of malaria
3444	0	a	artesunate for malaria
3445	1	a	dexmedetomidine receive patients in prevalence at occur hypotension
3446	1	a	dexmedetomidine receive patients in prevalence at occur hypotension bradycardia
3447	1	a	propofol dexmedetomidine receive patients in prevalence at occur hypotension
3448	1	a	propofol dexmedetomidine receive patients in prevalence at occur hypotension bradycardia
3449	1	a	cyclophosphamide induced lesions of bladder
3450	0	a	mesna by prevention investigations of lesions of bladder
3451	0	a	cyclophosphamide induced cystitis
3452	0	a	cyclophosphamide induced cystitis characterized by detachment edema
3453	0	a	cyclophosphamide induced cystitis characterized owing to damage to bed necroses
3454	0	a	morphine between synergy in models of pain
3455	0	a	morphine with combinations in models of pain
3456	0	a	sodium channel blocker morphine between synergy in models of pain
3457	0	a	sodium channel blocker with in combinations in models of pain
3458	0	a	CNSB002 blocker morphine between synergy in models of pain
3459	0	a	CNSB002 blocker with in combinations in models of pain
3460	0	a	carrageenan induced inflammation constructed using withdrawal in models pain
3461	1	a	carrageenan induced inflammation
3462	0	a	carrageenan induced inflammation streptozotocin neuropathy
3463	0	a	streptozotocin inflammation constructed using withdrawal in models pain
3464	0	a	STZ)-induced neuropathy streptozotocin inflammation constructed using withdrawal in models pain
3465	0	a	streptozotocin inflammation
3466	0	a	STZ)-induced neuropathy streptozotocin inflammation
3467	1	a	streptozotocin neuropathy
3468	1	a	STZ)-induced neuropathy
3469	0	a	carrageenan model 44.18 9.14 in model neuropathy
3470	0	a	carrageenan model in 0.56 in model neuropathy
3471	0	a	STZ induced model neuropathy
3472	0	a	CNSB002 for model neuropathy
3473	0	a	CNSB002 with combination in given values were mg/kg 0.56 in model neuropathy
3474	0	a	CNSB002 with increased from to reversal in models inflammatory neuropathic
3475	0	a	morphine CNSB002 for model neuropathy
3476	0	a	morphine for values were mg/kg 0.56 in model neuropathy
3477	0	a	morphine after antinociception increased from to reversal in models inflammatory neuropathic
3478	0	a	morphine after antinociception increased from to reversal of hyperalgesia
3479	0	a	CNSB002 with increased from to reversal of hyperalgesia
3480	0	a	Glibenclamide sensitive hypotension
3481	0	a	glibenclamide by attenuated Hypotension
3482	0	a	glibenclamide sensitive channels of activation to attributable is hypotension
3483	1	a	helodermin by produced hypotension
3484	1	a	Helodermin produced hypotension
3485	1	a	helodermin induced hypotension
3486	1	a	helodermin induced hypotension affect shortened duration of acetylcholine hypotension
3487	1	a	helodermin produced hypotension
3488	1	a	levcromakalim produced decrease abolished glibenclamide by attenuated Hypotension
3489	1	a	acetylcholine of duration shortened affect hypotension
3490	1	a	acetylcholine hypotension
3491	1	a	ACh)-produced hypotension acetylcholine of duration shortened affect hypotension
3492	1	a	ACh)-produced hypotension
3493	0	a	K+ channels of activation to attributable is hypotension
3494	0	a	K(ATP channels channels of activation to attributable is hypotension
3495	0	a	K(ATP channels channels of activation to attributable is hypotension
3496	1	a	isoproterenol induced infarction
3497	1	a	isoproterenol induced infarction
3498	0	a	isoproterenol of dosages of effects with associated mortality reduced had on severity of infarction
3499	1	a	dexmedetomidine following syncope
3500	1	a	dexmedetomidine following syncope bradycardia
3501	1	a	dexmedetomidine of administration following girl in report syncope bradycardia
3502	0	a	dexmedetomidine of administration following girl in report syncope
3503	0	a	olanzapine of comparison versus risperidone for treatment of schizophrenia
3504	0	a	olanzapine for outcomes versus risperidone in patients with disorders schizophrenia
3505	0	a	olanzapine with treatment to assigned with schizophrenia
3506	0	a	risperidone for treatment of schizophrenia
3507	0	a	risperidone in patients with disorders schizophrenia
3508	0	a	risperidone olanzapine with treatment to assigned with schizophrenia
3509	0	a	olanzapine with treatment to assigned with schizophrenia disorder
3510	0	a	olanzapine with treatment to assigned with schizophrenia disorder disorder
3511	0	a	risperidone olanzapine with treatment to assigned with schizophrenia disorder
3512	0	a	risperidone olanzapine with treatment to assigned with schizophrenia disorder disorder
3513	0	a	risperidone with were differ outcomes measures of parkinsonism
3514	0	a	risperidone with were differ outcomes measures of parkinsonism akathisia
3515	1	a	risperidone with were differ between scores severity symptom
3516	1	a	olanzapine with occurred gain
3517	1	a	olanzapine with greater was caused gain
3518	1	a	olanzapine with greater was gain
3519	1	a	risperidone with than Significantly more gain
3520	0	a	lenalidomide of efficacy in patients with myeloma
3521	0	a	lenalidomide of efficacy on data study of Group Myeloma
3522	0	a	Lenalidomide is standard for myeloma
3523	0	a	Lenalidomide is standard for myeloma RRMM
3524	0	a	RD dexamethasone Lenalidomide is standard for myeloma
3525	0	a	RD dexamethasone Lenalidomide is standard for myeloma RRMM
3526	0	a	RD received patients RRMM
3527	0	a	RD is in RRMM
3528	0	a	dexamethasone lenalidomide of efficacy in patients with myeloma
3529	0	a	dexamethasone lenalidomide of efficacy on data study of Group Myeloma
3530	0	a	dexamethasone Lenalidomide is standard for myeloma
3531	0	a	dexamethasone Lenalidomide is standard for myeloma RRMM
3532	0	a	RD dexamethasone Lenalidomide is standard for myeloma
3533	0	a	RD dexamethasone Lenalidomide is standard for myeloma RRMM
3534	0	a	RD received patients RRMM
3535	0	a	RD is in RRMM
3536	0	a	caffeine exposure by induced offspring in glomerulosclerosis
3537	1	a	caffeine exposure induce retardation
3538	1	a	caffeine exposure induce retardation IUGR
3539	0	a	creatinine of levels by accompanied glomerulosclerosis
3540	0	a	creatinine of levels by accompanied glomerulosclerosis fibrosis
3541	0	a	corticotropin releasing hormone modulate response hypercapnic
3542	0	a	thyrotropin releasing hormone modulate response hypercapnic
3543	0	a	cocaine of Smoking as factor for infection
3544	0	a	cocaine has on incidence of infection
3545	0	a	cocaine of use Given sought examine become factor for infection
3546	1	a	cocaine of smokers among seroconversion
3547	1	a	cocaine of smokers were participants among seroconversion
3548	1	a	cocaine of Smoking found be factor for seroconversion
3549	1	a	pilocarpine induced epilepsy
3550	0	a	pilocarpine treated rats in decrease caused maneuver hyperventilation
3551	0	a	oxide synthase of expression following irritation
3552	0	a	oxide synthase of expression in alterations examine following irritation of tract
3553	1	a	cyclophosphamide by induced cystitis
3554	1	a	CYP cyclophosphamide by induced cystitis
3555	0	a	acrolein to metabolized cyclophosphamide by induced cystitis
3556	1	a	vancomycin induced nephrotoxicity
3557	1	a	vancomycin examine investigate role of erdosteine agent has properties on tissue against impairment
3558	1	a	VCM)-induced stress vancomycin examine investigate role of erdosteine agent has properties on tissue against impairment
3559	1	a	VCM induced impairment
3560	1	a	VCM administration increased malondialdehyde MDA excretion glucosaminidase NAG marker of injury
3561	1	a	VCM induced nephrotoxicity
3562	1	a	VCM induced nephrotoxicity
3563	1	a	VCM induced nephrotoxicity in role plays reduces damage
3564	1	a	VCM induced kidney damage reduces plays role in nephrotoxicity
3565	1	a	VCM induced kidney damage
3566	0	a	erdosteine by protection role of stress in pathogenesis of nephrotoxicity
3567	0	a	erdosteine agent has properties on tissue against impairment
3568	0	a	Erdosteine showed protection against nephrotoxicity
3569	0	a	erdosteine with stress of modulation reduces plays role in nephrotoxicity
3570	0	a	erdosteine with stress of modulation reduces damage
3571	0	a	oxygen species of production promotes stress vancomycin examine investigate role of erdosteine agent has properties on tissue against impairment
3572	0	a	malondialdehyde MDA excretion glucosaminidase NAG marker of injury
3573	0	a	MDA excretion glucosaminidase NAG marker of injury
3574	0	a	superoxide dismutase excretion glucosaminidase NAG marker of injury
3575	0	a	VCM treated rats in vacuolization atrophy
3576	0	a	VCM treated rats in vacuolization atrophy desquamation
3577	0	a	VCM treated rats in vacuolization atrophy desquamation necrosis
3578	0	a	erdosteine groups control of those than more dilatation of lumens vacuolization atrophy
3579	0	a	erdosteine groups control of those than more dilatation of lumens vacuolization atrophy desquamation
3580	0	a	erdosteine groups control of those than more dilatation of lumens vacuolization atrophy desquamation necrosis
3581	1	a	sulfomethoxazole by induced crisis anemia
3582	0	a	sulfomethoxazole by induced crisis had resulting in anoxia
3583	1	a	Amiodarone reported cause hepatotoxicity
3584	1	a	amiodarone of effects hepatotoxic
3585	1	a	amiodarone of effects regarding information provide indicate protects against hepatotoxicity
3586	1	a	amiodarone induced hepatotoxicity against protects indicate provide information regarding effects hepatotoxic
3587	1	a	amiodarone induced hepatotoxicity
3588	1	a	Amiodarone induced hepatomegaly
3589	0	a	triglycerides in decrease accumulation hepatocyte induced hepatomegaly
3590	0	a	glucose triglycerides in decrease accumulation hepatocyte induced hepatomegaly
3591	0	a	amiodarone with treatment resulted in rate extent of loss
3592	0	a	amiodarone of inability activate expressed in cells hepatoma
3593	0	a	amiodarone of effects were indicates activate expressed in cells hepatoma
3594	0	a	Thalidomide neuropathy
3595	0	a	thalidomide induced neuropathy
3596	0	a	thalidomide of complication be Neuropathy
3597	0	a	Thalidomide neuropathy treated for cancer
3598	0	a	thalidomide of trial in men with cancer
3599	0	a	androgen independent cancer
3600	1	a	warfarin like anticoagulant to exposure causing hemorrhage
3601	0	a	warfarin induced coagulopathy due case of hematoma
3602	0	a	warfarin induced coagulopathy
3603	0	a	warfarin of absorption causing coagulopathy
3604	0	a	piroxicam with interaction exacerbated coagulopathy
3605	1	a	Succinylcholine apnoea
3606	1	a	succinylcholine apnoea
3607	0	a	succinylcholine of administration following antagonize blockade
3608	1	a	propranolol by induced block rhythm
3609	1	a	propranolol daily with angina for treatment under observed Alternating block rhythm
3610	1	a	propranolol by induced block
3611	1	a	propranolol daily with angina for treatment under observed Alternating block
3612	0	a	propranolol daily with angina
3613	0	a	propranolol being cause of disorder
3614	1	a	gentamicin mediated nephropathy
3615	1	a	gentamicin nephropathy
3616	1	a	GM)-mediated nephropathy
3617	1	a	GM of Administration induced reduction in flow clearance CIn damage
3618	1	a	GM mediated nephropathy
3619	1	a	GM mediated nephropathy
3620	0	a	monophosphate excretion in reduction observed in nephropathy
3621	0	a	cGMP ) excretion in reduction observed in nephropathy
3622	0	a	DMTU reduced damage
3623	0	a	DMTU SOD have effects on nephropathy
3624	0	a	bromide of effect on asthma
3625	0	a	bromide drug of of preparation upon asthma
3626	0	a	Oxitropium proves be alternative in asthma
3627	0	a	theophylline of of effect on asthma
3628	0	a	theophylline preparation upon asthma
3629	0	a	theophylline to alternative in asthma
3630	0	a	oxitropium of effects reported compared to subjects reporting nausea
3631	0	a	oxitropium of effects reported compared to subjects reporting nausea vomiting
3632	0	a	oxitropium of effects reported compared to subjects reporting nausea vomiting tremors
3633	1	a	theophylline after reporting nausea
3634	1	a	theophylline after reporting nausea vomiting
3635	1	a	theophylline after reporting nausea vomiting tremors
3636	1	a	sotalol by induced prolongation with producing trigger initiate torsade pointes
3637	1	a	sotalol by induced prolongation with producing trigger initiate torsade pointes TdP
3638	1	a	sotalol by increase facilitated propagation initiated episodes of TdP
3639	1	a	sotalol by induced prolongation
3640	1	a	Sotalol prolonged leading to prolongation
3641	1	a	sotalol induced produced EADs seen prolongation
3642	0	a	azimilide sotalol by induced prolongation with producing trigger initiate torsade pointes
3643	0	a	azimilide sotalol by induced prolongation with producing trigger initiate torsade pointes TdP
3644	0	a	azimilide sotalol by induced prolongation
3645	0	a	azimilide sotalol induced produced EADs seen prolongation
3646	0	a	maleate of mg containing combination of safety determine administered to patients hypertensive
3647	0	a	hydrochlorothiazide of mg mg containing combination of safety determine administered to patients hypertensive
3648	1	a	clonidine on on effect cataleptic
3649	1	a	clonidine by increased catalepsy
3650	1	a	naphazoline clonidine on on effect cataleptic
3651	1	a	naphazoline by decreased increased catalepsy
3652	1	a	xylometazoline naphazoline clonidine on on effect cataleptic
3653	1	a	xylometazoline naphazoline by decreased increased catalepsy
3654	1	a	morphine by induced analgesia on on effect cataleptic
3655	1	a	morphine of effect cataleptic
3656	1	a	morphine by induced catalepsy
3657	1	a	codeine morphine by induced analgesia on on effect cataleptic
3658	1	a	codine morphine of effect cataleptic
3659	1	a	Codeine catalepsy
3660	1	a	fentanyl codeine morphine by induced analgesia on on effect cataleptic
3661	1	a	fentanyl codine morphine of effect cataleptic
3662	1	a	fentanyl morphine by induced catalepsy
3663	0	a	pentazocine fentanyl codeine morphine by induced analgesia on on effect cataleptic
3664	0	a	NA receptors stimulating drugs failed found enhanced catalepsy
3665	0	a	sulfamethoxazole of study for toxicity
3666	0	a	trimethoprim sulfamethoxazole of study for toxicity
3667	0	a	cephalexin trimethoprim sulfamethoxazole of study for toxicity
3668	1	a	SMZ prescribed persons for similar was risk of disease
3669	0	a	sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3670	0	a	SMZ sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3671	0	a	sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3672	0	a	SMZ sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3673	0	a	sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3674	0	a	SMZ sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3675	0	a	sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3676	0	a	SMZ sulfamethoxazole prescribed people of study conducted estimate risk of liver blood skin disorders
3677	1	a	trimethoprim was risk of disease
3678	0	a	trimethoprim study conducted estimate risk of liver blood skin disorders
3679	0	a	trimethoprim study conducted estimate risk of liver blood skin disorders
3680	0	a	trimethoprim study conducted estimate risk of liver blood skin disorders
3681	0	a	trimethoprim study conducted estimate risk of liver blood skin disorders
3682	0	a	cephalexin trimethoprim study conducted estimate risk of liver blood skin disorders
3683	0	a	cephalexin trimethoprim study conducted estimate risk of liver blood skin disorders
3684	0	a	cephalexin trimethoprim study conducted estimate risk of liver blood skin disorders
3685	0	a	cephalexin trimethoprim study conducted estimate risk of liver blood skin disorders
3686	0	a	SMZ to exposed disorders of seven with multiforme
3687	0	a	SMZ to exposed experienced disorders of seven with multiforme
3688	1	a	SMZ to exposed disorders of seven with multiforme syndrome
3689	1	a	SMZ to exposed experienced disorders of seven with multiforme syndrome
3690	1	a	cephalexin took patient in occurred case of necrolysis
3691	0	a	Levodopa induced dyskinesias
3692	0	a	levodopa responsive patients in evaluated severity of disability dyskinesias
3693	0	a	levodopa- reduce dyskinesias
3694	1	a	fluoxetine by improved dyskinesias
3695	1	a	fluoxetine of administration after before challenge after evaluated severity of disability dyskinesias
3696	1	a	fluoxetine treatment After was improvement 0.05 of dyskinesias
3697	1	a	fluoxetine with transmission reduce dyskinesias
3698	0	a	levodopa responsive patients in evaluated severity of disability
3699	0	a	levodopa- reduce without disability
3700	0	a	levodopa responsive patients with disease
3701	0	a	levodopa- reduce without disability parkinsonian
3702	0	a	dopamine agonist with challenge after evaluated severity of disability
3703	0	a	dopamine dyskinesias reduce without disability
3704	0	a	dopamine agonist with challenge after evaluated severity of disability dyskinesias
3705	0	a	dopamine dyskinesias
3706	0	a	dopamine agonist with challenge after evaluated in patients with disease
3707	0	a	dopamine dyskinesias reduce without disability parkinsonian
3708	0	a	apomorphine agonist with challenge after evaluated severity of disability
3709	0	a	apomorphine induced dyskinesias of 0.05 improvement without modification of disability
3710	1	a	apomorphine agonist with challenge after evaluated severity of disability dyskinesias
3711	1	a	apomorphine induced dyskinesias
3712	0	a	apomorphine agonist with challenge after evaluated in patients with disease
3713	0	a	apomorphine induced dyskinesias of 0.05 improvement without modification of disability parkinsonian
3714	0	a	fluoxetine of administration after before challenge after evaluated severity of disability
3715	0	a	fluoxetine treatment After was improvement without modification of disability
3716	0	a	fluoxetine with transmission reduce without disability
3717	0	a	fluoxetine of administration after before challenge after evaluated in patients with disease
3718	0	a	fluoxetine treatment After was improvement without modification of disability parkinsonian
3719	0	a	fluoxetine with transmission reduce without disability parkinsonian
3720	0	a	nifedipine tablets for hypertension
3721	0	a	nifedipine blocker with treated patients with hypertension
3722	0	a	nifedipine is useful for patients hypertensive
3723	0	a	nifedipine tablets for hypertension in patients with psoriasis
3724	0	a	nifedipine blocker with treated patients psoriatic
3725	0	a	nifedipine is useful for patients psoriatic
3726	1	a	A induced hypertension
3727	1	a	A therapy of course during patients with hypertension
3728	1	a	A therapy before exhibited state hypertensive
3729	1	a	A with treatment under patients hypertensive
3730	0	a	A induced hypertension in patients with psoriasis
3731	0	a	A therapy of course during patients psoriatic
3732	0	a	A with treatment under patients psoriatic
3733	0	a	calcium channel blocker with treated patients psoriatic
3734	0	a	calcium channel blocker with treated patients with hypertension
3735	1	a	A with therapy during events included increase in 9 of patients of hyperplasia
3736	1	a	A with treatment under patients for useful is monitored for hyperplasia
3737	1	a	nifedipine A with therapy during events included increase in 9 of patients of hyperplasia
3738	1	a	nifedipine is monitored for hyperplasia
3739	0	a	nitrogen levels in increase in 9 of patients of hyperplasia
3740	1	a	acid induced neutropenia
3741	1	a	acid induced failure neutropenia
3742	1	a	acid induced neutropenia failure
3743	1	a	acid induced failure
3744	0	a	acid induced neutropenia with hypothyroidism
3745	0	a	acid use in patients hypothyroid
3746	0	a	acid use corrected hypothyroidism
3747	1	a	sumatriptan with infarction
3748	1	a	sumatriptan of administration after infarction
3749	0	a	sumatriptan of administration after infarction with describe for headache
3750	0	a	tacrolimus by induced crisis
3751	0	a	tacrolimus by induced SRC
3752	0	a	prednisolone tacrolimus by induced crisis
3753	0	a	corticosteroid use to Moderate recognized as factor for SRC
3754	0	a	corticosteroids tacrolimus by induced SRC
3755	1	a	cyclosporine by precipitated microangiopathy
3756	0	a	cyclosporine by precipitated in patients with SSc
3757	1	a	tacrolimus use in patients with SSc
3758	0	a	trazodone with pretreatment on stereotypies
3759	0	a	trazodone with pretreatment of effect on catalepsy
3760	0	a	trazodone induces catalepsy
3761	0	a	Trazodone induce catalepsy
3762	0	a	Trazodone induce antagonize apomorphine catalepsy
3763	0	a	trazodone stereotypy pretreatment antagonized catalepsy
3764	0	a	Trazodone at catalepsy
3765	0	a	trazodone that suggest releases potentiates antagonizes catalepsy
3766	0	a	dexamphetamine- on stereotypies
3767	0	a	dexamphetamine- on pretreatment of effect on catalepsy
3768	0	a	dexamphetamine stereotypy pretreatment antagonized catalepsy
3769	0	a	dexamphetamine apomorphine stereotypies antagonized Trazodone at catalepsy
3770	0	a	dexamphetamine stereotypy potentiates antagonizes catalepsy
3771	0	a	apomorphine induced stereotypies
3772	0	a	apomorphine haloperidol by induced catalepsy on effect of pretreatment on stereotypies
3773	1	a	apomorphine induced stereotypies on pretreatment of effect on catalepsy
3774	1	a	apomorphine haloperidol by induced catalepsy
3775	1	a	apomorphine antagonize induce catalepsy
3776	1	a	apomorphine catalepsy
3777	1	a	apomorphine stereotypy apomorphine antagonize induce catalepsy
3778	1	a	apomorphine stereotypy apomorphine catalepsy
3779	1	a	apomorphine stereotypies antagonized Trazodone at catalepsy
3780	0	a	haloperidol by induced catalepsy on effect of pretreatment on stereotypies
3781	1	a	haloperidol by induced catalepsy
3782	1	a	haloperidol catalepsy
3783	1	a	haloperidol catalepsy
3784	0	a	ergometrine induced shake on studied effect of pretreatment on stereotypies
3785	0	a	ergometrine induced shake on studied effect on catalepsy
3786	0	a	ergometrine induced behavior catalepsy
3787	0	a	fluoxetine induced erections behavior on studied effect of pretreatment on stereotypies
3788	0	a	fluoxetine induced erections behavior on studied effect on catalepsy
3789	0	a	fluoxetine induced erections behavior catalepsy
3790	0	a	5-HT receptors blocking by releases potentiates antagonizes catalepsy
3791	0	a	5-HT by caused inhibition from neurons releases potentiates antagonizes catalepsy
3792	1	a	lorazepam therapy with associated Myoclonus
3793	1	a	lorazepam of administration following experienced myoclonus
3794	0	a	Clonazepam for epilepsy
3795	0	a	clonazepam with treated patients with types of epilepsy
3796	0	a	clonazepam with treated patients with types than spasms
3797	1	a	isoproterenol induced tachycardia
3798	1	a	isoproterenol tachycardia
3799	1	a	isoproterenol activates are consistent with hypothesis results tachycardia
3800	0	a	atropine after before determined effects on tachycardia
3801	0	a	aminonucleoside nephrosis
3802	1	a	aminonucleoside of administration by developed model of sclerosis
3803	1	a	aminonucleoside of administration by developed model of sclerosis FSGS
3804	1	a	AMNS aminonucleoside of administration by developed model of sclerosis
3805	1	a	AMNS aminonucleoside of administration by developed model of sclerosis FSGS
3806	1	a	AMNS of toxicity enhances produces FSGS
3807	0	a	sulfate of administration by developed model of sclerosis
3808	0	a	sulfate of administration by developed model of sclerosis FSGS
3809	0	a	PS sulfate of administration by developed model of sclerosis
3810	0	a	PS sulfate of administration by developed model of sclerosis FSGS
3811	0	a	PS of administration enhances produces FSGS
3812	0	a	PS of administration enhances toxicity
3813	0	a	PS of administration enhances produces in rats resulting in disease
3814	0	a	AMNS of toxicity
3815	1	a	AMNS of toxicity enhances produces in rats resulting in disease
3816	0	a	Quinine induced arrhythmia
3817	0	a	quinine infusion reported getting presented with arrhythmia
3818	0	a	Quinine is alkaloid has property arrhythmic
3819	0	a	Quinine is cause it arrhythmic
3820	0	a	Quinine is cause arrhythmias
3821	0	a	Quinine is cause arrhythmias including arrhythmia
3822	0	a	quinine of Administration done because effect arrhythmic
3823	0	a	Quinine induced arrhythmia in patient with malaria
3824	0	a	quinine infusion reported getting presented jaundice with patient malaria
3825	0	a	quinine infusion got diagnosed as malaria
3826	0	a	quinine infusion reported getting presented jaundice
3827	0	a	quinine infusion got diagnosed as malaria with jaundice
3828	1	a	quinine infusion reported getting presented with arrhythmia contraction
3829	1	a	Quinine is cause arrhythmias including arrhythmia as PVC
3830	0	a	dextrose in infusion got diagnosed as malaria
3831	0	a	dextrose in infusion got diagnosed as malaria with jaundice
3832	0	a	quinine infusion of hours After felt palpitation
3833	0	a	quinidine like Quinine is alkaloid has property arrhythmic
3834	0	a	quinidine like Quinine is cause it arrhythmic
3835	0	a	quinidine like Quinine is cause arrhythmias
3836	0	a	quinidine like Quinine is cause arrhythmias including arrhythmia
3837	0	a	quinidine like Quinine is cause arrhythmias including arrhythmia as PVC
3838	0	a	quinine of Administration done in patients have diseases
3839	0	a	quinine of Administration done in patients have diseases patients with disorder
3840	0	a	quinine of Administration done in patients have diseases patients with disorder hypokalemia
3841	0	a	quinine of Administration done in patients have diseases patients with disorder hypokalemia occurs due vomiting
3842	0	a	quinine of Administration done in patients have diseases patients with disorder hypokalemia occurs due vomiting diarrhea
3843	0	a	quinine of Administration done in patients have diseases patients with disorder hypokalemia occurs due vomiting in cases malaria
3844	1	a	Amiodarone related mass
3845	1	a	amiodarone with treatment after developed mass
3846	1	a	amiodarone related lesion was indicating infiltrates suspected mass
3847	1	a	amiodarone related lesion
3848	1	a	amiodarone treatment of complication be suggests highlights possibility be diagnosis between lesion
3849	1	a	Amiodarone related mass glomerulonephritis
3850	1	a	amiodarone related lesion between diagnosis be possibility highlights suggests be glomerulonephritis
3851	1	a	amiodarone treatment of complication be glomerulonephritis
3852	0	a	Amiodarone related mass in patient with disease
3853	0	a	amiodarone with treatment after developed patient in is case of disease
3854	0	a	Amiodarone is drug arrhythmic
3855	0	a	Amiodarone is drug for tachycardia
3856	0	a	amiodarone with treatment after developed mass cm proteinuria
3857	0	a	amiodarone related lesion was indicating infiltrates suspected be cancer
3858	0	a	amiodarone related lesion neoplasm
3859	0	a	amiodarone treatment of complication be suggests highlights possibility be diagnosis between lesion neoplasm
3860	1	a	aminoglycoside nephrotoxicity
3861	1	a	aminoglycoside induced nephrotoxicity
3862	1	a	aminoglycosides cause damage indicate cause dysfunction
3863	1	a	aminoglycoside levels duration increase risk for nephrotoxicity
3864	1	a	aminoglycoside induced nephrotoxicity
3865	0	a	aminoglycosides of trials indicate ranges risk for developing failure
3866	0	a	aminoglycoside levels disease
3867	0	a	creatinine clearance age disease
3868	0	a	creatinine clearance age disease levels duration increase risk for nephrotoxicity
3869	1	a	verapamil therapy during rhythms
3870	1	a	verapamil receiving patients in rhythms
3871	0	a	verapamil increased In patients with syndromes pain
3872	1	a	acid induced dementia
3873	1	a	acid induced dementia
3874	0	a	acid induced dementia documented in man with epilepsy
3875	1	a	acid of effect system effect effect mediated through hyperammonemia
3876	1	a	acid induced hyperammonemia
3877	1	a	Valproate induced encephalopathy hyperammonemic
3878	1	a	Valproate induced encephalopathy hyperammonemic
3879	1	a	valproate treatment of effect is encephalopathy hyperammonemic
3880	1	a	valproate with therapy on was revealed with hyperammonemia
3881	0	a	Valproate induced encephalopathy
3882	0	a	Valproate induced encephalopathy
3883	0	a	valproate treatment of effect is encephalopathy
3884	0	a	valproate with therapy on was due epilepsy
3885	1	a	valproate with therapy on was revealed consciousness
3886	1	a	cyclosporine on infections
3887	1	a	cyclosporine patients than infections infections
3888	1	a	cyclosporine patients than infections
3889	1	a	cyclosporine patients than infections
3890	1	a	cyclosporine patients infections
3891	1	a	cyclosporine on deaths were played infection
3892	1	a	cyclosporine treated patients in common were infections
3893	1	a	Aza patients had infections
3894	1	a	Aza patients had infections infections
3895	1	a	Aza patients than infections patients than infections
3896	1	a	Aza patients than infections
3897	1	a	Aza cyclosporine on deaths were played infection
3898	1	a	Aza treated patients in than were infections
3899	0	a	cyclosporine on patients had bacteremias
3900	0	a	Aza patients had infections
3901	0	a	Aza patients had occurred infections
3902	0	a	cyclosporine patients Of had symptoms related to infection
3903	0	a	cyclosporine patients of % in found evidence for infection
3904	0	a	E of lack due Myopathy
3905	0	a	E myopathy
3906	0	a	E. in deficient diet by rendered rats in doses at effects investigate encouraged results obtained in departments in patients myopathic
3907	0	a	E. in deficient diet by rendered myopathic
3908	0	a	E of lack is occurs have conclude by affirming efficacy of steroids in disease
3909	1	a	E. in lacking diet giving by induced myodystrophy
3910	0	a	steroids anabolizing using by obtained in departments in patients myopathic
3911	0	a	steroids anabolizing using by obtained results encouraged investigate effects at doses in rats rendered myopathic
3912	0	a	steroids in disease
3913	0	a	Dianabol agent of effects investigate encouraged results obtained in departments in patients myopathic
3914	0	a	Dianabol agent of effects at doses in rats rendered myopathic
3915	0	a	CIBA Dianabol agent of effects investigate encouraged results obtained in departments in patients myopathic
3916	0	a	CIBA Dianabol agent of effects at doses in rats rendered myopathic
3917	1	a	telaprevir with treated patient Rhabdomyolysis
3918	0	a	telaprevir with treated patient infected
3919	0	a	telaprevir interferon received man with infection
3920	1	a	simvastatin telaprevir with treated patient Rhabdomyolysis
3921	0	a	simvastatin telaprevir with treated patient infected
3922	0	a	ribavirin with received man with infection
3923	0	a	interferon received man with infection
3924	0	a	simvastatin At discontinued due toxicity
3925	1	a	Simvastatin plasma concentration increased related toxicity
3926	1	a	statin induced toxicity
3927	1	a	statin of concentration to related toxicity
3928	0	a	lomustine of Tolerability in combination in dogs with lymphoma
3929	0	a	lomustine of protocol in dogs with lymphoma
3930	0	a	CCNU lomustine of protocol in dogs with lymphoma
3931	0	a	cyclophosphamide with combination in dogs with lymphoma
3932	0	a	cyclophosphamide lomustine of protocol in dogs with lymphoma
3933	0	a	CTX cyclophosphamide lomustine of protocol in dogs with lymphoma
3934	0	a	lomustine of protocol with associated toxicity
3935	0	a	CCNU lomustine of protocol with associated toxicity
3936	0	a	cyclophosphamide lomustine of protocol with associated toxicity
3937	0	a	CTX cyclophosphamide lomustine of protocol with associated toxicity
3938	1	a	CCNU CTX of treatment after frequency was was Neutropenia
3939	1	a	CCNU CTX of treatment after frequency of neutropenia
3940	1	a	CTX of treatment after frequency was was Neutropenia
3941	1	a	CTX of treatment after frequency of neutropenia
3942	0	a	doxorubicin of trial in cancers
3943	0	a	doxorubicin demonstrated be agent in cancer
3944	0	a	Doxil doxorubicin demonstrated be agent in cancer
3945	0	a	doxorubicin with treated Patients with cancers
3946	0	a	doxorubicin of trial in cancers
3947	0	a	doxorubicin with treated Patients with cancers
3948	0	a	doxorubicin of trial in cancers carcinoma of peritoneum
3949	0	a	doxorubicin with treated Patients with cancers carcinoma
3950	0	a	platinum ovarian cancers
3951	0	a	platinum resistant cancer
3952	0	a	platinum refractory disease with Patients with cancers
3953	0	a	platinum- cancer
3954	0	a	platinum ovarian cancers
3955	0	a	platinum refractory disease with Patients with cancers
3956	0	a	platinum ovarian cancers carcinoma of peritoneum
3957	0	a	platinum refractory disease with Patients with cancers carcinoma
3958	0	a	paclitaxel refractory ovarian cancers
3959	0	a	paclitaxel refractory disease with Patients with cancers
3960	0	a	paclitaxel refractory cancer
3961	0	a	paclitaxel refractory ovarian cancers
3962	0	a	paclitaxel refractory disease with Patients with cancers
3963	0	a	paclitaxel refractory ovarian cancers carcinoma of peritoneum
3964	0	a	paclitaxel refractory disease with Patients with cancers carcinoma
3965	0	a	doxorubicin demonstrated be with toxicity
3966	0	a	Doxil doxorubicin demonstrated be with toxicity
3967	0	a	doxorubicin liposomal results in toxicity
3968	1	a	doxorubicin demonstrated be with toxicity being erythrodysesthesia
3969	1	a	doxorubicin demonstrated be with toxicity being erythrodysesthesia syndrome
3970	1	a	Doxil doxorubicin demonstrated be with toxicity being erythrodysesthesia
3971	1	a	Doxil doxorubicin demonstrated be with toxicity being erythrodysesthesia syndrome
3972	1	a	doxorubicin liposomal results in toxicity stomatitis syndrome
3973	1	a	doxorubicin demonstrated be with toxicity being erythrodysesthesia syndrome stomatitis
3974	1	a	Doxil doxorubicin demonstrated be with toxicity being erythrodysesthesia syndrome stomatitis
3975	1	a	doxorubicin liposomal results in toxicity stomatitis
3976	0	a	platinum resistant cancer in agent be with toxicity
3977	0	a	platinum resistant cancer in agent be with toxicity being erythrodysesthesia
3978	0	a	platinum resistant cancer in agent be with toxicity being erythrodysesthesia syndrome
3979	0	a	platinum resistant cancer in agent be with toxicity being erythrodysesthesia syndrome stomatitis
3980	1	a	Phenytoin encephalopathy
3981	1	a	phenytoin encephalopathy
3982	1	a	DPH encephalopathy
3983	0	a	phenytoin encephalopathy with seizures
3984	0	a	DPH encephalopathy with seizures
3985	0	a	DPH treatment starting patient in increase in seizures
3986	0	a	DPH eliminating for need to alert in increase in seizures
3987	0	a	DPH of concentration was presented rash
3988	0	a	DPH treatment during presented rash
3989	0	a	DPH injection had was presented rash
3990	1	a	Metronidazole induced encephalopathy
3991	1	a	metronidazole intake following features of encephalopathy
3992	0	a	metronidazole toxicity
3993	1	a	isoproterenol induced cardiotoxicity
3994	1	a	dexamethasone induced hypertension
3995	1	a	Dex- ) hypertension
3996	1	a	Dex administration upon effect on stress hypertension
3997	1	a	Dex induced hypertension
3998	1	a	Dex induced hypertension
3999	0	a	H2O2 reduced prevented loss
4000	1	a	hydroxychloroquine taking patients in loss
4001	1	a	hydroxychloroquine treatment to attributed abnormalities
4002	0	a	glutamate of injections are attractive use in models pain
4003	0	a	glutamate of injections are mimic hyperalgesia
4004	0	a	glutamate of injections are mimic hyperalgesia allodynia
4005	0	a	glutamate yield responses hyperalgesic
4006	0	a	glutamate yield responses hyperalgesic allodynic
4007	0	a	glutamate of injections are mimic aspects of disorders
4008	0	a	capsaicin glutamate of injections are attractive use in models pain
4009	1	a	capsaicin glutamate of injections are mimic hyperalgesia
4010	1	a	capsaicin glutamate of injections are mimic hyperalgesia allodynia
4011	1	a	capsaicin For detected hyperalgesia
4012	1	a	Capsaicin injection was reproducible for hyperalgesia
4013	1	a	Capsaicin injection was reproducible for hyperalgesia allodynia
4014	1	a	capsaicin glutamate yield responses hyperalgesic
4015	1	a	capsaicin glutamate yield responses hyperalgesic allodynic
4016	0	a	capsaicin glutamate of injections are mimic aspects of disorders
4017	0	a	levodopa induced dyskinesias disease
4018	0	a	levodopa induced dyskinesias disease PD
4019	1	a	levodopa induced dyskinesias
4020	1	a	levodopa induced dyskinesias LIDs
4021	1	a	Thalidomide neurotoxicity
4022	1	a	thalidomide of doses with treated patients in incidence of neuropathy
4023	0	a	thalidomide with treated amplitude in patients with erythematosus
4024	0	a	thalidomide with treated amplitude in patients with erythematosus CLE
4025	0	a	thalidomide of potential identify use treated amplitude in patients with erythematosus
4026	0	a	thalidomide of potential identify use treated amplitude in patients with erythematosus CLE
4027	0	a	thalidomide with treatment during data in patients with CLE
4028	0	a	thalidomide with treated use identify potential neurotoxic
4029	0	a	thalidomide of potential neurotoxic
4030	0	a	thalidomide of potential neurotoxic
4031	1	a	cocaine use with associated ulcers
4032	1	a	cocaine use with associated ulcers
4033	1	a	cocaine use associated with development of ulcers
4034	1	a	heparin induced II
4035	1	a	heparin induced II
4036	1	a	heparin induced II of impact II
4037	1	a	heparin induced II of impact as cause of thrombocytopenia
4038	1	a	heparin of use avoided For reduction of II
4039	1	a	heparin with performed avoided For reduction of II
4040	1	a	pilocarpine induced seizures
4041	1	a	pilocarpine injections by induced seizures
4042	1	a	1,25(OH)2D by induced syndrome
4043	1	a	calcitriol carbonate with treated resulting in admissions to hospital for syndrome
4044	0	a	1,25(OH)2D by induced in patient with hypoparathyroidism
4045	0	a	calcitriol carbonate with treated patient with hypoparathyroidism
4046	1	a	calcium of amounts with treatment of context in described syndrome
4047	0	a	calcium of amounts with treatment of disease
4048	1	a	alkali calcium of amounts with treatment of context in described syndrome
4049	0	a	alkali calcium of amounts with treatment of disease
4050	0	a	omeprazole blockers therapy ulcer
4051	0	a	omeprazole blockers therapy with decreased frequency of syndrome
4052	0	a	omeprazole blockers therapy with decreased remains triad of hypercalcemia
4053	0	a	omeprazole blockers therapy with decreased remains triad of hypercalcemia alkalosis
4054	0	a	omeprazole blockers therapy with decreased remains triad of hypercalcemia alkalosis impairment
4055	0	a	sucralfate omeprazole blockers therapy ulcer
4056	0	a	sucralfate omeprazole blockers therapy with decreased frequency of syndrome
4057	0	a	sucralfate omeprazole blockers therapy with decreased remains triad of hypercalcemia
4058	0	a	sucralfate omeprazole blockers therapy with decreased remains triad of hypercalcemia alkalosis
4059	0	a	sucralfate omeprazole blockers therapy with decreased remains triad of hypercalcemia alkalosis impairment
4060	0	a	carbonate with treated patient with hypoparathyroidism
4061	1	a	carbonate with treated resulting in admissions to hospital for syndrome
4062	0	a	pamidronate illustrates presents syndrome
4063	0	a	pamidronate illustrates presents as emergency
4064	1	a	Disoprivan with than frequently occurred Pain
4065	1	a	Disoprivan with than frequently occurred Pain 0.01 thrombophlebitis
4066	0	a	Ifosfamide encephalopathy
4067	0	a	ifosfamide receiving patients of % in reported Encephalopathy
4068	0	a	ifosfamide encephalopathy
4069	0	a	ifosfamide encephalopathy
4070	0	a	ifosfamide receiving experienced symptoms of encephalopathy
4071	0	a	ifosfamide encephalopathy
4072	0	a	ifosfamide receiving develop features of encephalopathy
4073	0	a	Ifosfamide is agent useful in treatment of range of cancers
4074	0	a	Ifosfamide is agent useful in treatment of range of cancers including sarcomas lymphoma cancers
4075	0	a	ifosfamide encephalopathy developed done admitted to Center Cancer
4076	0	a	Ifosfamide is agent useful in treatment of range of cancers including sarcomas
4077	0	a	Ifosfamide is agent useful in treatment of range of cancers including sarcomas lymphoma
4078	0	a	pentobarbital to dysfunction
4079	0	a	pentobarbital to dysfunction hypersensitivity
4080	0	a	pentobarbital to was hypersensitivity
4081	0	a	pentobarbital to characteristics disturbances hypersensitivity
4082	0	a	chloride ingestion by induced pentobarbital to dysfunction
4083	0	a	chloride ingestion by induced pentobarbital to dysfunction hypersensitivity
4084	0	a	Barium supplemented rats characterized by hypertension
4085	0	a	barium of month treatment after was hypertension
4086	0	a	barium induced disturbances within system
4087	0	a	barium effect of aspect was hypersensitivity
4088	0	a	barium exposure by induced disorder of existence suggest characteristics disturbances hypersensitivity
4089	0	a	pentobarbital to characteristics disturbances
4090	0	a	pentobarbital to characteristics suggest existence of disorder
4091	0	a	barium exposure by induced disorder of existence suggest characteristics disturbances
4092	0	a	barium exposure by induced disorder
4093	1	a	galactose treatment prevents deficits
4094	1	a	galactose of effects treatment on deficits
4095	1	a	galactose treatment of month initiated prevented development of deficits
4096	1	a	galactose exposure have be worth investigating for improvement of deficits
4097	1	a	streptozotocin with treated prevents deficits
4098	1	a	streptozotocin induced model in deficits
4099	1	a	STZ icv model in deficits
4100	1	a	STZ icv administration after initiated prevented development of deficits
4101	1	a	STZ icv induced deficits
4102	0	a	glucose transport by followed system of dysfunction with associated dementia
4103	0	a	glucose transporter GLUT4 via transport by followed system of dysfunction with associated dementia
4104	0	a	glucose metabolism decreased associated dementia
4105	1	a	glucose transport by followed system of dysfunction with associated dementia of type disease
4106	1	a	glucose transporter GLUT4 via transport by followed system of dysfunction with associated dementia of type disease
4107	1	a	glucose metabolism decreased associated dementia of type disease
4108	0	a	galactose of injections induce deterioration
4109	0	a	galactose treatment of effects tested induce deterioration
4110	0	a	galactose exposure have be worth investigating for improvement of deficits associated with hypometabolism
4111	0	a	galactose exposure have be worth investigating for improvement of deficits associated with hypometabolism in AD
4112	1	a	A behavior like anxiety
4113	1	a	BPA to exposed mice in increased behavior like anxiety
4114	1	a	BPA exposure increased behavior like anxiety
4115	1	a	suxamethonium induced fasciculations
4116	1	a	suxamethonium by caused fasciculations
4117	1	a	suxamethonium by caused fasciculations
4118	1	a	suxamethonium induced fasciculations
4119	0	a	alfentanil by inhibition Increase during fasciculations
4120	0	a	alfentanil group in than were incidence of fasciculations
4121	0	a	alfentanil group in than was pressure during fasciculations
4122	0	a	H2O group in was pressure during fasciculations
4123	0	a	propranolol of effects of hypoglycaemia
4124	1	a	oestrogen HT increased risk of stroke
4125	1	a	oestrogen HT increased risk of stroke disease
4126	1	a	azathioprine of effects include anemia
4127	1	a	Azathioprine triggers effect contributing to anemia
4128	1	a	azathioprine induced anemia
4129	0	a	phosphatidylserine of exposure by characterized death from result anemia
4130	0	a	PS phosphatidylserine of exposure by characterized death from result anemia
4131	1	a	methamphetamine abuse with associated brain
4132	1	a	MA abuse with associated brain
4133	1	a	MA used subjects in ventricles
4134	1	a	MA abuse of symptoms for account help providing targets for injury
4135	0	a	MA used subjects of Studies revealed deficits in systems abnormalities
4136	0	a	MA abuse with associated alterations of pattern determined related to impairment
4137	0	a	MA abusers had 0.05 hypertrophy
4138	1	a	methamphetamine abuse causes pattern contributes to performance
4139	1	a	aspirin disease
4140	1	a	aspirin disease ESRD
4141	1	a	aspirin with associated ESRD
4142	1	a	aspirin of use increase risk of ESRD
4143	0	a	aspirin with associated ESRD of risk related was among subset of patients with nephropathy
4144	0	a	dopamine neurons in changes hyperprolactinemia
4145	0	a	dopamine antagonist haloperidol with treatment by induced Hyperprolactinemia
4146	0	a	dopamine concentrations After months of hyperprolactinemia
4147	0	a	DA concentrations After months of hyperprolactinemia
4148	0	a	DA concentrations in increase produced months of hyperprolactinemia
4149	0	a	DA response lost followed hyperprolactinemia
4150	0	a	DA of levels in change was after 6-months of hyperprolactinemia
4151	0	a	DA of levels in change was increase after 9-months of hyperprolactinemia
4152	0	a	DA concentrations in increase was after 6-months of hyperprolactinemia
4153	0	a	DA concentrations in increase after 9-months of hyperprolactinemia
4154	1	a	haloperidol with treatment by induced Hyperprolactinemia
4155	1	a	haloperidol induced hyperprolactinemia
4156	0	a	norepinephrine DA of levels in change was after 6-months of hyperprolactinemia
4157	0	a	norepinephrine DA of levels in change was increase after 9-months of hyperprolactinemia
4158	0	a	NE norepinephrine DA of levels in change was after 6-months of hyperprolactinemia
4159	0	a	NE norepinephrine DA of levels in change was increase after 9-months of hyperprolactinemia
4160	0	a	serotonin was after 6-months of hyperprolactinemia
4161	0	a	serotonin was increase after 9-months of hyperprolactinemia
4162	0	a	5-HT serotonin was after 6-months of hyperprolactinemia
4163	0	a	5-HT serotonin was increase after 9-months of hyperprolactinemia
4164	0	a	acid in decrease for except serotonin was after 6-months of hyperprolactinemia
4165	0	a	acid in decrease for except serotonin was increase after 9-months of hyperprolactinemia
4166	0	a	5-HIAA acid in decrease for except serotonin was after 6-months of hyperprolactinemia
4167	0	a	5-HIAA acid in decrease for except serotonin was increase after 9-months of hyperprolactinemia
4168	0	a	acid seizure
4169	0	a	TNA of overdose be believed cause of convulsions
4170	0	a	acid seizure in failure
4171	1	a	TNA of dose after had episode of convulsions
4172	0	a	TNA of overdose
4173	1	a	nitroprusside under dogs in studied hypotension
4174	1	a	SNP nitroprusside under dogs in studied hypotension
4175	1	a	nitroprusside hypotension used confirm Regarding effects of hypotension
4176	1	a	nitroprusside hypotension
4177	1	a	nitroprusside hypotension used to decrease hypotension
4178	1	a	SNP hypotension
4179	1	a	trimetaphan hypotension
4180	1	a	TMP hypotension
4181	1	a	trimetaphan hypotension decrease to used confirm Regarding effects of hypotension
4182	1	a	trimetaphan hypotension decrease to used hypotension
4183	1	a	trimetaphan hypotension
4184	0	a	Verapamil stimulation test in hyperprolactinemia
4185	0	a	Verapamil stimulation test investigated as tool for diagnosis of hyperprolactinemia
4186	0	a	Verapamil increased PRL PRL hyperprolactinemia
4187	0	a	verapamil to defined unresponsiveness discriminated revealed sensitivity specificity % associated with pseudoprolactinoma hyperprolactinemia
4188	0	a	Verapamil responsiveness is finding for diagnosis of hyperprolactinemia
4189	0	a	verapamil unresponsiveness discriminates from causes of hyperprolactinemia
4190	0	a	verapamil of value investigate in population screened for macroprolactinemia
4191	0	a	Verapamil increased PRL PRL macroprolactinoma
4192	0	a	Verapamil increased PRL PRL macroprolactinoma microprolactinoma
4193	0	a	Verapamil increased PRL PRL macroprolactinoma macroprolactinemia
4194	0	a	Verapamil increased PRL PRL macroprolactinoma in pseudoprolactinoma
4195	0	a	verapamil to defined unresponsiveness discriminated revealed sensitivity specificity % associated with pseudoprolactinoma
4196	0	a	risperidone induced hyperprolactinemia PRL macroprolactinoma
4197	0	a	risperidone induced hyperprolactinemia PRL macroprolactinoma microprolactinoma
4198	0	a	risperidone induced hyperprolactinemia PRL macroprolactinoma macroprolactinemia
4199	0	a	risperidone induced hyperprolactinemia PRL macroprolactinoma in pseudoprolactinoma
4200	0	a	risperidone induced hyperprolactinemia pseudoprolactinoma
4201	1	a	risperidone induced hyperprolactinemia
4202	1	a	risperidone induced hyperprolactinemia
4203	0	a	ACC-9653 sodium have activity against seizures
4204	0	a	sodium have activity against seizures
4205	0	a	ACC-9653 sodium have activity against tachycardia
4206	0	a	sodium have activity against tachycardia
4207	1	a	ouabain induced tachycardia
4208	0	a	ACC-9653 sodium necessary convert arrhythmia
4209	0	a	sodium necessary convert arrhythmia
4210	0	a	sodium displayed in activity against arrhythmias
4211	1	a	strophanthidin induced arrhythmias
4212	0	a	ACC-9653 sodium of studies toxicity
4213	0	a	sodium of studies toxicity
4214	0	a	ribavirin induced anemia
4215	0	a	ribavirin induced anemia
4216	0	a	ribavirin induced anemia
4217	0	a	Ribavirin induced anemia
4218	0	a	Interferon therapy for C
4219	0	a	alpha-2b received patients with C
4220	1	a	Interferon produces anemia
4221	0	a	ribavirin Interferon therapy for C
4222	0	a	ribavirin with combination in weeks for administered MU of dose at received patients with C
4223	1	a	ribavirin Interferon produces anemia
4224	1	a	methamphetamine psychosis
4225	1	a	methamphetamine dependent patients in factors of psychosis
4226	1	a	methamphetamine induced psychosis
4227	1	a	methamphetamine dependence with patients in risk of lifetime psychosis
4228	1	a	methamphetamine induced psychosis
4229	1	a	methamphetamine of diagnosis with Patients interviewed using for psychosis
4230	1	a	methamphetamine induced psychosis
4231	1	a	methamphetamine uses disorder disorder associated with psychosis
4232	1	a	methamphetamine induced psychosis
4233	1	a	methamphetamine dependence with patients in risk of psychosis
4234	1	a	methamphetamine dependence of cases screened for symptoms
4235	1	a	methamphetamine uses disorder disorder
4236	1	a	methamphetamine induced psychosis with associated disorder
4237	1	a	methamphetamine uses disorder
4238	1	a	methamphetamine induced psychosis with associated disorder disorder
4239	1	a	methamphetamine use personality
4240	0	a	methamphetamine use personality disorder
4241	1	a	Caffeine test in disorder
4242	1	a	Caffeine test with attacks
4243	1	a	caffeine challenge test by induction to way in respond patients with disorder
4244	1	a	caffeine challenge test by induction to way in respond patients with disorder PD
4245	1	a	caffeine challenge test by induction to way in respond patients patients with depression with attacks
4246	1	a	caffeine challenge test by induction of attacks
4247	1	a	caffeine challenge test after had total of % of patients with PD
4248	1	a	caffeine challenge test after had attack
4249	1	a	caffeine to sensitive were patients with PD
4250	1	a	caffeine free intake after observed attack
4251	1	a	caffeine challenge test to hyperreactivity matter is association between attacks
4252	1	a	caffeine challenge test to hyperreactivity matter associated with PD
4253	0	a	caffeine challenge test by induction to way in respond patients patients with depression with attacks MDP
4254	0	a	caffeine challenge test after had total % of patients with MDP
4255	0	a	caffeine to sensitive were patients with PD MDP
4256	0	a	caffeine challenge test to hyperreactivity matter associated with PD MDP
4257	0	a	Caffeine test in disorder depression
4258	0	a	caffeine challenge test by induction to way in respond patients patients with depression
4259	0	a	caffeine challenge test by induction to way in respond patients patients with depression with attacks MDP
4260	0	a	caffeine challenge test after had total % of patients with MDP
4261	0	a	caffeine challenge test after had total % of patients with MDP % of patients with MD
4262	0	a	caffeine to sensitive were patients with PD MDP
4263	0	a	caffeine to sensitive were patients with MD
4264	0	a	caffeine challenge test to hyperreactivity matter associated with PD MDP
4265	0	a	caffeine challenge test by induction to way in respond patients patients with depression with attacks Manual of Disorders
4266	0	a	caffeine administered in form scales anxiety
4267	0	a	caffeine free solution caffeine administered in form scales anxiety
4268	1	a	aminonucleoside nephropathy
4269	1	a	aminonucleoside nephropathy
4270	1	a	aminonucleoside nephropathy model of disease
4271	1	a	PAN nephropathy
4272	1	a	PAN nephropathy model of disease
4273	1	a	PAN nephropathy
4274	1	a	PAN of injections by induced glomerulopathy
4275	1	a	PAN nephropathy
4276	1	a	PAN animals nephropathy
4277	1	a	PAN nephropathy
4278	1	a	PAN nephropathy
4279	0	a	PAN nephropathy with rats in failure
4280	0	a	malondialdehyde content injury glomerulosclerosis increased associated with hypertrophy
4281	0	a	malondialdehyde content damage
4282	0	a	malondialdehyde content injury glomerulosclerosis
4283	0	a	malondialdehyde content injury
4284	0	a	malondialdehyde content area GFR proteinuria
4285	0	a	glutathione in change following injury reperfusion ischemia
4286	0	a	glutathione in change following injury
4287	1	a	Famotidine associated delirium
4288	1	a	famotidine with associated shown propensity cause delirium
4289	1	a	famotidine associated delirium
4290	1	a	famotidine of removal upon cleared patients in cases of delirium
4291	0	a	Famotidine is antagonist used in settings for prevention of ulcers
4292	1	a	cimetidine by caused hypotension
4293	1	a	cimetidine of activity mediated preventing hypotension
4294	1	a	vincristine after secretion of hormone
4295	1	a	vincristine infusion to attributed hormone
4296	0	a	vincristine of infusion with treated woman with myeloma
4297	0	a	doxorubicin vincristine of infusion with treated woman with myeloma
4298	0	a	dexamethasone of days infusion with treated woman with myeloma
4299	0	a	Metformin protects against seizures
4300	0	a	metformin of effects on seizures
4301	0	a	metformin be agent for treatment medicine against impairment induced by seizures
4302	0	a	Metformin protects against seizures impairments
4303	0	a	Metformin protects against seizures impairments
4304	1	a	pentylenetetrazole induced kindling by induced damage impairments seizures
4305	1	a	pentylenetetrazole induced animals in observed markers impairment seizures
4306	1	a	pentylenetetrazole induced kindling by induced damage impairments
4307	1	a	pentylenetetrazole induced kindling by induced damage impairments
4308	0	a	metformin of effects on seizures impairment
4309	0	a	metformin suppressed ameliorated impairment
4310	0	a	metformin be agent for treatment medicine against impairment
4311	1	a	pentylenetetrazole induced animals in observed markers impairment
4312	0	a	metformin be agent for treatment of epilepsy
4313	0	a	VNR comparing with agents in treatment of malignancies
4314	0	a	VNR comparing in treatment of cancer
4315	1	a	VNR events of risk was similar to vindesine drugs cardiotoxic
4316	0	a	vindesine drugs cardiotoxic
4317	0	a	VDS vindesine drugs cardiotoxic
4318	0	a	fluorouracil drugs cardiotoxic
4319	0	a	anthracyclines leader drugs cardiotoxic
4320	0	a	gemcitabine leader drugs cardiotoxic
4321	0	a	GEM leader drugs cardiotoxic
4322	1	a	simvastatin increment with association in Rhabdomyolysis
4323	1	a	statin rhabdomyolysis
4324	1	a	clarithromycin in increment with association in Rhabdomyolysis
4325	1	a	clarithromycin of dose in increase after occurred rhabdomyolysis
4326	0	a	isotretinoin drug in treatment of acne
4327	0	a	Isotretinoin contraindicated because abnormalities
4328	0	a	Isotretinoin contraindicated because abnormalities after use including microphthalmos
4329	0	a	Isotretinoin contraindicated because abnormalities after use including microphthalmos hypertelorism
4330	0	a	Isotretinoin contraindicated because abnormalities after use including microphthalmos hypertelorism hypoplasia
4331	0	a	6-hydroxydopamine lesion development of dyskinesias
4332	0	a	DOPA+benserazide with Treatment resulted in dyskinesias
4333	0	a	DA lesion impairment of severity increased reduced dyskinesias
4334	1	a	DOPA induced dyskinesias
4335	1	a	DOPA induced dyskinesias
4336	1	a	quetiapine by induced agitation
4337	1	a	quetiapine of introduction following h Within presented agitation
4338	1	a	quetiapine of reintroduction led to agitation
4339	1	a	quetiapine of reintroduction withdrawal enabled attribute agitation
4340	1	a	quetiapine to attribute enabled withdrawal reintroduction led to agitation
4341	1	a	quetiapine to attribute agitation
4342	0	a	quetiapine in disorder
4343	0	a	zuclopenthixol antipsychotics of combination by treated report case of suffering from disorder
4344	0	a	lithium day zuclopenthixol antipsychotics of combination by treated report case of suffering from disorder
4345	0	a	quetiapine of introduction following h Within presented contrasting with absence of history of aggressiveness
4346	0	a	quetiapine of introduction following h Within presented contrasting with absence of history of aggressiveness disorder
4347	0	a	Isradipine treatment for hypertension
4348	1	a	5-fluorouracil of infusion received patients in encephalopathy
4349	1	a	5-fluorouracil of infusion to related episodes of encephalopathy
4350	1	a	5-FU of infusion to related episodes of encephalopathy
4351	1	a	5-FU of doses receiving patients in seen levels onset of hyperammonemia
4352	1	a	5-FU of infusion receiving patients in occur encephalopathy
4353	1	a	5-fluorouracil of infusion received patients in encephalopathy
4354	1	a	5-fluorouracil of infusion to related episodes of encephalopathy
4355	1	a	5-FU of infusion to related episodes of encephalopathy
4356	1	a	5-FU of infusion receiving patients in occur encephalopathy
4357	0	a	5-fluorouracil of infusion received patients cancer
4358	0	a	5-fluorouracil of infusion to related episodes had patients cancer
4359	0	a	5-FU of infusion to related episodes had patients cancer
4360	0	a	5-fluorouracil of infusion received with complication of dehydration
4361	0	a	5-fluorouracil of infusion received with complication of dehydration infection
4362	0	a	ammonium levels onset of hyperammonemia
4363	0	a	ammonium levels seen in patients with infections
4364	0	a	5-FU of doses receiving patients in seen in patients with infections
4365	1	a	rifampin therapy following hemolysis
4366	1	a	rifampin therapy following failure to leading hemolysis
4367	1	a	rifampin following developed hemolysis
4368	1	a	rifampin therapy following hemolysis failure
4369	1	a	rifampin therapy following failure
4370	1	a	rifampin following developed hemolysis failure
4371	0	a	rifampin of use with associated complication is failure
4372	0	a	rifampin following developed patients with leprosy
4373	1	a	epirubicine based chemotherapy during detection of cardiotoxicity
4374	0	a	epirubicin exposure after predict alterations of strain
4375	0	a	epirubicin exposure after predict dysfunction
4376	0	a	epirubicin with treated patients with lymphoma
4377	0	a	anthracycline based chemotherapy receiving patients in dysfunction
4378	0	a	alanine aminotransferase with jaundice hepatitis CD4 limits % in observed anemia
4379	0	a	alanine aminotransferase with jaundice hepatitis
4380	0	a	alanine aminotransferase with jaundice
4381	1	a	NVP therapy associated with rash
4382	0	a	NVP therapy associated with rash with developing neuropathy
4383	0	a	T therapy rash
4384	1	a	T therapy rash with developing neuropathy
4385	0	a	sulphonylurea treatment with associated disease
4386	0	a	sulphonylureas with treatment with associated CAD disease
4387	0	a	sulphonylureas with treatment with associated CAD
4388	0	a	sulphonylurea treatment of patients with diabetes
4389	0	a	sulphonylureas with treatment of diabetes
4390	1	a	glibenclamide with increased hazard of CAD
4391	1	a	glibenclamide with diabetes of treatment Initiating associated with risk of CAD
4392	0	a	glipizide with increased hazard of CAD
4393	0	a	glipizide glibenclamide with diabetes of treatment Initiating associated with risk of CAD
4394	0	a	metformin with unchanged was increased hazard of CAD
4395	0	a	glibenclamide with diabetes
4396	0	a	glipizide glibenclamide with diabetes
4397	0	a	gliclazide to comparison in associated Initiating treatment of diabetes
4398	0	a	gliclazide to comparison in associated with risk of CAD
4399	0	a	glimepiride gliclazide to comparison in associated Initiating treatment of diabetes
4400	0	a	glimepiride gliclazide to comparison in associated with risk of CAD
4401	1	a	Amiodarone induced coma
4402	1	a	amiodarone induced coma
4403	1	a	amiodarone induced coma
4404	1	a	Amiodarone induced coma
4405	1	a	amiodarone induced coma
4406	1	a	amiodarone induced coma
4407	1	a	amiodarone therapy of initiation after have bradycardia
4408	1	a	amiodarone therapy of initiation after have bradycardia hypothermia
4409	1	a	amiodarone therapy of initiation after have bradycardia hypothermia failure
4410	0	a	amiodarone therapy of initiation for fibrillation
4411	0	a	amiodarone induced coma with history significant for disease
4412	1	a	carbamazepine induced myocarditis had had myocarditis
4413	1	a	carbamazepine induced myocarditis
4414	1	a	carbamazepine induced myocarditis
4415	0	a	carbamazepine induced myocarditis had had resulting in shock
4416	1	a	remoxipride metabolites by apoptosis cells relevance to anemia
4417	1	a	remoxipride induced anemia
4418	1	a	remoxipride agent associated with anemia
4419	1	a	amide remoxipride agent associated with anemia
4420	1	a	remoxipride induce anemia
4421	1	a	remoxipride induce contribute to mechanism anemia
4422	1	a	remoxipride with associated anemia mechanism to contribute induce anemia
4423	1	a	remoxipride with associated anemia
4424	0	a	NCQ436 with treated cells in observed necrosis
4425	0	a	NCQ344 had inducing at concentrations necrosis
4426	1	a	benzene remoxipride induce anemia
4427	1	a	benzene remoxipride induce contribute to mechanism anemia
4428	0	a	NCQ436 of ability contribute induce anemia
4429	0	a	NCQ436 of ability contribute to mechanism anemia
4430	0	a	NCQ344 NCQ436 of ability contribute induce anemia
4431	0	a	NCQ344 NCQ436 of ability contribute to mechanism anemia
4432	1	a	Cocaine induced ischemia
4433	1	a	cocaine by induced ischemia
4434	0	a	nitroglycerin agents by reversed ischemia
4435	0	a	nitroglycerin agents by reversed ischemia induced by spasm
4436	0	a	calcium nitroglycerin agents by reversed ischemia
4437	0	a	calcium nitroglycerin agents by reversed ischemia induced by spasm
4438	0	a	propranolol of isomers of properties effects on arrhythmias
4439	0	a	propranolol of isomers were capable of preventing arrhythmias
4440	0	a	-)-propranolol of dose was were capable of preventing arrhythmias
4441	0	a	-propranolol of that whereas was were capable of preventing arrhythmias
4442	1	a	adrenaline induced arrhythmias
4443	1	a	adrenaline.7 of dose increasing by was Blockade of arrhythmias
4444	1	a	halothane with anaesthetized cats in arrhythmias
4445	0	a	propranolol of isomers were capable of reversing tachycardia
4446	1	a	ouabain by caused tachycardia
4447	0	a	sotalol d of use with Efficacy proarrhythmia
4448	0	a	sotalol d of use for tachyarrhythmias
4449	0	a	sotalol for tachyarrhythmias
4450	0	a	sotalol d received patients with tachycardia
4451	0	a	sotalol d received prevent induction of tachyarrhythmia
4452	0	a	sotalol prevented induction of tachycardia
4453	0	a	sotalol d by prevented Induction of tachyarrhythmia
4454	0	a	sotalol d by prevented remained tachyarrhythmia
4455	0	a	sotalol d of mg tolerate remained prevented Induction of tachyarrhythmia
4456	0	a	sotalol d of mg tolerate remained tachyarrhythmia
4457	1	a	sotalol factors incidence of pointes
4458	1	a	sotalol factors for pointes
4459	1	a	sotalol had from pointes
4460	1	a	sotalol was in patients with pointes
4461	1	a	sotalol pointes
4462	1	a	sotalol occurred pointes
4463	1	a	sotalol identify with risk for pointes
4464	1	a	sotalol d of application before parameters identify at risk for pointes
4465	0	a	sotalol d received patients with disease
4466	0	a	sotalol d received patients 20 with cardiomyopathy
4467	0	a	sotalol d received patients with tachycardia fibrillation
4468	0	a	sotalol prevented induction of tachycardia fibrillation
4469	0	a	sotalol pointes had patient with disease
4470	0	a	tobramycin combined with carbenicillin for infections
4471	0	a	tobramycin combined with carbenicillin for infections in patients cancer
4472	0	a	carbenicillin for infections
4473	0	a	carbenicillin for infections in patients cancer
4474	0	a	tobramycin given overcome effects of neutropenia
4475	0	a	carbenicillin with combined infusion by given overcome effects of neutropenia
4476	0	a	creatinine azotemia
4477	1	a	tobramycin concentration therapy of duration to related Azotemia
4478	0	a	monoHER administration between interval on protection against cardiotoxicity
4479	0	a	monohydroxyethylrutoside showed against cardiotoxicity
4480	0	a	monoHER monohydroxyethylrutoside showed against cardiotoxicity
4481	0	a	doxorubicin monoHER administration between interval on protection against cardiotoxicity
4482	0	a	doxorubicin induced cardiotoxicity
4483	0	a	doxorubicin continues Despite cardiotoxicity
4484	0	a	DOX doxorubicin continues Despite cardiotoxicity
4485	0	a	DOX induced cardiotoxicity
4486	0	a	DOX induced damage
4487	0	a	DOX by formation from results damage
4488	0	a	DOX with treatment induced damage
4489	0	a	flavonoid monohydroxyethylrutoside showed against cardiotoxicity
4490	0	a	iron properties scavenging through showed against cardiotoxicity
4491	0	a	MPTP model of disease
4492	0	a	MPTP lesioned marmoset used as model in patients PD
4493	0	a	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administered resulting in parkinsonism
4494	0	a	levodopa treated marmoset used as model of symptoms
4495	0	a	levodopa induced fluctuations behaviors
4496	0	a	levodopa to prior evaluated for disability dyskinesia fluctuations behaviors
4497	0	a	levodopa induced behaviors
4498	0	a	levodopa treatment of Day on present were behaviors
4499	0	a	levodopa between interaction are disorders
4500	0	a	levodopa treated marmoset used as model in patients PD
4501	0	a	levodopa between interaction are disorders in PD
4502	0	a	MPTP lesioned marmoset used as model of symptoms
4503	0	a	levodopa to prior evaluated for disability
4504	1	a	levodopa to prior evaluated for disability dyskinesia
4505	1	a	levodopa induced fluctuations dyskinesia
4506	1	a	levodopa therapy of duration with correlated increase in fluctuations dyskinesia
4507	0	a	citrate anticoagulation is carries risk of toxicity
4508	0	a	citrate toxicity
4509	0	a	citrate toxicity
4510	1	a	acetaminophen induced failure
4511	1	a	acetaminophen induced failure with AKI
4512	0	a	citrate dialysate with anticoagulated transplantation during underwent failure
4513	0	a	Citrate dialysate is alternative for support in failure
4514	0	a	citrate dialysate with anticoagulated transplantation during underwent failure with AKI
4515	1	a	indomethacin by induced Hyperkalemia
4516	1	a	indomethacin by caused hyperkalemia
4517	1	a	indomethacin therapy continued allowing correcting hyperkalemia
4518	1	a	naproxen indomethacin by induced Hyperkalemia
4519	1	a	naproxen indomethacin by caused hyperkalemia
4520	0	a	fludrocortisone by reversed induced Hyperkalemia
4521	0	a	fludrocortisone added correcting hyperkalemia
4522	0	a	acid nephropathy of history patient with arthritis
4523	1	a	acid nephropathy
4524	0	a	acid nephropathy caused hyperkalemia
4525	0	a	acid nephropathy caused hyperkalemia hypoaldosteronism
4526	0	a	indomethacin by caused nephropathy of history patient with arthritis
4527	0	a	indomethacin by caused nephropathy
4528	1	a	indomethacin by caused hyperkalemia hypoaldosteronism
4529	0	a	naproxen indomethacin by caused nephropathy of history patient with arthritis
4530	0	a	naproxen indomethacin by caused nephropathy
4531	1	a	naproxen indomethacin by caused hyperkalemia hypoaldosteronism
4532	0	a	prostaglandin inhibitors with type predisposed disease
4533	0	a	prostaglandin inhibitors with type acidosis
4534	0	a	acetonide implant of Safety in retinochoroidopathy
4535	0	a	acetonide implant of outcomes report in patients with retinochoroidopathy
4536	0	a	acetonide implant helps control in cases of retinochoroidopathy
4537	0	a	acetonide implant helps control inflammation
4538	1	a	propylthiouracil associated hepatitis
4539	1	a	propylthiouracil associated syndrome of case case described cases of hepatitis
4540	0	a	propylthiouracil associated hepatitis of cases described case of necrosis
4541	0	a	propylthiouracil associated syndrome of case case of necrosis
4542	1	a	propylthiouracil associated hepatitis of cases described case case of syndrome
4543	1	a	propylthiouracil associated syndrome
4544	0	a	methimazole associated necrosis of case described cases of hepatitis
4545	1	a	methimazole associated necrosis
4546	0	a	methimazole associated necrosis of case case of syndrome
4547	0	a	capsaicin in neuralgia
4548	0	a	capsaicin to response of action of course treated patients with neuralgia
4549	0	a	capsaicin to response of action of course treated patients with neuralgia PHN
4550	0	a	capsaicin cream with treated patients with neuralgia
4551	0	a	capsaicin cream with treated patients with neuralgia PHN
4552	0	a	capsaicin in PHN
4553	1	a	capsaicin induced sensations 4 mastitis
4554	1	a	ouabain by induced model of mania
4555	1	a	ouabain of administration intracerebroventricular suggested mimic symptoms of mania
4556	1	a	ouabain induced behavior like mania
4557	1	a	ouabain induced behavior provide model test hypothesis of involvement of stress in disorder
4558	0	a	Na(+)/K(+)-ATPase inhibitor ouabain of administration intracerebroventricular suggested mimic symptoms of mania
4559	0	a	Na(+)/K(+)-ATPase inhibitor ouabain of administration intracerebroventricular suggested mimic symptoms of mania
4560	0	a	ouabain induced hyperlocomotion
4561	1	a	quinine amblyopia
4562	1	a	sulfate of use after developed potentials supersensitivity response with blindness
4563	1	a	sulfate of use after developed potentials supersensitivity response pupillary
4564	1	a	quinine toxicity in potentials supersensitivity response pupillary
4565	0	a	sulfate of use for cramps
4566	0	a	quinine toxicity
4567	0	a	Propranolol antagonism of hypertension
4568	0	a	propranolol of efficacy studied in treatment of hypertension
4569	1	a	phenylpropanolamine induced hypertension
4570	1	a	Phenylpropanolamine overdose cause hypertension
4571	1	a	PPA Phenylpropanolamine overdose cause hypertension
4572	1	a	PPA induced hypertension
4573	0	a	Phenylpropanolamine overdose
4574	0	a	PPA Phenylpropanolamine overdose
4575	0	a	Phenylpropanolamine overdose cause hypertension hemorrhage
4576	0	a	PPA Phenylpropanolamine overdose cause hypertension hemorrhage
4577	0	a	PPA increased volume stroke
4578	1	a	Rifampicin associated glomerulonephritis
4579	1	a	rifampicin therapy of complication as reported glomerulonephritis
4580	1	a	rifampicin with treated developed secondary to glomerulonephritis
4581	1	a	rifampicin therapy of complication regarding review developed secondary to glomerulonephritis
4582	0	a	Rifampicin associated glomerulonephritis in endocarditis
4583	0	a	rifampicin for infections
4584	0	a	rifampicin with treated developed patient with IE
4585	0	a	rifampicin therapy of complication regarding review developed patient with IE
4586	0	a	Rifampicin associated glomerulonephritis in endocarditis
4587	0	a	rifampicin of use in increase to led Changing epidemiology of infections as endocarditis
4588	0	a	rifampicin of use in increase to led Changing epidemiology of infections as endocarditis IE
4589	0	a	rifampicin with treated developed patient with IE
4590	0	a	rifampicin therapy of complication regarding review developed patient with IE
4591	0	a	rifampicin therapy in patients receiving treatment for tuberculosis
4592	0	a	rifampicin of use in increase to led Changing epidemiology of infections
4593	1	a	rifampicin with treated developed failure
4594	1	a	rifampicin therapy of complication regarding review developed failure
4595	1	a	methylphenidate syndrome
4596	1	a	methylphenidate by caused female presented with syndrome
4597	1	a	methylphenidate by caused patient with syndrome
4598	1	a	hydrobromide infusion of end After decreased amplitudes tremor
4599	1	a	HCl infusion following those than faster decreased amplitudes tremor
4600	1	a	acid induced myositis
4601	1	a	ATRA induced myositis
4602	0	a	acid induced myositis in patient with leukemia
4603	0	a	acid component for leukemia
4604	0	a	acid component for leukemia APL
4605	0	a	ATRA acid component for leukemia
4606	0	a	ATRA acid component for leukemia APL
4607	1	a	morphine of administration with associated nystagmus
4608	1	a	morphine of dose receiving developed with nystagmus
4609	1	a	morphine of dose receiving developed dizziness
4610	1	a	etomidate prove because incidence of myoclonia
4611	0	a	FC with pretreated in seizures
4612	0	a	GFC effects evaluate at doses of mg/kg on parameters seizure
4613	0	a	GFC effects evaluate determine after seizures
4614	0	a	GFC produced latency to seizure
4615	0	a	GFC exert reduce demonstrated by increase in latency to seizure
4616	1	a	pilocarpine induced seizures
4617	1	a	pilocarpine induced status epilepticus of installation of frequency reduce demonstrated by increase in latency to seizure
4618	0	a	acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4619	0	a	acid levels on effects activity determine after seizures
4620	0	a	acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4621	0	a	acid levels on effects activity determine after seizures
4622	0	a	GABA acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4623	0	a	GABA acid levels on effects activity determine after seizures
4624	0	a	glutamine acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4625	0	a	glutamine acid levels on effects activity determine after seizures
4626	0	a	aspartate glutamine acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4627	0	a	aspartate glutamine acid levels on effects activity determine after seizures
4628	0	a	glutathione aspartate glutamine acid levels on effects activity determine evaluate at doses of mg/kg on parameters seizure
4629	0	a	glutathione aspartate glutamine acid levels on effects activity determine after seizures
4630	0	a	GFC exert reduce frequency of installation of epilepticus
4631	1	a	pilocarpine induced status epilepticus
4632	0	a	Theophylline neurotoxicity
4633	0	a	theophylline of neurotoxicity
4634	0	a	theophylline to response neurotoxic
4635	1	a	aminophylline of infusions received until onset of seizures
4636	0	a	diphosphanilate of study agent for burns
4637	0	a	phosphanilate evaluated as burn
4638	0	a	CHP phosphanilate evaluated as burn
4639	0	a	CHP concentrations of each with treated site burn
4640	0	a	CHP concentrations of each with treated from vehicle cream agent used for treatment of wounds burn
4641	0	a	sulphadiazine AgSD 1 cream vehicle from treated site burn
4642	0	a	sulphadiazine AgSD 1 cream agent used for treatment of wounds burn
4643	0	a	AgSD 1 cream vehicle from treated site burn
4644	0	a	AgSD 1 cream agent used for treatment of wounds burn
4645	1	a	CHP concentration ratings of pain
4646	1	a	CHP cream was closest in tolerance pain
4647	0	a	AgSD to closest in tolerance pain
4648	0	a	AgSD from differed was closest in tolerance pain
4649	1	a	paracetamol to due serum in patients with failure
4650	1	a	paracetamol to due were in patients with failure
4651	0	a	paracetamol to due serum overdose
4652	0	a	paracetamol to due overdose
4653	0	a	paracetamol to due overdose than those to hepatitis
4654	1	a	heroin dependent male in stroke Rhabdomyolysis
4655	1	a	heroin after presented with rhabdomyolysis
4656	1	a	heroin methadone using Those increase risk of rhabdomyolysis
4657	1	a	heroin related rhabdomyolysis
4658	1	a	heroin abusers in stroke rhabdomyolysis
4659	0	a	heroin dependent male in stroke
4660	0	a	heroin after presented with rhabdomyolysis stroke
4661	0	a	heroin methadone using Those increase risk of rhabdomyolysis stroke
4662	1	a	methadone therapy under stroke Rhabdomyolysis
4663	1	a	methadone using Those increase risk of rhabdomyolysis
4664	0	a	methadone therapy under stroke
4665	0	a	methadone using Those increase risk of rhabdomyolysis stroke
4666	1	a	heroin related rhabdomyolysis stroke
4667	1	a	heroin abusers in stroke
4668	0	a	inhibitors of doses in patients with failure
4669	0	a	inhibitors enzyme with Treatment reduces in patients with failure
4670	0	a	inhibitors enzyme with Treatment reduces in patients with failure CHF
4671	0	a	inhibitor therapy in patients with CHF
4672	0	a	lisinopril in CHF
4673	0	a	inhibitor receiving Of titrated because symptoms related to hypotension
4674	0	a	inhibitor receiving Of titrated because because dysfunction
4675	0	a	inhibitor receiving Of titrated because because dysfunction hyperkalemia
4676	0	a	dopamine precursor of Administration enhances learning in subjects patients stroke
4677	0	a	dopamine enhances learning in subjects patients stroke
4678	0	a	levodopa precursor of Administration enhances learning in subjects patients stroke
4679	0	a	dopamine agonist learning
4680	0	a	warfarin induced embryopathy
4681	0	a	warfarin induced embryopathy showed with hypoplasia
4682	0	a	warfarin with treated mothers to born infants in reported hypoplasia
4683	1	a	warfarin induced embryopathy showed with hypoplasia epiphyses
4684	1	a	warfarin induced embryopathy showed with hypoplasia epiphyses punctata
4685	1	a	warfarin with treated mothers to born infants in reported hypoplasia with without epiphyses
4686	1	a	cyclophosphamide induced cystitis
4687	1	a	cyclophosphamide on antagonists of function explore is cystitis
4688	1	a	CYP)-induced is cystitis
4689	1	a	CYP induced cystitis
4690	1	a	CYP of administration following behaviors pain
4691	1	a	Cyclophosphamide treatment increased scores behaviors pain
4692	0	a	lithium use polydipsia
4693	1	a	Lithium implicated in DI
4694	1	a	Lithium implicated changed focus on DI
4695	1	a	lithium received changed implicated in DI
4696	1	a	lithium received changed focus on DI
4697	1	a	lithium induced DI
4698	1	a	lithium induced DI treating developed secondary DI
4699	0	a	lithium induced DI treating developed to trauma
4700	0	a	propranolol therapy with correlated are conclude reported hypoglycemia
4701	0	a	propranolol therapy with correlated are conclude reported hypoglycemia hyperbilirubinemia
4702	0	a	propranolol therapy with correlated are conclude reported hypoglycemia hyperbilirubinemia polycythemia
4703	0	a	propranolol therapy with correlated are conclude reported hypoglycemia hyperbilirubinemia polycythemia apnea
4704	0	a	propranolol therapy with correlated are conclude reported hypoglycemia hyperbilirubinemia polycythemia apnea bradycardia
4705	1	a	contraceptives with associated thromboembolism
4706	1	a	contraceptives used women in was incidence of thromboembolism
4707	1	a	contraceptives used women in was incidence VTE
4708	1	a	OCs contraceptives used women in was incidence of thromboembolism
4709	1	a	OCs contraceptives used women in was incidence VTE
4710	1	a	OCs of users in than used women in was incidence of thromboembolism
4711	1	a	OCs of users in than used women in was incidence VTE
4712	1	a	OC VTE
4713	1	a	OC preparations of users in incidence of VTE
4714	1	a	OC preparations of users in incidence compare estimate analysis did study calculate ratios of VTE
4715	1	a	OC of types of use with associated ratios calculate study did analysis estimate compare incidence of VTE
4716	1	a	OC of types of use with associated ratios of VTE
4717	1	a	OCs progestagen of users were VTE
4718	1	a	OCs of use with associated cases of VTE
4719	1	a	OC of users in 4.10 was rate of VTE
4720	1	a	OCs of users in 3.10 OC of users in 4.10 was rate of VTE
4721	1	a	OCs to relative of users in ratio of VTE
4722	1	a	OCs of users between risk of VTE
4723	1	a	OCs With were ratios for VTE
4724	0	a	progestagens gestodene containing contraceptives used women in was incidence of thromboembolism
4725	0	a	progestagens gestodene containing contraceptives used women in was incidence VTE
4726	0	a	progestagens containing OCs of users in than used women in was incidence of thromboembolism
4727	0	a	progestagens containing OCs of users in than used women in was incidence VTE
4728	0	a	progestagens of users Among was risk of VTE
4729	0	a	progestagens for 3.49 were ratios for VTE
4730	0	a	gestodene containing contraceptives used women in was incidence of thromboembolism
4731	0	a	gestodene containing contraceptives used women in was incidence VTE
4732	0	a	gestodene of users in than higher was risk of VTE
4733	0	a	desogestrel gestodene containing contraceptives used women in was incidence of thromboembolism
4734	0	a	desogestrel gestodene containing contraceptives used women in was incidence VTE
4735	0	a	desogestrel of users in was risk of VTE
4736	0	a	desogestrel gestodene of users in than higher was risk of VTE
4737	0	a	desogestrel for 3.49 were ratios for VTE
4738	0	a	progestagen of users were VTE
4739	0	a	OCs of use with associated cases Of recorded as thrombosis
4740	0	a	OCs of use with associated cases Of recorded as thrombosis 35 five specified thrombosis
4741	0	a	OCs of use with associated cases Of recorded as thrombosis 35 as thrombosis
4742	0	a	ethinyloestradiol with was risk of VTE
4743	0	a	ethinyloestradiol with was risk of VTE
4744	0	a	ethinyloestradiol 3.49 were ratios for VTE
4745	1	a	diphenylhydantoin taking patient in aplasia
4746	1	a	diphenylhydantoin taking patient developed rash lymphadenopathy aplasia
4747	1	a	diphenylhydantoin medication with associated aplasia
4748	1	a	diphenylhydantoin of ingestion occurrence of rash lymphadenopathy aplasia
4749	1	a	diphenylhydantoin taking patient in aplasia dermatitis
4750	1	a	diphenylhydantoin taking patient in aplasia dermatitis lymphadenopathy
4751	1	a	diphenylhydantoin taking patient developed rash lymphadenopathy
4752	1	a	diphenylhydantoin treatment of complication is lymphadenopathy
4753	1	a	diphenylhydantoin of ingestion occurrence of rash lymphadenopathy
4754	0	a	diphenylhydantoin taking patient developed rash
4755	0	a	diphenylhydantoin treatment of complication is rash
4756	0	a	diphenylhydantoin of ingestion occurrence of rash
4757	0	a	aspirin on put took for fever
4758	0	a	ibuprofen took for fever
4759	0	a	5-Fluorouracil cardiotoxicity
4760	0	a	5-fluorouracil treatment during occurring complication is Cardiotoxicity
4761	0	a	5-FU treatment during occurring complication is Cardiotoxicity
4762	0	a	5-FU induced cardiotoxicity
4763	0	a	5-FU induced cardiotoxicity
4764	0	a	5-FU of administration abandoned considered been due to cardiotoxicity
4765	0	a	5-FU induced cardiotoxicity
4766	0	a	5-FU induced cardiotoxicity
4767	0	a	alanine by induced cardiotoxicity
4768	0	a	alanine of level observed cardiotoxicity
4769	0	a	FBAL alanine of level observed cardiotoxicity
4770	0	a	FBAL related to cardiotoxicity
4771	0	a	5-fluorouracil treatment for malignancies
4772	0	a	5-FU treatment for malignancies
4773	1	a	5-FU of infusion occurred pain
4774	1	a	5-FU of discontinuation after disappeared pain
4775	1	a	5-FU induced cardiotoxicity to due been considered pain
4776	1	a	5-FU of administration abandoned considered pain
4777	1	a	5-FU of infusion occurred pain with block
4778	0	a	FBAL concentration with occurred pain
4779	0	a	FBAL concentration with occurred pain with block
4780	0	a	Histamine antagonists hypotension
4781	1	a	tubocurarine induced hypotension
4782	1	a	Pilsicainide Pointes to due Case of Death
4783	1	a	pilsicainide received developed death
4784	1	a	Pilsicainide Pointes
4785	1	a	pilsicainide of dose was impaired was been produce pointes
4786	1	a	pilsicainide of concentration been produce pointes
4787	0	a	pilsicainide received convert fibrillation
4788	0	a	pilsicainide including drugs of administration is effective terminate fibrillation
4789	0	a	sodium channel blocker pilsicainide received convert fibrillation
4790	0	a	sodium channel blocker pilsicainide received developed death
4791	1	a	pilocarpine by produced seizures
4792	1	a	Pilocarpine reproduces provides model for studying mechanisms of buildup of operative activity convulsive
4793	1	a	Pilocarpine reproduces provides model for studying mechanisms of buildup of operative in generalization of seizures
4794	1	a	pilocarpine by produced seizures
4795	1	a	pilocarpine of doses reticulata into inhibitor micrograms resulted in seizures
4796	1	a	pilocarpine induced convulsions
4797	1	a	pilocarpine with observed formation to damage related seizure
4798	1	a	pilocarpine by produced seizures
4799	1	a	pilocarpine by produced seizures
4800	1	a	pilocarpine by produced convulsions
4801	1	a	pilocarpine induced seizures
4802	0	a	isoniazid of microinjection after produced seizures
4803	0	a	isoniazid of microinjections with pretreated animals In resulted in seizures
4804	0	a	isoniazid of injections augment seizures
4805	0	a	GABA isoniazid of microinjection after produced seizures
4806	0	a	GABA transaminase of inhibitor of Application suppressed appearance of electrographic seizures
4807	0	a	acid D GABA transaminase of inhibitor of Application suppressed appearance of electrographic seizures
4808	0	a	GABA of Microinjections failed prevent development of convulsions
4809	0	a	Pilocarpine reproduces sequelae of epilepsy
4810	0	a	acid inhibition within nigra on seizures
4811	0	a	GABA)-mediated inhibition within nigra on seizures
4812	0	a	GABA synthesizing enzyme of activity of inhibitor micrograms resulted in seizures
4813	0	a	GABA transaminase of inhibitor of Application suppressed appearance of electrographic seizures
4814	0	a	GABA mediated inhibition of regulation to subjected threshold for seizures
4815	0	a	isoniazid of microinjections with pretreated animals In resulted in seizures epilepticus
4816	0	a	GABA synthesizing enzyme of activity of inhibitor micrograms resulted in seizures epilepticus
4817	0	a	acid decarboxylase enzyme of activity of inhibitor micrograms resulted in seizures
4818	0	a	acid decarboxylase enzyme of activity of inhibitor micrograms resulted in seizures epilepticus
4819	0	a	pilocarpine of doses reticulata into inhibitor micrograms resulted in seizures epilepticus
4820	1	a	BaCl2 with used types of arrhythmia
4821	1	a	BaCl2 with manifests in models of arrhythmia
4822	1	a	BaCl2 with manifests in models used causing inhibition on arrhythmia
4823	1	a	chloroform adrenaline with used types of arrhythmia
4824	1	a	chloroform adrenaline by induced arrhythmia on inhibition causing used models of arrhythmia
4825	1	a	chloroform adrenaline by induced arrhythmia
4826	1	a	adrenaline with used types of arrhythmia
4827	1	a	adrenaline by induced arrhythmia on inhibition causing used models of arrhythmia
4828	1	a	adrenaline by induced arrhythmia
4829	1	a	G with used types of arrhythmia
4830	1	a	aconitine with with used types of arrhythmia
4831	0	a	aspirin discuss with adults are at risk for disease
4832	0	a	aspirin taking for prevention of infarctions
4833	0	a	Aspirin reduces risk for infarction
4834	1	a	aspirin taking for prevention of infarctions strokes
4835	1	a	aspirin of reviews selected aspirin events strokes
4836	1	a	aspirin of reviews selected aspirin events strokes death from events stroke
4837	1	a	aspirin events strokes
4838	1	a	aspirin events strokes death from events stroke
4839	1	a	aspirin increase strokes
4840	1	a	aspirin use with risk for strokes
4841	1	a	Aspirin reduces risk for infarction in men strokes
4842	0	a	aspirin versus control for prevention of disease
4843	0	a	aspirin versus control for prevention of disease CVD
4844	0	a	aspirin of reviews selected aspirin without CVD
4845	0	a	aspirin selected reviews of aspirin versus control for prevention of disease
4846	0	a	aspirin selected reviews of aspirin versus control for prevention of disease CVD
4847	0	a	aspirin without CVD
4848	0	a	aspirin use reduces number of events CVD
4849	0	a	aspirin use reduces number of events in patients without CVD
4850	0	a	Aspirin seem affect mortality CVD
4851	0	a	aspirin for prevention of CVD
4852	1	a	aspirin increase strokes bleeding
4853	1	a	aspirin of use increases risk for events events bleeding
4854	1	a	aspirin increase strokes
4855	1	a	aspirin use with risk for strokes
4856	0	a	aspirin of use increases risk for events bleeding
4857	0	a	Aspirin use increases risk for events bleeding
4858	0	a	bupivacaine of effects on release expression pain
4859	0	a	bupivacaine of effects in model pain
4860	0	a	bupivacaine group reported pain
4861	0	a	bupivacaine placebo group reported pain
4862	0	a	bupivacaine stimulates after injury associated with production pain
4863	0	a	lidocaine bupivacaine of effects on release expression pain
4864	0	a	lidocaine bupivacaine of effects in model pain
4865	0	a	E2 release expression pain
4866	0	a	E2 release on effects in model pain
4867	0	a	PGE2 h levels at reported pain
4868	0	a	PGE2 production pain
4869	1	a	bupivacaine of effects expression increases pain
4870	0	a	E2 on effects expression increases pain
4871	0	a	PGE2 production E2 on effects expression increases pain
4872	0	a	rofecoxib group reported pain
4873	0	a	bupivacaine stimulates after injury
4874	0	a	PGE2 production with associated injury
4875	0	a	1,3-Butadiene CML
4876	0	a	1,3-butadiene of studies suggest associated with leukemia
4877	0	a	1,3-butadiene of studies suggest associated with leukemia CML
4878	0	a	GEM P chemotherapy is active in treatment of lymphoma
4879	0	a	Gemcitabine have activity in HL
4880	0	a	gemcitabine day with treated patients with HL
4881	0	a	GEM P is in treatment of HL
4882	0	a	cisplatin Gemcitabine have activity in HL
4883	0	a	methylprednisolone treated patients with HL
4884	0	a	angiotensin converting inhibitor with therapy of use during caused Syncope
4885	0	a	angiotensin converting inhibitor with therapy of use during caused by hyperkalemia
4886	0	a	spironolactone inhibitor with therapy of use during caused Syncope
4887	1	a	spironolactone inhibitor with therapy of use during caused by hyperkalemia
4888	1	a	spiranolactone of doses be considered cause of hyperkalemia
4889	0	a	aldosterone antagonist spiranolactone of doses be considered cause of hyperkalemia
4890	1	a	ramipril of intake to addition in considered cause of hyperkalemia
4891	0	a	potassium agents with combination in using patients in possibility of hyperkalemia
4892	0	a	potassium agents with combination in using have disturbance
4893	1	a	Prednisone induces anxiety
4894	1	a	prednisone produces anxiety
4895	1	a	PDN prednisone produces anxiety
4896	1	a	PDN of groups in documented Anxiety
4897	1	a	PDN to exposure induced anxiety
4898	1	a	Indomethacin resulted in findings typical of cystitis
4899	1	a	Indomethacin resulted in findings typical of cystitis as epithelium mastocytosis
4900	0	a	B is has toxicity
4901	0	a	Fungizone of that with compared toxicity
4902	0	a	B of study of study using compared toxicity
4903	0	a	deoxycholate Fungizone of that with compared toxicity
4904	0	a	AmB deoxycholate Fungizone of that with compared toxicity
4905	1	a	AmB treated rats in showed necrosis
4906	0	a	B of incorporation attenuates nephrotoxicity
4907	0	a	B. of nephrotoxicity
